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ABSTRACT OF THE DISSERTATION 
THIOREDOXIN AND JAB1 CONTROL ESTROGEN- AND ANTIESTROGEN-
MEDIATED PROGRESSION OF THE CELL CYCLE THROUGH P27 
INTERACTIONS 
by 
Rosalind Brigham Penney 
Florida International University, 2011 
Miami, Florida 
Professor Deodutta Roy, Major Professor 
A major problem with breast cancer treatment is the prevalence of antiestrogen 
resistance, be it de novo or acquired after continued use. Many of the underlying 
mechanisms of antiestrogen resistance are not clear, although estrogen receptor-mediated 
actions have been identified as a pathway that is blocked by antiestrogens. Selective 
estrogen receptor modulators (SERMs), such as tamoxifen, are capable of producing 
reactive oxygen species (ROS) through metabolic activation, and these ROS, at high 
levels, can induce irreversible growth arrest that is similar to the growth arrest incurred 
by SERMs. This suggests that SERM-mediated growth arrest may also be through ROS 
accumulation. Breast cancer receiving long-term antiestrogen treatment appears to adapt 
to this increased, persistent level of ROS. This, in turn, leads to the disruption of 
reversible redox signaling that involves redox-sensitive phosphatases and protein kinases 
and transcription factors. This has downstream consequences for apoptosis, cell cycle 
progression, and cell metabolism. For this dissertation, we explored if altering the ROS 
formed by tamoxifen also alters sensitivity of the drug in resistant cells. We explored an 
 vi 
association with a thioredoxin/Jab1/p27 pathway, and a possible role of dysregulation 
of thioredoxin-mediated redox regulation contributing to the development of antiestrogen 
resistance in breast cancer. We used standard laboratory techniques to perform proteomic 
assays that showed cell proliferation, protein concentrations, redox states, and protein-
protein interactions.  We found that increasing thioredoxin reductase levels, and thus 
increasing the amount of reduced thioredoxin, increased tamoxifen sensitivity in 
previously resistant cells, as well as altered estrogen and tamoxifen-induced ROS. We 
also found that decreasing levels of Jab1 protein also increased tamoxifen sensitivity, and 
that the downstream effects showed a decrease p27 phosphorylation in both cases. We 
conclude that the chronic use of tamoxifen can lead to an increase in ROS that alters cell 
signaling and causing cell growth in the presence of tamoxifen, and that this resistant cell 
growth can be reversed with an alteration to the thioredoxin/Jab1 pathway. 
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I. INTRODUCTION 
 
It is estimated that 1.2 million people will be diagnosed with breast cancer every year. 
Through research on hormone replacement therapies and estrogen-receptor (ER)-based 
therapies, estrogen has been found to be involved in the development of breast cancer.1 
Currently, there are several options for the treatment of breast cancer, including surgery, 
radiation, chemotherapy, and hormonal therapy. Antiestrogens (AEs) are a known 
adjunctive therapy, and are used as a preventive measure as well. The most common form 
of hormonal therapy has been, for many years, selective estrogen receptor modulators 
(SERMs) such as tamoxifen, raloxifene, and toremifene.2  
 
A major problem with the use of antiestrogens (AE) is the prevalence of resistance, either 
at the outset of treatment or after continued use. The underlying mechanisms of 
antiestrogen resistance remain unclear. ER-mediated actions were identified initially as a 
pathway that was blocked in AE-treated cells, and inhibition of this pathway has been 
shown to cause permanent growth arrest/cell death. Reactive oxygen species (ROS) are 
an outcome of oxidative processes and can induce an irreversible growth arrest similar to 
selective estrogen receptor modulator (SERM) antiestrogens. SERMs are capable of 
producing ROS through their metabolic activation. These findings suggest that SERMs 
may mediate growth arrest by a mechanism involving ROS accumulation. 
 
The antioxidant thioredoxin may have a role in antiestrogen resistance in breast cancer. 
As cells are chronically exposed to ROS from long-term tamoxifen treatment, they can 
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adapt to this increasing level of ROS and oxidative stress. This can lead to oxidation of 
certain cellular antioxidant systems, such as thioredoxin, causing them to become 
inactive. The inactivation of the thioredoxin antioxidant family can then affect other 
proteins such as PTPs or Jab1, or lead to the continued activation of cell signaling 
pathways such as MAPKs (mitogen activating protein kinases), leading to the activation 
of transcription factors such as AP-1 or NF-κB and subsequent cell proliferation.  
 
We hypothesized that antiestrogen generated ROS, through the oxidization of Trx, 
increases the amount of free Jab1 accessible to bind to p27. This, in turn, promotes the 
loss of the inhibitory functions of p27, leading to antiestrogen resistance. Our goal, then, 
was to investigate whether reducing oxidized Trx in antiestrogen-resistant breast cancer 
cells restores the anti-proliferative function of antiestrogen treatments through restoring 
the Trx to compete for Jab1 binding, and thus renewing the inhibitive quality of p27.  
 
The following specific aims were set up to test the hypothesis: 
Aim 1: To investigate whether reducing oxidized Trx restores the anti-proliferative action 
of antiestrogen by: (i) determining if reducing Trx using ROS inhibitors and/or ROS 
detoxifying enzymes and/or an overexpression of Trx reductase restores the anti-
proliferative effect of antiestrogens by increasing Trx binding with Jab-1 and renewing 
the inhibitory function of p27; and (ii) investigating whether a persistent increase in 
oxidative stress leads to antiestrogen resistance in previously sensitive breast cancer cells 
through downregulating Trx reductase, upregulating Jab-1, and thus impairing the p27 
inhibitory function. 
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Aim 2: To determine the molecular mechanisms by which a pro-oxidative state may 
promote the oxidation/inhibition of Trx, p27 inactivation by Jab-1, and cell cycle 
progression by investigating whether redox signaling pathways in antiestrogen resistant 
cells can either directly or indirectly regulate levels of oxidized Trx and p27 in 
antiestrogen-resistant breast cancer cells. 
 
Aim 3: Testing of the hypothesis using in vivo conditions by investigating whether ROS 
inhibitors and/or Trx reductase can cooperate with antiestrogens to inhibit the 
proliferation of estrogen-independent, antiestrogen-resistant breast cancer cells in a 3-
dimensional culture. 
 
After beginning experiments, we chose to alter Aim 1 (ii) and not to perform Aim 3. We 
wanted instead to explore the role of the protein tyrosine phosphatase PTEN in estrogen-
mediated oxidative stress in breast cancer cells, as PTP alteration may also occur due to 
increased estrogen. We thought it important to explore the cell signaling pathways, 
namely those associated with thioredoxin/Jab1 and p27, which occur due to estrogen 
exposure in ER+ cells, as well as those initiated by the treatments. Both estrogen and 
tamoxifen have been shown to increase levels of ROS in breast cancer cells,3 and thus our 
findings may be applied to the formation of tamoxifen resistance through increased ROS. 
Our specific aim was to show the alteration of ROS through the thioredoxin/Jab1 
pathway and the effect on p27 phosphorylation in MCF-7 cells. 
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II. LITERATURE REVIEW: 
THIOREDOXIN, CHANGES IN REDOX STATE OF CELLS AND A NEW 
PERSPECTIVE IN AN UNDERSTANDING OF TAMOXIFEN RESISTANCE IN 
BREAST CANCER TREATMENT 
 
Abstract 
A major problem with the use of antiestrogens (AE) is the prevalence of resistance, either 
at the outset of treatment or after continued use. The underlying mechanisms of 
AE resistance remain unclear. Estrogen receptor (ER)-mediated actions were identified 
initially as a pathway that was blocked in AE-treated cells, and inhibition of this 
pathway has been shown to cause permanent growth arrest/cell death. Reactive oxygen 
species (ROS), a byproduct of oxidative processes, can induce an irreversible growth 
arrest similar to selective estrogen receptor modulator (SERM) antiestrogens. SERMs are 
capable of producing ROS through their metabolic activation. These findings suggest that 
SERMs may mediate growth arrest by a mechanism involving ROS accumulation.  
 
Breast cancer cells have higher amounts of ROS than normal cells, and chronic treatment 
with tamoxifen or fulvestrant adds additional ROS. Breast cancer cells receiving long-
term antiestrogen treatment appear to adapt to this increased, persistent level of ROS. 
This, in turn, leads to the disruption of reversible redox signaling that involves redox-
sensitive phosphatases and protein kinases such as ERK and AKT, and also 
involves transcription factors such as AP-1 and NF-κB. This has downstream 
consequences for apoptosis, cell cycle progression, and cell metabolism. This review 
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discusses concepts in support of a possible role of dysregulation of thioredoxin-mediated 
redox regulation contributing to the development of AE resistance in breast cancer. The 
inactivation of the thioredoxin antioxidant family can disrupt reversible redox signaling 
pathways and cause the cell to become unresponsive to AE-induced cell cycle arrest or 
cell death, or lead to the continued activation of cell signaling pathways such as MAPKs, 
leading to the activation of transcription factors and subsequent cell proliferation.  
  
1. Introduction 
Through research on hormone contraception, postmenopausal hormonal therapies and 
estrogen-receptor (ER)-based endocrine therapies, we know that estrogen is a major risk 
factor of breast cancer. 1, 4-14 Therefore, preventive strategies are predominantly restricted 
to antiestrogenic (AE) stimulation of its cognate receptor. The ER-based endocrine 
therapy includes selective estrogen receptor modulators (SERMs) (tamoxifen, raloxifene 
[Evista], and toremifene [Fareston]), pure antiestrogens (fulvestrant [Faslodex]), 
luteinizing hormone-releasing hormone agonists (leuprolide, goserelin [Zoladex]), and 
aromatase inhibitors (anastrozole [Arimidex], letrozole [Femara], exemestane 
[Aromasin]).2 Currently, there are several other options for the treatment of breast cancer, 
including surgery, radiation, and chemotherapy. Endocrine therapy is an effective 
treatment strategy for breast cancer and is responsible for a significant reduction in breast 
cancer mortality. However, while approximately 70% of newly diagnosed breast cancers 
express the estrogen receptor (ER), up to 50% of these do not respond to the above 
endocrine therapeutic agents 15-17. Furthermore, after a certain period of treatment with 
antiestrogens or aromatase inhibitors, breast tumors can become resistant to these agents.  
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Along with the acquired form of resistance, there is also “de novo,” or primary, 
resistance. The mechanisms of acquired AE and de novo resistances are not completely 
understood, and are likely quite complex. Tamoxifen and other AEs are thought to 
prevent cancer through their actions at the ER. These compounds also scavenge free 
radicals and block the metabolism and redox cycling of estrogen, so other mechanisms of 
action cannot be ruled out.18 Another scenario is that the ER is functional and driving 
estrogen-dependent processes with the exception of growth. This would indicate that 
other independent pathways are stimulating growth. In this case, estrogen-deprivation 
therapies would reduce expression of classically estrogen-regulated genes, but not those 
associated with cellular proliferation. This phenotype has been observed in ER-positive 
tumors treated with neoadjuvant letrozole.19, 20  
 
These findings suggest that nuclear ER genomic signaling pathways do not solely 
regulate estrogen-dependent growth of cells. Both estrogen and AEs cause the production 
of ROS.3, 9 As a known signaling molecule and second messenger, ROS has the potential 
to make dramatic changes in cell cycle progression. While there are systems in cells to 
counteract this production, the chronic exposure of cells to low to medium levels of 
oxidants can lead to a shift in the “normal” environment of the cell. In the pro-oxidant 
state of cells (i.e., high oxidative stress), the balance of thioredoxin (Trx) status is shifted 
towards the oxidized form of Trx. There are several studies showing indirect evidences in 
support of the concept that high expression of oxidized Trx may be associated with drug 
resistance in primary breast cancer.21, 22 In this review, we will discuss the role of Trx in 
AE resistance in breast cancer and recent studies in this area. First, estrogen’s and AE’s 
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actions are reviewed in brief. Then the role of AE-induced generation of oxidants and 
emerging data on the ability of AE-induced RO/NS to modify Trx-mediated redox-
sensitive signal transduction pathways are discussed. 
 
2. Mechanisms of estrogen actions in breast cancer 
In order to understand the AE actions in cells, it is important that we understand estrogen 
actions in normal breast epithelial and cancer cells. Therefore, we have briefly 
summarized here estrogen actions. It is widely recognized that estrogen promotes pre-
neoplastic and malignant growth via interaction with estrogen receptors alpha and beta 
(ERα and ERβ). This interaction then can lead to transcription either by directly binding 
to estrogen response elements, or through non-genomic pathways. The non-genomic 
action of estrogen very often includes ligand-binding to the ER at the plasma membrane, 
and leads to the activation of signaling pathways such as MAPK, protein kinases A and 
C, and calcium pathways,23 initiating a cell signaling sequence that leads to proliferation. 
Another non-classical action of the ER is its direct binding to AP-1. When the DNA 
binding domain of mouse ERα is mutated, there is an interaction with Jun, an AP-1 
coactivator.24 In MCF-7 breast cancer cells, estrogen has been demonstrated to activate 
the growth regulatory gene cyclin D1 by 2 to 3 fold. It has also been seen that estrogen 
can upregulate c-jun and c-fos in this cell line, which can combine to bind and activate 
AP-1 sites on DNA.25, 26 Other studies, however, present that estrogen creates increased 
AP-1 activity without the expected increase in c-fos and c-jun synthesis, implying that 
estrogen activates, but does not synthesize, other proteins that activate AP-1.27 Estrogen 
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activates transcription factors such as NF-κB, and CREB. Estrogen actions through ER 
have been extensively reviewed; therefore we have limited our discussion in this area. 
 
More recently, a new mechanism of estrogen action in breast cancer cells has emerged. 
Estrogen produces intracellular ROS rapidly, which can lead to cell signaling, and 
oxidants contribute to the growth of estrogen-dependent breast cancer cells.28 29 
Importantly, the ROS produced in breast cancer as a result of estrogen stimulation does 
not require estrogen receptors, as the ER-negative cell line MDA-MB 468 produces a 
similar amount of ROS as the ER-positive cell lines MCF-7, T47D, and ZR75.9 It has 
also been demonstrated that estrogen is able to stimulate growth in the non-ER-
expressing cell line HEK293. This ER-independent growth shows that other factors are 
involved in estrogen-stimulated cell growth, and further studies have implicated 
mitochondrial ROS formation.30 Free radical generation by estrogen has been 
demonstrated, as has the instigation of redox cycling in both stilbene and catechol 
estrogens. The damage that can occur due to these estrogen-induced free radicals can lead 
to DNA strand breakage, 8-hydroxylation of purine bases of DNA, and lipid 
hydroperoxide-mediated DNA modification.9, 12, 31 Redox cycling of estrogen is a delayed 
event, because estrogen has to be first metabolized to catechol estrogens to participate in 
redox reactions. In the cells of target tissues, there has to be free catechol estrogen 
available to participate in redox reactions. Hydroxylated estrogens do not cause the rapid 
production of ROS intracellularly through redox cycling, as the metabolites and the 
adducts of these hydroxylated estrogens are not seen immediately after E2 treatment, 
while the ROS are.9 
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There is evidence in support of the concept that: i) Physiologically achievable 17β-
estradiol (E2) concentration of 1 nM, which corresponds to the estrogenic menstrual 
peak, induces rapid formation of mitochondrial ROS in MCF-7 cells. We and others have 
also shown similar findings in MDA-MB-231 and other ER-negative cells, indicating that 
ER status is not relevant to this effect.32-34 ii) Overexpression of biological ROS 
scavengers (e.g., MnSOD and catalase), treatments of cells with chemical antioxidants, 
(e.g., N-acetylcysteine and ebselen) or silencing of mitochondrial biogenesis (source of 
ROS), inhibits estrogen-induced colony formation in MCF-7 cells. This suggests that 
estrogen-induced mitochondrial ROS promote in vitro tumor formation in breast cancer 
cells. iii) The expression of early cell cycle genes (such as cyclin D1, D3, E1, E2, and 
B2) as well as PCNA, PRC1, and bcl2 that are normally induced by estrogen, were 
inhibited by the addition of mitochondrial blockers. This is important because neither 
antioxidants nor mitochondrial blockers have presented with ER binding. As such, it 
suggests that the transition from G1 to S in estrogen-exposed cells is modulated by 
mitochondrial ROS.35 Figure 1-LR shows the different pathways of estrogen-mediated 
cell growth. 
 
Recently estrogens have been implicated as antioxidants through scavenging lipid 
peroxyl radicals and thus interrupting lipid peroxidation. They also scavenge hydroxyl 
radicals at higher levels, and can inhibit superoxide radical generation.36 Estrogen inhibits 
the apoptotic oxidative effects of TNF- α (ROS generation, lipid peroxidation, 
antioxidant enzyme consumption and disruption of mitochondrial membrane potential).37 
Estrogens are phenolic chemicals. In the presence of an oxidant-generating environment, 
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the phenolic hydroxyl group present at the C3 position of the A ring of estrogens or 
catechol estrogens can readily accept electrons, and can become oxidized by either 
accepting these electrons or losing a proton. This can explain the anti-oxidative function 
of estrogens.31, 38, 39 There are structural similarities between estrogens and Vitamin E in 
terms of an aromatic ring. A hydroxyl group in both compounds donate a hydrogen atom 
to reduce free radicals, which allows estrogens and vitamin E to act in an antioxidant way 
in the presence of an oxidative environment. Additionally, it has been suggested that 
estrogen exerts its antioxidative actions through suppressing inflammatory cytokines or 
modulating antioxidant enzyme status.40, 41 In support, there is a link between cell 
viability that is enhanced by the estrogen receptor and thioredoxin expression. This was 
shown through inhibiting thioredoxin reductase, and noting a reduction in 
cytoprotection.42 This was also explored in bovine aortic endothelial cells, and found that 
17β-estradiol increased the levels of thioredoxin, glutaredoxin, and thioredoxin reductase. 
Tamoxifen treatment inhibited the induction of these three proteins.43  
 
In summary, these studies suggest that estrogen-generated oxidants, together with an 
estrogen-driven increase in epithelial cell proliferation, may initiate and promote 
neoplastic lesions in estrogen-sensitive tissues. As such, the importance of the ROS 
generated by estrogen cannot be ignored when exploring antiestrogen resistance. 
 
3. Actions of endocrine therapeutic agents 
The actions of endocrine therapy are primarily based on either lowering ER function or 
reducing the levels of circulating free estrogens. Molecular mechanisms of actions of 
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individual endocrine therapeutic agents have been extensively reviewed; therefore we 
have limited our discussion in this area here. Tamoxifen is one of the effective endocrine 
therapies for breast cancer that promotes a conformational change in the estrogen 
receptors that effectively blocks coactivator binding, and restricts AF-2 (a protein found 
in early G1 phase cells)-induced transcription. However, it also acts as an agonist on AF-
1-dependent genes.26 As AF-1 and AF-2 are tissue specific,44 this could explain the 
tissue-dependent dual antagonistic/agonistic roles of tamoxifen.26 While tamoxifen is a 
breast cancer antagonist, it also has agonistic qualities in the uterus and bone. It is 
through this duality that tamoxifen is called a selective estrogen receptor modulator 
(SERM).45 Tamoxifen’s role as a non-steroidal estrogen antagonist allows it to inhibit 
proliferation and induce apoptosis of breast cancer cells.46 This was demonstrated with 
the use of ER-positive MCF-7 cells and ER-negative MDA MB-231 cells in which 
tamoxifen (5-7uM) induced rapid (within 60 minutes) breast cancer cell death.3 It has 
been noted that tamoxifen will act as an estrogen agonist in the non-genomic, membrane-
bound ER pathways, where ER activates kinases such as Src, PI3K, MAPK, EGFR 
(epidermal growth factor receptor) and ErbB2. The levels of these kinases play a role in 
this, however. Thus if cancer cells express low levels of EGFR and ErbB2, for example, 
the membrane ER function, and thus tamoxifen’s agonistic effects, on these tyrosine 
kinase receptors may be slight.26  
 
Tamoxifen has also been shown to be a potent antioxidant in certain cells. While its 
actions in breast cancer cells lead to cell death, it offers neuroprotection after middle 
cerebral artery occlusion. Tamoxifen effects in this disease are thought to be through 
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agonistic actions on ER and antioxidant actions. Just as estrogen can be an antioxidant to 
low-density lipoproteins (LDLs), tamoxifen and raloxifene are also able to decrease the 
oxidation of LDLs.18 A similar antioxidant effect on LDLs is seen in human umbilical 
vein endothelial cells.47 Tamoxifen also has presented with antioxidant qualities in 
myocardial ischemia-reperfusion (I/R) injury. In rats with induced I/R injury there was a 
significant decrease in glutathione and glutathione peroxidase as compared to rats that 
also had tamoxifen treatment.48 With focal cerebral ischemia, the antioxidant effects of 
tamoxifen may be due to an increase in manganese superoxide dismutase (MnSOD)  
levels and a subsequent decrease in the activation of kinases and caspase-3, which are 
downstream of superoxide production.49 In the uterus, tamoxifen increases superoxide 
dismutase (SOD) activity, and decrease NADPH oxidase (a superoxide generator) 
activity.50 Tamoxifen is derived from the estrogen-mimetic hydrocarbon stilbene, and the 
stilbene structure can act as a substitute for estradiol. In the presence of an oxidant 
generating environment, tamoxifen can readily react quantitatively with hydroxyl free 
radicals, and this can explain the anti-oxidative function of tamoxifen.51  
 
When tamoxifen is present alone in cells it can lead to the formation of ROS in breast 
cancer cells. While tamoxifen induces breast cancer cell death, it also results in an 
increase of ROS production by 1.7 to 2.0 fold. Tamoxifen has rapid non-genomic effects 
such as releasing cytochrome c, decreasing mitochondrial membrane potential (Δψm), 
and increasing ROS.52 Tamoxifen also is known to inhibit the mitochondrial electron 
transport chain.53 Studies have shown that tamoxifen decreases the Δψm and rapidly 
releases mitochondrial cytochrome c in p53-negative breast cancers.3, 54 This occurs 
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through the stimulation of mitochondrial nitric oxide synthase and the ensuing decrease 
in mitochondrial respiration and release of cytochrome c.55 This release is accompanied 
by ROS production, leading to oxidative stress in the cell.28, 29, 56 This oxidative stress 
may then lead to apoptosis, as it has been suggested that this disruption of the function of 
the mitochondria may play an important role in tamoxifen’s fast death response.52 
However when inhibitors of complexes I, II, or III are added to HepG2 cells, the levels of 
ROS and apoptosis that are typically induced by tamoxifen are not altered significantly. 
This is also true when the mitochondrial uncoupler carbonylcyanide-p-
(triflouromethyoxy)phenylhydrazone (FCCP) is used.57 A novel use for tamoxifen 
utilizing its ability to produce ROS was seen when tamoxifen was used as a carrier for 
iron (ferrocene). When tamoxifen delivered the metal to tumor cells, the iron interacted 
with the hydrogen peroxide already present, and resulted in large amounts of hydroxyl 
ions and hydroxyl radicals, which then induced apoptosis in the cell. In this way the high 
amount of hydrogen peroxide in tumor cells was used as a prodrug for treatment.58  
 
Another SERM that works in a similar way to tamoxifen is raloxifene. Raloxifene also 
binds to the estrogen receptor, and its affinity for it is similar to that of estrogen. While 
the bond with the ER creates a change in the special configuration of the ER that 
prohibits both activation of and binding of estrogen to the ER, it also contains a 
peculiarity in its binding that allows it to block AF-2 interactions, which some say is the 
key to its ability to be an estrogen antagonist in both breast and uterine tissues. This 
interaction of raloxifene and the ER are quite different in bone and non-reproductive 
tissues where it acts as an estrogen agonist through the use of helper/adapter proteins.59 
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A more “pure” estrogen antagonist is ICI 182780, or fulvestrant. Fulvestrant acts in three 
ways on the ER. First, in binding to the ER, it impairs the ability of the ER to dimerize as 
well as its ability to move into the nucleus. It also disables the ER activation functions of 
AF1 and AF2, which recruit coactivators and other necessary proteins to the 
transcriptional complex, both of which are necessary for estrogen agonistic activity. And 
lastly, when fulvestrant binds to the ER, the complex becomes unstable, which leads to 
an accelerated degradation of the ER protein, though not of ER mRNA.60  
 
The prototype SERM (tamoxifen) and its derivatives (toremifene, droloxifene, and, 
idoxifene), the second-generation SERM raloxifene, the third-generation SERM 
arzoxifene, and the fourth-generation SERM alcolbifene undergo metabolic activation 
and their metabolites are more capable of participating in redox reactions. 61, 62 
 
The ER-mediated actions were identified initially as a pathway blocked in AE-treated 
cells, and inhibition of this pathway causes permanent growth arrest/cell death. Reactive 
oxygen species, a byproduct of oxidative processes, can induce an irreversible growth 
arrest similar to SERM antiestrogens. SERMs are capable of producing ROS through 
their metabolic activation. These findings suggest that SERMs may mediate growth arrest 
by a mechanism involving ROS accumulation.61, 62 
  
Third-generation aromatase inhibitors (AIs), such as anastrozole, letrozole, and 
exemestane that have a non-steroidal structure, also play a role in breast cancer treatment. 
As their name implies, AIs prevent conversion of androgen to estrogen by inhibiting 
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aromatase enzyme activity in the cells. Thus AIs inhibit the mitogenic response in the 
breast tissue by inhibiting both estrone (E1) and estradiol (E2) production.63 While first- 
and second-generation AIs have been found to be quite effective, the side effects have 
caused the use of them to be controversial. Third-generation AIs, on the other hand, 
appear to have complete specificity without adrenal axis affects. AIs are used on women 
with ER/PR expression, but who do not have functional ovaries or who are pre-
menopausal. The amount AIs lower estrogen expression in those who do not fit this 
description is not enough to have an effect on tumor growth.64 
  
In summary, antiestrogen-mediated oxidative stress has received attention as an ER-
independent mechanism. Like stilbene estrogen, tamoxifen and its metabolites produce 
ROS, which can lead to oxidative damages to macromolecules, such as lipids and 
DNA.65-68 Like tamoxifen, other SERMs can also participate as substrates in metabolic 
redox reactions, which in turn can also produce oxidative stress.61 This increase in redox 
reactions could lead to a more oxidized state of the breast cancer cell, leading to cellular 
adaptation to ROS signaling, and a new cellular state that allows cell cycle progression in 
the presence of tamoxifen and possibly other SERMs. 
 
4. Overview of existing paradigms of antiestrogen resistance 
A major problem with the use of antiestrogens is the prevalence of resistance, either at 
the outset of treatment or after continued use. De novo, or primary, resistance can occur 
when tumors do not express estrogen or progesterone receptors.69 70, 71 As most 
estrogenic actions are considered to be mediated through the ER, lack of this protein 
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causes an inherent resistance to endocrine therapies,72 but this does not explain the 40-
50% of people who do not respond to treatment despite steroid hormone receptor 
expression.73 A more recent discovery in de novo resistance is inactive alleles of 
cytochrome P450 2D6. This allelic inactivity keeps patients from being able to convert 
tamoxifen to its active metabolite, endoxifen, leading to a decreased response to 
tamoxifen. Patients who initially respond to antiestrogen treatment often become resistant 
to the drug within 2 to 5 years.26 The decreasing sensitivity of ER-positive breast cancer 
cells to antiestrogens with time is caused by several factors, and different mechanisms 
have been proposed to explain antiestrogen resistance. Since mechanisms of AE 
resistance have been widely reviewed,72 we have briefly summarized them here.  
 
Cross talk between ER and growth factor signaling has emerged as one of the important 
mechanisms in endocrine resistance. Since ERα expression plays a key role in predicting 
the response a patient will have to hormonal therapy such as antiestrogens,69 it is 
considered that a loss of ERα expression would be responsible for an acquired resistance 
to antiestrogens. Most data is related to tamoxifen treatment,69 and it shows that only 
approximately 17-28% of patients with acquired resistance to tamoxifen have a loss of 
ERα expression.26 There is also the possibility of ER mutations causing loss of 
functionality, or that the ER continues to drive all estrogenic actions except growth.72 But 
again, fewer than 1% of ER positive tumors have been found to have ERα mutations.74 
Another possibility lies in a truncated version of ERα, ERα36. When ERα36 is in the 
presence of the full ERα, there is decreased responsiveness. Posttranslational 
modification of ERα regulates its function as well as its interactions with other proteins 
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such as ERα co-regulators. Co-regulators include AP-1 and NF-κB, and phosphorylation 
and overexpression of these co-regulators can cause an increase in ERα-mediated 
transcription, which has been associated with endocrine resistance.74 
 
Mechanisms different from the ER have been proposed in antiestrogen resistance, with 
ErbB2 overexpression being the best characterized. Breast cancers that are resistant to 
tamoxifen have shown an increase in the expression of receptor tyrosine kinase (RTK) 
members, such as epidermal growth factor receptor pathway members like ErbB1 and 
ErbB2.75 76 When ErbB1 and ErbB2 (also known as HER-2) are overexpressed, they can 
reduce the levels of the cyclin-dependent kinase inhibitor p27 and inhibit its function, and 
thus keep tamoxifen from activating this molecule to keep the cell in G1 arrest.76 Not 
only does Her2 overexpression contribute to resistance on its own, but Her2 dimerization 
with other members of the ErbB receptor family can also lead to antiestrogen resistance.77 
Overexpression of other tyrosine kinases, such as Src kinase family members, is seen in 
breast cancer, and has been implicated in resistance through its substrate BCAR1.74 
 
Overexpression of cell cycle proteins such as Myc and cyclin D1 is associated with 
tamoxifen resistance, as is a decrease in expression of the NF-κB-binding interferon-
responsive putative tumor suppressor, IRF1.74 Response to tamoxifen is also correlated 
with the expression of the MAPK inhibitor, MAPK phosphatase 3 (MKP3), with resistant 
cells expressing increased levels of MKP3.78 
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Current hypotheses in tamoxifen resistance do not include the effect of a chronic 
exposure to ROS that is created by tamoxifen. Certainly tamoxifen is not known to    
work through a ROS-mediated pathway, but it does increase ROS. As such, the long- 
term exposure of breast cancer cells to tamoxifen- (and estrogen-) mediated ROS 
production may play a role in tamoxifen resistance. In the following section we explore 
this novel hypothesis.  
 
5. Redox signaling and antiestrogen resistance 
Before we discuss the role of redox signaling in antiestrogen resistance, we would like to 
briefly introduce the basic conditions that produce changes in the redox state of cells, 
generation of ROS and concepts of redox signaling.  
 
Redox state of cells: Historically, the term redox state has been used to describe the ratio 
of the interconvertible oxidized and reduced forms of a specific redox couple. The three 
major redox couples in cells are NADP+/NADPH, GSSG/2GSH, and TrxSS/Trx(SH)2. 
These redox couples are not isolated systems; rather they are thermodynamically 
connected to each other in the maintenance of redox equilibrium of cells. For example, 
both the Trx and GSH systems use NADPH as a source of reducing equivalents,79 and a 
decrease in thioredoxin reductase affects glutathione reductase activity in glucocorticoid-
resistant Alopecia areata.80 Redox couples in cells are responsive to electron flow, that is, 
changes in the reducing/oxidizing environment. When the products of the reducing 
capacity and the reduction potential of a linked set of redox couples in cells or tissue are 
added, it is considered the redox environment.79 
 19 
As is true with the control of pH within the body, the redox environment is well governed 
through what is known as redox regulation. In this process, redox homeostasis is 
disturbed by increases in the formation of ROS or decreases in the actions of antioxidant 
systems. This imbalance towards oxidation allows for redox signaling to occur. When 
pathological conditions are present, however, these oxidizing conditions can accumulate 
and have the potential to cause changes in cell signaling, which is commonly seen in 
disease states.81 
 
When a cell loses its capacity to reduce redox couples,82 there is a higher production of 
ROS or reactive nitrogen species, which result in a production or reaction from the 
antioxidants and reducers within the cells. This is explained below. 
 
Reactive oxygen species (ROS) is a term extended to a range of molecules, including free 
radicals (which contain one or more unpaired electrons) and include superoxide (O2·-), 
hydrogen peroxide (H2O2), hydroxyl radical (OH), and peroxynitrite (ONOO-).83 Several 
enzymatic systems and organelles create ROS, such as NADPH oxidase complex, 
cytochrome 450, nitric oxide synthases, xanthine oxidase, peroxisomes, endoplasmic 
reticulum and mitochondria.84, 85 The mitochondria, however, are the largest source of 
ROS in epithelial cells,29 and most ROS in endothelial cells are developed in the 
mitochondria through the electron transport chain.83 ROS are created when oxygen (O2) 
is put through an oxidoreduction conversion in the mitochondrial electron transport chain. 
There are four complexes relating to this chain through which electrons travel; the 
electrons are accepted by complex I (NADH-ubiquinone oxidoreductase) from NADH. 
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The electrons then move to complex II, succinate dehydrogenase. At this complex, the 
succinate is oxidized to fumarate, and the electrons continue to complex III, ubiquinol-
cytochrome c oxidoreductase, and then to complex IV, cytochrome c oxidase. When they 
finish the travel through all four complexes, they reduce molecular oxygen to water. 
Throughout this process, however, a small amount (1-4%) of the oxygen is not fully 
reduced and results in O2·-. This release of O2·- from the transport process occurs mainly 
at complexes I and III, with complex I-generated O2·- being released only into the 
mitochondrial matrix, and complex III- O2·- being released into both sides of the inner 
membrane of the mitochondria.86  
 
The enzymes that reduce proteins or destroy ROS are as important players as the ROS 
themselves.87 When there is a production of ROS within the cells, there is the reaction of 
the production of antioxidants. This is called redox (reduction and oxidation) 
regulation.81 There are several antioxidant systems, both enzymatic and non-enzymatic, 
in place to counteract redox imbalance. Enzymatic systems include superoxide dismutase 
(SOD), catalase, peroxiredoxins and glutathione peroxidase, while non-enzymatic 
systems include glutathione, thioredoxin, and vitamins C and E.88 Superoxide does not 
easily diffuse across the membrane of the mitochondria. While mechanisms do exist for 
this to occur (voltage dependent anion channels), SOD can reduce the superoxide to 
hydrogen peroxide (H2O2), which does easily cross the membrane.81, 86, 89 SOD has three 
isoforms; copper-zinc (CuZnSOD) in the cytoplasm, nucleus, and mitochondrial 
intermembrane space, a second form of CuZnSOD in the extracellular space, and 
magnesium SOD (MnSOD) in the mitochondrial mix. While they serve similar functions, 
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MnSOD appears to be highly important physiologically, for it’s genetic removal is 
embryonically lethal.86 Once SOD has changed the O2·- to H2O2, catalase and glutathione 
peroxidase within the cell can then reduce the H2O2 to water, or, in the presence of 
transition metals, to the hydroxyl radical (OH-).86 81, 89 Figure 2-LR summarizes the major 
mammalian ROS and antioxidant systems. For a more in depth discussion on these 
processes see88,90,91. 
 
Reactive oxygen species as signaling molecules: ROS are known signaling molecules, 
meaning there is a stimulus and a response to the ROS from a protein of either activation 
or inhibition. This response is amplified through the activation or inhibition of effector 
molecules further downstream in the pathway, and there is reversibility so that the 
pathway can be responsive to more than just the one stimulus. While not all ROS 
modifications are regulatory in function, glutathione and thioredoxin, as well as enzymes 
that are associated with each, have been found to reduce the thiol oxidation that occurs 
through ROS. It has been compared to the regulatory effect of phosphorylation and de-
phosphorylation of proteins.92 
 
ROS can instigate both apoptosis and cell proliferation, depending on the dose.25, 93 For 
example, in HT-29 colon cancer cells, toxic levels of H2O2 (1,000 uM) lead to apoptosis, 
while lower doses, (10 uM) induce cell proliferation.94 And when MCF-7 clones 
overexpress IL-1β, which leads to a high IL-1β output and thus a high ROS generation, 
cells undergo apoptosis. When, however, a moderate level of IL-1β is secreted in these 
clones, it leads to clonal expansion.9 Mitochondrial ROS have been implicated in cell 
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signaling in several pathways, including integrins, platelet-derived growth factor, 
epidermal growth factor, and nerve growth factor.95 When the cells undergo stress such 
as chronic inflammation (often from infections) and chronic chemical insults (such as 
tobacco smoke), there can be a transformation of the cell due to the ROS created by these 
irritants. This transformation often causes a lack of cell cycle regulation at cell cycle 
checkpoints. As such, the cells will overexpress growth factors that are oncogenic, 
leading to cell proliferation.96 In a number of cell lines, hormones, cytokines, 
neurotransmitters and growth factors can instigate cell signaling97 through inducing a 
low-concentration oxidative burst that may lead to signal initiation.98 For example, in 
endothelial cells, TNF-α, IL-1, bradykinin and thrombin can generate superoxide, and 
TGF-β1 and bradykinin can generate H2O2. These ROS are created to mediate mitogenic 
signaling, to regulate gene expression, to induce mRNA, and to move the cell cycle 
progression from G0/G1 to S phase.95 ROS produced by the estrogen-induced cytokine 
Interleukin-1β can lead to cell proliferation through AP-1 and NF-κB binding sites and 
through the MAPK/AP-1 and ROS/NF-κB pathways.99 Estradiol can lead to an 
overexpression of IL-1β in MCF-7 cells, which then leads to cell proliferation. When 
these cells are exposed to antioxidants and mitochondrial blockers, both a decrease in 
cyclin D1 expression and a suppression of cell growth can be seen.100 In a study of MCF-
7 cells treated with 17β-estradiol and insulin-like growth factor, it was shown that the 
combination of these elements increased peroxide production.101 The role of 
mitochondrial ROS production in regards to signal transduction can be seen in HeLa cells 
that lack mitochondrial DNA, which show a reduced ROS level, as well as a decrease of 
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cell cycle progression at all phases, and a decrease in certain cell-cycle regulators such as 
p21 and p27. This decrease is attributed to the lack of ROS production.102  
 
The apoptotic effect of cytotoxic levels of ROS is one way in which mitochondria play a 
role in chemotherapy-induced apoptosis.96 Camptothecin, mechlorethamine, and 
doxorubicin all induce apoptosis in breast cancer cells.103 Other ROS-utilizing 
chemotherapies include epirubicin, topotecan, and cisplatin.104 Dicumarol, an 
anticoagulant that creates oxidative stress and induces cytotoxicity in human pancreatic 
cancer cells, is thought to work through the electron transport chain in the     
mitochondria to create superoxide and hydrogen peroxide. This action of increasing 
cytotoxicity in these cells is decreased in pancreatic cancer cells that do not express 
functional mitochondria.105  
  
Redox signaling: Redox changes in the cell are critical for initiating various signaling 
pathways [see above]. Three of the major cell signaling pathways involve: (i) protein 
phosphorylation, (ii) protein acetylation or (iii) protein thiol status change that occurs 
because of alterations in cellular redox environment. Change in the thiol status of the cell 
can be triggered by both oxidants and reductants. We now know that signal transduction, 
DNA and RNA synthesis, protein synthesis, enzyme activation, cell cycle regulation, 
ligand binding, DNA binding, and nuclear translocation are altered by changes in the 
cellular redox environment. Most eukaryotic transcription factors such as AP-1, NF-κB, 
and Sp-1106 and glucocorticoid107 and estrogen receptors108 are affected by the redox 
environment. They must be in their reduced form to be active, and their translocation to 
 24 
the nucleus is often redox-dependent.79, 106 We discuss below the molecular mechanisms 
of redox signaling in more detail.  
 
As a known signaling molecule and second messenger, ROS has the potential to make 
dramatic changes in cell cycle progression. As mentioned earlier, high levels of ROS can 
lead to apoptosis while low levels can lead to cell cycle progression. Yet another action 
of ROS includes cell adaptation to chronic exposure of low to moderate levels. 
At moderate levels, ROS can use reversible protein oxidation to regulate signaling 
pathways. The common foci of this are protein kinases and transcription factors. This 
regulation can lead to an adaptation of the cell to changes in its environment.109 For 
example, when renal cells are exposed to oxalate, the initial reaction is cell death, but 
after 48-72 hours they can adapt to the exposure and begin to grow.110 In muscles, it has 
been suggested that exercise-induced ROS, as well as muscle-derived cytokines, play a 
role in muscle adaptation to exercise.111 The treatment of cisplatin on HepG cells 
increases ROS tremendously, with levels returning to normal after 120 hours.  At the 
same time, the mitochondria membrane potential changes, but then also returns to normal 
by 120 hours despite continued exposure. It is suggested that this occurs due to the cells 
adapting to the experience of cisplatin exposure.112 
 
This adaptation to ROS could play a role in breast cancer resistance to tamoxifen. As 
tamoxifen is known to increase levels of ROS and this increase is not at a high level that 
leads to apoptosis, there appears to be a low to medium exposure of cells to tamoxifen-
related ROS. The ROS produced may alter cell signaling, and the cell may begin to adapt 
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to this new signaling function and learn to grow in the presence of tamoxifen. Figure 3-
LR summarizes these ROS actions in the cell. In the next sections we discuss possible 
protein adaptations that can occur from this constant exposure to ROS via tamoxifen. 
  
Redox regulation of protein tyrosine phosphatases/kinases: Along with the    
alteration of transcription factors and certain receptors, the modification of protein 
phosphatases and kinases by ROS must also be considered.113 Cell proliferation, 
differentiation, activation, homeostasis and apoptosis are all furthered by tyrosine 
phosphorylation, as well as threonine and serine phosphorylation (though these play a 
lesser role). This phosphorylation is regulated by protein tyrosine kinases and protein 
tyrosine phosphatases.114 
 
Protein-tyrosine phosphatases (PTPs) are a part of the family of cysteine-based 
phosphatases. ROS plays its role most especially in PTPs, which have a signature motif 
made up of a cysteine, five X (any) amino acids, and Arginine (Cys-Xaa(5)-Arg). This 
motif allows for redox regulation of proteins when the cysteine residues react with 
ROS.115 The PTP catalytic cysteine, which remains as an etiolate anion (Cys-S-) under 
reducing conditions, only requires mild oxidative conditions to be oxidized to sulfenic 
acid (Cys-SOH). Once in this oxidized form, there is a continued vulnerability to ROS, 
and it can become terminally oxidized as sulfinic (Cys-SO2) and sulfonic (Cys-SO3) 
acids. This can be averted by interactions with a protein structure such as a thiol. This 
interaction can protect the cell through creating an inter- or intra-molecular disulfide 
bond that does not allow any other reactions to occur at the catalytic cysteine.87, 115-117  
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The counter proteins to PTPs are protein tyrosine kinases (PTKs). An important role of 
PTPs and PTKs is their ability to turn on and off the action of the protein on which they 
are exerting their influence.117 The PTP’s common active motif exists as a thiolate,118 
which allows PTPs to perform their dephosphorylation activity on phosphoproteins or 
phospholipids. Oxidation of PTPs can be reversed by thiol compounds118 once the 
catalytic cysteine forms a disulfide bond with an N-terminal cysteine. This disulfide bond 
can originate from same site cysteines, as is the case with low molecular weight PTPs,119 
from “distant” cysteines such as with PTEN and cdc25,120 or from a bond between the 
PTP and a thiol, such as with PTP1B.121 The important step of the disulfide bond blocks 
the oxidation of the thiolate to Cys-SOH by connection to another thiolate. Oxidation and 
phosphorylation have the potential of influencing each other in the signaling of PTPs and 
PTKs. It is suggested that one may actually be a preparatory modification for the other. 
For example, PTP phosphorylation can increase the catalytic activity of the protein. This, 
in turn, opens the protein to oxidation.118  
 
The reversibility of PTP oxidation is critical to cell signaling response. It has been 
suggested that at physiologic levels, one of the roles of ROS is to oxidize PTPs to 
encourage redox signaling.122 Structural changes to PTPs, as well as serine/threonine and 
phospholipid phosphatases, are induced by ROS, and the altered protein conformation 
leads to signaling cascade upregulation. Included in these cascades are growth factor 
kinase-dependent, src/Abl kinase-dependent, MAPK-dependent, and PI3 kinase-
dependent pathways, leading to activation of AP-1, NF-κB, HIF-1, and other redox-
regulated transcription factors.88 
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Redox regulation of transcription factors: Certain transcription factors such as AP-1 
and NF-κB are known to be redox regulated.106 AP-1 is a heterodimeric transcription 
factor that has been found to regulate cell proliferation, death, survival, and 
differentiation,123 depending on several factors. These factors include the balance of 
target genes that are either pro- or anti-apoptotic, the type of stimulus that induced the 
AP-1, and the persistence of that stimulus.88 The components of AP-1, c-Jun and c-Fos, 
can be induced by reactive radicals, and can positively regulate proliferation.88 
  
Because of their regulatory actions on transcription factors, most especially MAP-
kinase/AP-1 and NF-κB, ROS are able to alter cell proliferation, differentiation, and 
apoptosis.81, 124, 125 Since certain cell cycle genes contain response elements for these 
transcription factors, ROS can activate these genes and lead to cell proliferation.126 ROS 
actions regarding these transcription factors can be different depending on the cell line, 
however. For example, H2O2 is known to activate NF-κB,127 and in cardiovascular 
vessels, ROS activates AP-1 and NF-κB.128 In normal melanocytes, oxidative stress can 
be “suppressed” without the recruitment of NF-κB and AP-1. In melanoma cells, on the 
other hand, redox changes easily recruit NF-κB and AP-1. In these cells, NF-κB is 
correlated to H2O2 and not superoxide, and AP-1 to superoxide anion and not H2O2.129 
AP-1 can, however, be induced by H2O2 in other cells, mainly through the JNK and p38 
MAPK signaling pathways. This can be done through either ASK1 (apoptosis signal-
regulating kinase 1, which is released on thioredoxin oxidation as discussed below) or 
through the inhibition of MAPK phosphatases (which in turn leads to increased kinase 
activity).88 In tamoxifen resistant breast cancer, oxidative stress is implicated in an 
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increased AP-1 DNA binding with c-JUN NH2 terminal kinase activity in tamoxifen 
resistant breast cancer.68, 130, 131  
 
Reactive oxygen species are significant outcomes of estrogen and tamoxifen actions in 
cells. Tamoxifen resistance has an association with oxidative stress in breast cancer cells, 
and this leads to an increase in c-Jun and phosphorylated JNK levels, as well as an 
increase in AP-1 activity. A significant decrease in glutathione levels has been shown in 
tamoxifen resistant MCF-7 xenograft tumors, though there is an increase in SOD and 
glutathione S-transferase levels.68 And when vitamin E is added to tamoxifen-treated 
breast cancer cells, cell proliferation and ERK phosphorylation, which are normally 
decreased with tamoxifen treatment, are restored.132 It is with this in mind that we now 
discuss the thioredoxin system.  
 
Thioredoxin system and redox regulation: For this review, our focus is not on the 
mechanisms of antiestrogen treatment, but rather the resistance that occurs with 
treatment. To explore how redox regulation may play a role in antiestrogen resistance, we 
will discuss the possible involvement of thioredoxin and the thioredoxin family. In the 
following section we discuss the role of ROS in Trx oxidation, and then a potential role 
in tamoxifen resistance.  
 
Thioredoxin (Trx) is a 12 KD disulphide reducing enzyme that is excreted by a variety of 
cells.133, 134 The importance of thioredoxin can be seen with its role within the DNA-
binding sites of several transcription factors, where it reduces cysteine moieties and thus 
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plays a role in gene expression.135 There are five cysteines in Trx (32, 35, 62, 69, and 
73),136 two of which (32 and 35) are in the highly conserved domain of redox 
regulation137 with the sequence Trp-Cys-Gly-Pro-Cys.106 There are three forms of Trx; 
Trx1 (herein called Trx) that is cytosolic, the mitochondrial form (Trx2), and a third 
(SpTrx) that is found in spermatazoa.138 The cytosolic mammalian Trx, lack of which is 
embryonically lethal, has numerous functions in the defense against oxidative stress, 
control of growth and apoptosis. It also has co-cytokine and chemokine activities.139 
Thioredoxin is secreted in times of oxidative stress and inflammation in both normal and 
neoplastic cells.139 It has been suggested that Trx2 may be protective to cells during such 
exogenous insults as radiation and certain anticancer drugs.140 It has also been suggested 
that Trx2 and peroxiredoxins (Trx peroxidases) regulate the release of cytochrome c.  
 
As discussed above, an important aspect of the redox state is the role of cysteine residues 
and thiol chemistry.92 ROS is particularly drawn to cysteine and methionine residues,88 
and when these residues are oxidized, they are reduced by thioredoxin and 
glutathione/glutaredoxin-dependent reactions.139 Thioredoxin and glutathione are the 
major factors in maintaining reduced proteins,81, 139 and these reducing agents are found, 
in normal cells, in their reduced form. When they perform their reduction actions on 
oxidized proteins, they themselves are oxidized. They are then returned to their reduced 
forms through the use of thioredoxin reductase and glutathione reductase, respectively. 
Cysteine residues have been found to be specific targets for ROS when in the thiolate (-S) 
form, making them susceptible to ROS modification. ROS is drawn to reactive cysteine 
residues in target proteins. When the cysteine residue is in the thiol form (-SH) it is not 
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highly reactive and requires some catalyst to encourage reaction with a hydroperoxide. 
When the cysteine residue is in the thiolate form, however, it can react easily with 
ROS.141 Thiol chemistry has been well reviewed, and thus is only discussed in the context 
of this paper. For an extensive review, see Forman et al.141 
 
Trx is ubiquitous and has a variety of functions, including gene regulation (such as with 
NF-κB and p53), regenerating antioxidant enzymes, and catalyzing antioxidant reactions. 
Trx also can indirectly affect MAPKs and phosphoprotein phosphatases. When in the 
cytoplasm, Trx functions more as a reducing agent and an antioxidant, whereas in the 
nucleus it is a transcription factor regulator.142 In breast carcinomas, immunoreactivity of 
Trx in the nucleus is related to p53 positivity and to proliferation, as well as to an inverse 
association with estrogen and progesterone receptor status.143  
 
Trx is induced by stressors, including mitogens and H2O2. In stromal cells, both Trx 
mRNA and protein are increased with 17β-estradiol treatment. This effect is suppressed 
when tamoxifen treatment is given. It is also suggested that Trx might act with EGF, 
another secretion of stromal cells upon E2 treatment, as a co-mitogen.144 Intracellular 
levels of Trx increase when human skin fibroblasts have been UVA-irradiated, as have, 
in a time-dependent manner, Trx mRNA. This irradiation may lead to the translocation of 
Trx from the cytosol to the nucleus, and to an increase in thioredoxin reductase.145 In 
HIV patients, it has been seen that the loss of CD4+ T-cells by apoptosis is preceded by 
depletion of, among other redox molecules, glutathione and thioredoxin. An increase in 
ROS and a change in the Δψm are also seen before the T-cell loss.146  
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Thioredoxin has been linked to cancer in a variety of ways, and it is associated with 
several effects, such as decreased survival and aggressive tumor growth. Cancer cells can 
secrete Trx, and there have been reports of high levels of Trx in certain cancers, namely 
cervical, hepatoma, gastric, lung, and colorectal. In human leukemia cells and solid tumor 
lines, growth can be stimulated by Trx.81 
 
The redox state of Trx is important to its function, and as such, the role of Trx reductase 
(TrxR) is key. In both Trx and TrxR there are cysteine molecules that are key to redox 
regulation.133, 134 TrxRs are NADPH-dependent, and they catalyze disulfide reduction at 
thioredoxin active sites. In turn, reduced thioredoxins catalyze the movement of active 
site dithiols to a disulfide state. This process has given the thioredoxin family a crucial 
role in cell-growth and apoptosis, as it is through this process they can regulate enzymes 
such as ribonucleotide reductase, peroxiredoxins and transcription factors.147  
 
When exposed to oxidants or nitrosothiols, Trx quickly translocates to the nucleus,148 and 
acts in the control of transcription factors.149 A growing number of transcription factors, 
including NF-κB or Ref-1-dependent AP-1, are showing a need for thioredoxin reduction 
for DNA binding.139, 150 123 When Trx is overexpressed, NF-κB is downregulated and AP-
1 is upregulated and enhanced. Interestingly, while thioredoxin-induced NF-κBNF-κB 
inhibition is found in the cytoplasm, Trx can increase NF-κB binding to nuclear DNA.  
 
The TXNRD1 gene encodes for thioredoxin reductase 1, and transcription involves 
alternate splicing, and thus leads to several isoforms.151 The three TrxR enzymes that 
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have been identified in mammals are TrxR1, TrxR2, and TGR. TGR is expressed mostly 
in the testis, and TrxR2 is a mitochondrial form. TrxR1 (herein called TrxR) is the 
cytosolic enzyme, and, like Trx, is widely expressed.149, 152 TrxR belongs to the 
homodimeric pyridine nucleotide disulfide oxidoreductase class.152 It is a homodimeric 
selenocysteine-containing protein, and thus is dependent on selenium for its synthesis.149 
82 Selenium (selenite, 1uM) increases the mRNA levels of TrxR by two- to five-fold.149 
TrxR has the capability of metabolizing certain selenium compounds, and it is thought 
that through this process, TrxR can reduce the active site of plasma glutathione 
peroxidase, another selenoprotein.153 TrxR has been found to be elevated in several 
cancerous cell lines133, 149 including pancreatic, cervical, hepatocellular, and certain lung 
cancers,21 and repressed in cells that overexpress the p53 protein. Several studies have 
looked at the rise of TrxR in cancer cells.149  
 
Thioredoxin and thioredoxin reductase work together with NADPH to form a system 
that, through redox regulation, control processes such as DNA synthesis, transcriptional 
regulation, and cell growth. They also confer resistance to cytotoxic agents that produce 
oxidative stress and lead to apoptosis. While thioredoxin is a reducer of proteins that have 
oxidized cysteine residues, it also is susceptible to oxidation as it contains one cysteine in 
the thiolate form. The reaction of thioredoxin is described as follows: 
 RS- +H2O2→RSO- +H2O+H+ 
As is true with other cysteine-based proteins, thioredoxin can create a disulfide bond, 
either intramolecularly or with peroxiredoxin. This form of the protein then is not open 
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for interaction with other thiols or thiolates, and requires thioredoxin reductase to reduce 
its disulfide status. To do this, thioredoxin reductase works with NADPH as follows: 
   Trx reductase 
Trx(S2)+NADPH              →                Trx(SH)(S-)+NADP+   
In Trx and TrxR, the redox signal can change the cysteine sulfur molecule from –CH2—
SH to –CH2—S-. This “sulfhydryl switch” allows for changes in the enzymes’ activities. 
Once oxidative stress has occurred, the TrxR charges the sulfur atoms on the Trx, 
activating the Trx. And once activated, Trx can move from the cytoplasm to the nucleus 
where it activates Ref-1, which further activates transcription factors that can protect the 
cell from oxidative stress.133  
 
Thioredoxin reductase and glutathione reductase have similar homologies, and also have 
some overlap of function. Similarly, thioredoxin and glutaredoxin also have an overlap  
of function. Thioredoxins, however, are able to catalyze disulfide reduction much faster 
than GSH. 139 
 
Trx family and ROS: There are several published examples of Trx’s susceptibility to 
ROS. There is a variety of compounds that have been found to oxidize Trx, such as H2O2, 
superoxide,154 paraquat, rotenone,155 and 2-[(1-methylpropyl)dithio]-1H-imidazole (PX-
12).156 PX-12 (also called IV-2) not only oxidizes TrxR, but also irreversibly inhibits Trx 
protein function through cysteine residue oxidation.156 In human lens epithelial HLE B3 
cells, when H2O2 treatment was given, Trx expression increased.157 In keratinocytes, 
lymphoid, and HeLa cells, H2O2 exposure leads to an increase in Trx mRNA levels.158 
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When endothelial cells are exposed to low doses of ROS, (10 and 50 μM H2O2 and short-
term exposure to shear stress), significant increases in Trx mRNA and protein levels are 
seen. It follows, then, that there would also be a reduction in apoptosis induction, and 
when Trx expression is reduced and low doses of ROS administered, apoptosis is 
induced. Thus a portion of the anti-apoptotic nature of low-dose ROS in endothelial cells 
could be due to the increase in Trx expression.159  
 
It is thought that lung injury that occurs with bleomycin anticancer therapy is due in part 
to ROS. Trx, but not Cu/Zn-SOD, mnSOD, catalase, or glutathione peroxidase is strongly 
induced in the lungs of mice treated with bleomycin, suggesting that Trx may modify the 
reduction and oxidation state in bleomycin resistance, and perhaps may be protective 
against bleomycin-induced lung injury.160  
 
Trx scavenges ROS that has been created by diesel exhaust particles (DEP). While acute 
lung disease and an increase in inflammatory cells were seen in control mice, human Trx 
transgenic mice appeared to be protected from this injury. L929 cells that had been hTrx-
1 transfected and A549 cells pretreated with recombinant human Trx were utilized. A 
downregulation of the phosphorylation of Akt was shown, which led to apoptosis. This 
downregulation and subsequent cell death was prevented by treatment with Trx. It was 
also seen that when Akt was inhibited in the cells, the protective effect of Trx was 
canceled. These results show that Trx may play a protective role against DEP and 
subsequent lung damage via Akt regulation.161  
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It is thought that oxidative stress that is present in hyperhomocysteinemia is due to 
impaired Trx and subsequent increased ROS.162 Low-dose exposure to 5-aminolaevulinic 
acid-based photodynamic therapy (ALA-PDT, a treatment for superficial skin cancer) 
increases Trx expression and leads to cell growth, while high-dose exposure showed 
apoptosis with minimal Trx expression.163  
 
Trx acts as a cofactor for peroxiredoxins in their role as H2O2 scavengers. Trx and 
peroxiredoxin I are elevated in human lung tissues by hypoxia.140 MCF-7 cells that have 
been transfected with Trx also have an increase in the expression of Trx peroxidase-1, an 
H2O2 scavenger. This expression protects against H2O2-induced apoptosis, but not against 
apoptosis induced by anti-cancer drugs such as etoposide and doxorubicin.164 In a study 
of 89 non-small cell lung carcinomas, Trx and TrxR were found in all but 3 and 8 cases, 
respectively, and were both cytoplasmic and nuclear. When the expression of these 
proteins was nuclear, there was an inverse association with apoptosis. When the grade of 
the carcinoma was high, there was a decrease in Trx and TrxR expression.165 Thioredoxin 
peroxidase II (also known mitochondrial peroxiredoxin 3)166 can decrease H2O2 when 
overexpressed, and through this mechanism can inhibit apoptosis.139  
 
The dietary isothiocyanates sulforaphane, erucin, and iberin have been found to induce 
thioredoxin reductase in MCF-7 cells.167 In HepG2 and undifferentiated Caco-2 cells, not 
only does sulforaphane induce TrxR, but also its substrate Trx.168 Selenium 
supplementation increases TrxR activity in high risk prostate cancer patients,169 and 
mercury toxicity can lead to the selective inhibition of TrxR.170 
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Redox regulation of proteins by Trx: Trx family under- or over-expression has been 
related to a number of diseases and their effects, from airway remodeling,171 H. felis-
induced gastritis,172 Sjögren's syndrome,173 and angina174 to alopecia areata-based 
glucocorticoid resistance,80 decreased cystic fibrosis sputum,175, 176 and ischemia-
reperfusion injury prevention.177, 178 Trx is also both a biomarker and a therapeutic agent 
for cardiac disorders.179 It has been suggested that an increase in Trx in lung transplant 
patients can be a biomarker for organ rejection, as a significant increase in Trx was seen 
in bronchoalveolar lavage fluid of graft-rejecting patients in an 18-patient study.180 
Metastatic colorectal cancer liver resection patients whose metastases were Trx positive 
presented with shorter survival than those whose tumors were Trx negative.181 Trx 
inhibits the activity of PPARα, a transcription factor in the nuclear receptor family   
which is involved with lipid catabolism, and whose genes are targets of lipid lowering 
fibrate drugs.182 
 
The majority of studies performed on the thioredoxin family are on its role as an 
apoptosis inhibitor. This inhibition has been seen by Trx2 overexpression in SH-SY5Y 
human neuroblastoma,183 lung and other cells by overexpression of Trx.184 185 In mice, 
TrxR overexpression inhibits apoptotic signaling and gastric ulcer formation that occurs 
with the treatment of the non-steroidal anti-inflammatory drug indomethacin.186 For Trx 
to suppress apoptosis of cisplatin-treated breast cancer cells, it must be nuclear. In MCF-
7 cells, when total Trx was increased with no increase in nuclear Trx, there was no 
change in cisplatin-mediated apoptosis. There was, however, a decrease in cisplatin-
induced apoptosis when nuclear Trx was increased with no change in total Trx.187 
 37 
This propensity for inhibition has made TrxR a target of certain drugs. TrxR has been 
inhibited by auranofin to induce apoptosis in cisplatin-resistant C13* ovarian cancer 
cells,188 and by 1,2-[bis(1,2-benzisoselenazolone-3(2H)-ketone)] ethane and 
cyclophosphamide to induce apoptosis in several human cancer cell lines.189 190 Green tea 
extracts inhibit TrxR in HeLa cells, which also show a concentration-dependent decrease 
in cell viability.191 GRIM-12 has been identified as being identical to TrxR, and GRIM-
12 overexpression increases apoptosis that is interferon/tamoxifen induced. On the other 
hand, when GRIM-12 is underexpressed, there is a resistance to interferon/tamoxifen-
induced cell death and an increase in cell growth. Thus TrxR may play an important role 
in tamoxifen resistance.192 
 
Thioredoxin interactions with other proteins: Thioredoxin interacts with many 
different proteins and acts as both an inhibitor and a regulator. One MAP3K protein that 
is directly affected by Trx is apoptosis signal-regulating kinase 1 (ASK1).149 In its 
reduced form, thioredoxin is known to inhibit ASK1 through binding to the protein.193 
However, Trx becomes disassociated with ASK1 in the presence of ROS,193, 194 149, 195 
allowing ASK1 to activate the JNK/p38 pathway.140 196  
 
Under reduced conditions, Trx binds to the N-terminus of ASK1. However, upon 
oxidation it become dissociated from ASK1.197 Competition with Txnip can also interfere 
with Trx/ASK1 interactions.198 The importance of the Trx relationship with ASK1 can be 
seen with H2O2 exposure. This exposure leads to the oxidation of ASK1, which can be 
reversed by Trx.199 The loss of interaction ASK1 has with Trx upon Trx oxidation has 
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been studied in several diseases. Overexpression of Trx can reduce cigarette smoke-
stimulated apoptosis through the ASK1/JNK pathway.200 Oxidation of Trx may play a 
role in Alzheimer’s disease as amaloid beta causes Trx oxidation and the nuclear export 
of the ASK1 downstream protein Daxx.201 Oxidation of Trx2, and subsequent release of 
ASK1, by the anti-inflammatory drug troglitazone can lead to mitochondrial 
permeabilization.202 The Trx/ASK1 pathway is also used in therapy modes. For example, 
the chemotherapeutic cisplatin has mechanisms of action that include the activation of 
ASK1/p38 through decreasing TrxR activity and enhancing Akt activation.203 
Thioredoxin inhibiting protein (Txnip) is upregulated by ceramide, a tumor-suppressor 
lipid that is generated by cells under stress conditions, as well as by cancer cells exposed 
to genotoxic chemotherapy. This upregulation of Txnip can lead to an increase in 
Trx/Txnip interactions and a decrease in Trx/ASK1 interactions, freeing ASK1 to 
promote apoptosis.204 
  
Trx also has regulatory abilities with cytochrome 450s, hypoxia-inducible factor-1 (HIF-
1), and Nrf-2.150 In non-small cell lung cancer, Trx is a HIF-1α stabilizer,205 and in 
HT1080 cells the overexpression of Trx leads to the increase in HIF-1α when under 
hypoxic conditions.206 Silencing of Trx decreases HIF-1α, as well as vascular endothelial 
growth factor expression.206 On the other hand, HIF-1 accumulation is decreased by Trx2 
overexpression. Trx increases and Trx2 decreases cap-dependent translation, and HIF-1 
transactivation is stimulated by Trx, but decreased by Trx2. From this data, it has been 
suggested that thioredoxins may contribute to the synthesis of HIF-1α.207  
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Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that transcribes 
genes for antioxidants, xenobiotic detoxifiers, and other cytoprotective proteins.208 Nrf2 
is a transcription factor of thioredoxin that is activated in the cytoplasm by an oxidative 
signal.209 Nrf-2 increase in expression is correlated with an increase in Trx.210 Nrf2 may 
assist in the regulation of the entire Trx system, as cadmium-induced Nrf2 activation and 
binding to antioxidant response element in the TrxR gene promoter leads to TrxR gene 
expression.211 For Nrf2 to bind to the DNA it must be reduced at a critical cysteine,209 
and while Nrf2 translocation is regulated by glutathione, nuclear Trx regulates the 
antioxidant reporter element.212 An increase of Nrf2 in tamoxifen-resistant MCF-7 cells 
has been shown and may be due either to an enhancement in the stability in the protein 
with long-term exposure to tamoxifen, or to an increase in gene transcription. It has been 
suggested that the Nrf2/ARE-mediated increase in antioxidant proteins such as 
thioredoxin and peroxiredoxin 1 is involved in tamoxifen resistance.213 It does not appear 
to have been explored, however, if such an increase in Trx results in an increase in active 
Trx, as opposed to oxidized Trx, which could occur from the increase in ROS from 
tamoxifen treatment. 
 
Macrophage migration inhibitory factor (MIF) is now recognized as being part of the 
thioredoxin superfamily,214 and Trx is able to suppress MIF production. 215 It has been 
shown that as nuclear MIF increases, p27 levels decrease. It would seem to follow,    
then, if Trx were increased, MIF levels would decrease and allow p27 levels to increase. 
The association with Jab1 may also play a role in this as Jab1 is also known to interact 
with MIF.216  
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Thioredoxin inhibiting protein (Txnip) is also known as vitamin D3 up-regulated protein 
1 (VDUP1) and Trx-binding protein-2 (TBP-2).21 As mentioned earlier, Txnip is an 
antagonist of Trx, and various stressors, including ROS, regulate its expression.217 Txnip 
is often decreased in tumor cells and tissues. It negatively regulates Trx, and VDUP1 
(Txnip) -/- mice present with a higher susceptibility to carcinogenesis and defective 
immune system.218 Txnip forms a stable complex with reduced Trx that is disulfide 
linked.219 In the mouse uterus, estrogen treatment decreases Txnip expression and 
increases Trx, Trx2, and TrxR expression, as evidenced by mRNA levels. 220 Txnip is 
found at low levels in human cancers.21 An overexpression of Txnip leads to a decrease 
in Trx activity, as well as slow growth and apoptosis susceptibility.157 For example, 
colonic mucosa from ulcerative colitis and colorectal cancer specimens have significantly 
decreased Txnip levels as compared to normal tissue.221 
 
Txnip appears to be closely linked to hyperglycemia. Txnip-deficient mice that have been 
fed are metabolically similar to mice that have fasted. While the thioredoxin activity of 
the fed Txnip-deficient mice was similar to wild type, the deficient mice also presented 
with an increase in the NADH to NAD+ ratio.222 In beta cells, glucose increases 
expression of Txnip and apoptosis.223 High glucose levels also increase Txnip expression 
in renal proximal tubule cells (HK-2).224 In breast cancer cells, hyperglycemia affects 
Txnip levels, with tumorigenic cells expressing a low level and metastatic cells 
expressing a high level. Hyperglycemia was found to increase paclitaxel cytotoxicity, and 
this was also associated with Txnip expression.225 In MDA-MB-231 breast cancer cells, 
hyperglycemia increases Txnip RNA within 6 hours of exposure.226  
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When Txnip was explored for its metabolic effects in type 2 diabetes, patients with one 
particular variant, TXNIP-T, had both higher diastolic blood pressure (5.5 mmHg) and 
higher trigliceride concentrations (1.6 fold).227 In INS-1 insulinoma beta cells that 
overexpressed Txnip, 90 of 98 genes that were differentially expressed were 
downregulated. It is thought that Txnip is able to enhance beta-cell death and decrease 
insulin secretion through its modulation of genes that are involved with cell death, cell 
survival, and insulin secretion.228 
 
There are many proteins that interact with members of the Trx family. Table 1 explores 
many of these interacting proteins. From this table we can see the variety of ways in 
which thioredoxin family members may play a role in cell cycle progression, as well as  
how oxidation of thioredoxin can lead to a disruption in regular cell function. 
 
TABLE 1  Intracellular Trx family interactions 
Trx enhances AP-1 binding to DNA via Ref-1 (redox factor-1) 
Trx inhibits PPAR 
Trx inhibits  Apoptosis signal-regulating kinase (ASK) 1 
Trx1 suppresses MIF production 
Nuclear Trx regulates the antioxidant reporter element of Nrf2 
Nrf2 transcription factor may assist in the regulation of the Trx system 
Nrf-2 increase in expression is correlated with an increase in Trx 
Overexpression of Trx2 decreases HIF-1 accumulation 
Cyanidin elevates Trx expression 
H2O2 increases Trx expression 
H2O2 increases Trx mRNA 
UVA-irradiation increases intracellular levels of Trx 
Homocysteine upregulates Trx expression 
5-aminolaevulinic acid-based photodynamic therapy (ALA-PDT) increases Trx 
expression 
Sulforaphane induces Trx 
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Cancer cells secrete Trx 
Superoxide and H2O2 oxidize Trx 
Paraquat and Rotenone oxidize Trx 
2-[(1-methylpropyl)dithio]-1H-imidazole (PX-12) oxidizes Trx 
Trx is a HIF-1a stabilizer 
Overexpression of Trx leads to the increase in HIF-1a under hypoxic conditions 
Silencing of Trx decreases vascular endothelial growth factor expression. 
Selenium supplementation increases TrxR activity 
Sulforaphane, Erucin, Iberin induce TrxR 
1,2-[bis(1,2-benzisoselenazolone-3(2H)-ketone)] ethane (BBSKE) inhibits TrxR 
Auranofin inhibits TrxR 
Green tea extracts inhibit TrxR 
Cyclophosphamide inhibits TrxR 
Mercury toxicity leads to the selective inhibition of TrxR 
Estrogen increases Trx, Trx2, and TrxR expression 
Overexpression of thioredoxin peroxidase II decreases H2O2 
Txnip can interfere with Trx/ASK-1 interactions 
Txnip is an antagonist of Trx 
Estrogen decreases Txnip expression 
Histone deacetylase inhibitors upregulate Txnip 
Glucose increases expression of Txnip 
 
 
 
Background to a new paradigm for antiestrogen resistance 
Thioredoxin and cell cycle progression/arrest: As we look at the role thioredoxin may 
play in antiestrogen resistance, we briefly discuss how estrogen actions are controlled by 
redox regulation and other interacting proteins that can affect this change in a breast 
cancer cell’s sensitivity to AE treatment and AR resistance. 
 
Thioredoxin appears to play an important role in the redox state of the estrogen receptor. 
Using the breast cancer cell line ZR-75-1, researchers have shown that when cells were 
treated with H2O2, there was a decrease in the levels of pS2, a gene induced by estrogen. 
When, however, cells were transfected with thioredoxin, the expression of pS2 was 
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restored in the H2O2-treated cells.106 In a study regarding estrogen and congestive heart 
failure, subcutaneous slow release pellets of estrogen (0.5 mg/60 day release) offered 
antioxidative properties. These properties were also associated with an increase in the 
expression of Trx, TrxR, and TrxR activity. In this form, estrogen also reduced ASK-1 
activation, JNK activation, and p38 MAPK, which can all be related to the increase in 
availability of thioredoxin. These data may show that thioredoxin could be conferring the 
antioxidative properties that are being linked to estrogen.231 
 
In another example of Trx and estrogen interactions, 17β-estradiol normalizes 
thioredoxin reductase and glutathione reductase levels in rats that had been 
ovariectomized. As this was not also seen when 17α-estradiol, which is non-receptor 
binding, was administered, it has been suggested that glutathione and thioredoxin systems 
may be stimulated by estrogen through estrogen-receptor positivity.41 Endometrial 
stromal cells not only increase Trx secretions with estrogen treatment in a time-dependent 
manner, but this effect has been enhanced with an estrogen and progesterone combined 
treatment.144 In the interaction between estrogen and the thioredoxin system in mice, the 
main component of the thioredoxin system found affected by estrogen was thioredoxin-
interacting protein (Txnip). While Txnip mRNA levels rise in the initial treatment of 
mice with estrogen, after 2 hours both mRNA and protein amounts drop approximately 
20 per cent, followed by a rise in levels of the other members of the thioredoxin family 
by 2.5- to 4-fold over 24 hours. This reaction was prevented when the mice were treated 
with the estrogen antagonist ICI 182780, which suggests a role for the estrogen receptor 
in Txnip decrease upon estrogen treatment.220 Inhibition of TrxR reduces estrogen’s 
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cytoprotection against neurodegeneration.42 When this was explored in bovine aortic 
endothelial cells, it was found that 17β-estradiol increased the levels of thioredoxin, 
glutaredoxin, and thioredoxin reductase. When cells were treated with tamoxifen, it 
inhibited the induction of these three proteins.43 Estrogen metabolites 4-OH and 2-OH 
have been found to be mediated by p450 CYP1B1 and CYP1A1 respectively. CYP1B1 is 
induced by Trx in MCF-7 cells, and in MCF-7 cells that have been Trx-1 transfected, 
there is a decrease in ERα expression.232 
 
We have discussed the link between Trx family members and estrogen, and the role ROS 
plays in the inhibition of Trx actions. We will now discuss other proteins that play a role 
in our novel paradigm of tamoxifen resistance. 
 
p27: p27KIP1 is a 27 kD protein found in the nucleus, where it is active and inhibits 
cyclin-dependent kinases (cdks),233 most specifically by binding with the cyclin E/cdk2 
or cyclin A/cdk2 complexes.234, 235 p27KIP1 (herein called p27) belongs to the CIP/KIP 
(cdk inhibiting and kinase inhibiting proteins) family and suppresses the G1-to-S phase of 
the cell cycle233, 236 in G0 and early G1, where it inhibits cyclin E/cdk2 through binding to 
the cyclin E protein.235, 237 Highest concentrations of p27 can be found bound to the 
cyclin E/cdk2 complex during cell quiescence in normal epithelial cells.238 Cyclin E, 
when bound to the cyclin-dependent kinase cdk2, activates cdk2. If p27 is not available to 
inhibit this complex, the activated cdk2 phosphorylates the tumor suppressing 
retinoblastoma protein, which then disassociates from the E2F transcription factor, 
leading to the transcription of genes that allow progression into the S phase of the cell 
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cycle.235, 237 The phosphorylation of the retinoblastoma protein is necessary for the cell to 
move from the G1 to the S phase of the cell cycle, and both D-type and E-type cyclins 
can lead to this phosphorylation.239 Cyclins E, A, and D are involved with G1 
progression, and p27 can play a dual role when interacting with these cyclins. While 
unphosphorylated p27 inhibits cell cycle progression through cyclin E/cdk2 and cyclin 
A/cdk2 binding,237 properly phosphorylated p27 can assist in assembling cyclin D with 
cdk4 and cdk6, creating complexes that further G1 progression. Many cell lines require 
high levels of p27 to stay in quiescence, and thus the down regulation of p27 is necessary 
for cell cycle progression.240 There are several ways in which p27 can become 
inactivated, and thus lose its inhibitory action and promote cell cycle progression. 
Localization, phosphorylation, and proteolysis are three known factors affecting the 
activity state of p27. The location of p27 plays an important role in the inhibition of the 
cell cycle, because while it is inhibiting cell cycle progression it remains bound to the 
cyclin E/cdk2 complex in the nucleus. However, upon proper phosphorylation, it moves 
to the cytoplasm as the cell moves into G1, where it can either assemble cyclin D/cdk 
complexes or undergo proteolysis. p27 has been found in the cytoplasm in approximately 
40% of primary breast cancers, and this relocation of p27 can increase the de-
differentiation of tumors, and decrease the chances for survival.237 Phosphorylation of 
p27 can change the function of the protein. Several phosphorylation sites and their 
functions are currently known. Phosphorylation at threonine 157 can both impair the 
nuclear import of p27 and promote the assembly of cyclin D/cdk complexes.241 Through 
phosphorylation at threonine 198, p27 can help a cell survive through autophagy in 
cellular metabolic stress, and can also promote cyclin D/cdk assembly, with the addition 
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of tyrosine phosphorylation.242 When E2 binds to the ER, there is as activation of Src, 
which can lead to phosphorylation of p27 at tyrosines 74 and 88. This encourages 
phosphorylation at T187 as well as reduces the half-life of p27. Tamoxifen also interacts 
with Src, furthering the role of p27 in breast cancer inhibition. When Src is inhibited, the 
actions of tamoxifen are enhanced. This shows an important role for Src, and thus p27 
phosphorylation, in breast cancer cell survival.243 
 
The phosphorylation of p27 at tyrosines 74, 88, and 89 can also reduce p27’s affinity for 
cdk2.238 Cyclin E-cdk2 can phosphorylate p27 at threonine 187, an action that can lead to 
the marking of p27 to be recognized by its ligase (SCF-type E3), which further leads to 
the ubiquitylation of p27 and its 26S proteasome-related degradation.235, 244 Serine 10 
phosphorylation is necessary for p27 to be transported out of the nucleus,237 and in this 
way assists with ubiquitination (and subsequent proteolysis) of p27 in late G1. In many 
human cancers, activation of p27 proteolysis appears excessive, with it being seen 
approximately 41-69% in breast cancer.237  
 
Approximately 60% of primary human breast cancer and other cancers express a reduced 
amount of p27 and are associated with poor patient outcome.244 Loss of p27 is also 
correlated with tumor grade increase.245 Low concentrations of p27 have been found to be 
associated with a 3.4-fold increased risk of death (p=0.0306), and an increase of risk of 
relapse of 2.7-fold (p=0.01). Other studies have shown a decrease in overall survival 
when there is a low p27 concentration and high cyclin E content (RR=2.7, p=0.01).246 
Reduced levels of p27 are a poor prognostic factor in several other carcinomas as well, 
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including colon, lung, prostate, esophageal, and gastric carcinomas,247 and oral dysplasias 
and carcinomas.248 
 
A key to p27 ubiquination is its nuclear export to the cytoplasm. This can be influenced 
by p27 binding to CRM1.249 It has been implied that Jab1 may be a bridging protein 
between p27 and CRM-1, as treatment of NIH3T3 cells with leptomycin B (a specific 
CRM-1 nuclear export inhibitor) decreased p27 nuclear export by Jab1.250 It also has 
been shown, however, that CRM-1 binds to p27 at its cdk2 binding site to export it from 
the nucleus.251 We next explore Jab1 as part of our paradigm for tamoxifen resistance. 
 
Jab1: Jab1 (Jun activation domain-binding protein 1) is a ~40 kD protein that was named 
for its interaction with c-Jun at its activation domain. Jab1 is the 5th subunit in the COP9 
signalosome, and is also known as CSN5.252 The COP9 signalosome is a known co-
activator of the AP-1 transcription factor,123 and Jab1 is known to interact with at least 4 
other subunits in the COP9 complex; CSNs 1, 2, 4, and 7.253 Jab1 stabilizes c-Jun or JunD 
complexes at their AP-1 binding sites, which allows the specificity of the target gene 
activation to be increased. When Jab1 interacts with the c-Jun protein, it enhances the 
binding power of AP-1 complexes that contain c-Jun. This increases AP-1-dependent 
transcription, which then leads to cell proliferation.123, 252 Nuclear receptor transcriptional 
transactivation can be modulated by Jab1, as can be seen with progesterone receptors. 
The addition of Jab1 can enhance the capability of the progesterone receptor to perform 
hormone-dependent transactivation. This enhancing ability has also been shown with 
glucocorticoid, mineralocorticoid, androgenic and estrogenic receptors, and NF-κB.254 
 48 
Nuclear receptor binding protein (NRBP) may be a negative regulator of Jab1-mediated 
functions, as phosphorylation of c-Jun and AP-1 activation is inhibited by the addition of 
NRBP, and thus may inhibit tumor progression.255  
 
There is a difference in action between the smaller Jab1 complex and the larger COP9 
complex. Researchers note that a loss of anchorage leads to the downregulation of the 
smaller Jab1 complex, that when p27 is downregulated the smaller Jab1 complex was 
upregulated, and that throughout the cell cycle the small Jab1 complex moves between 
the monomeric state and the COP9 signalosome.216  
 
One of the significant common themes with Jab1 is its numerous interactions with multi-
protein complexes that appear to be connected to ubiquitin-dependent protein degradation 
pathways.253 Jab1 interaction with p27 is a good example of this. It has been suggested 
that Jab1 can lead to cell proliferation through the translocation of p27 from the nucleus 
to cytoplasm and accelerating p27 degradation through the ubiquitin/proteosome 
pathway.256 Jab1 has been negatively associated with p27 expression in a variety of 
cancer cells. The expression of both Jab1 and p27 in breast carcinomas in regards to 
clinical outcomes has been explored, and it has been found that in 60% of the carcinomas 
studied there is a reduced or depleted existence of p27. Researchers also looked at the 
possibility of using this information in a prognostic way, and saw that those patients with 
tumors that were Jab1-negative did not relapse or show signs of disease progress.257 
Translocation of p27 can occur due to mitogenic stimuli,233 and Jab1 has been implicated 
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as a major cause for the translocation of p27 from the nucleus to the cytoplasm. When 
p27 and Jab1 are cotransfected, there is acceleration in p27 proteolysis.249 
 
Vitamin D3 upregulated protein 1 (Txnip) is also a Jab1 inhibitor that blocks the ability of 
Jab1 to move p27 from the nucleus to the cytoplasm, as well as blocking its co-activation 
of AP-1.258 The proteolysis of p27 is thought to be mediated by not just Jab1, but by the 
COP9 signalosome as well. There are at least three other parts of COP9 (namely CSN6, 
CSN7, and CSN8) which also can lead to the downregulation of p27 when they are 
expressed ectopically. 259 
 
In a study of levels of p27 in benign and malignant lesions in 94 randomly selected cases 
at the University of Texas MD Anderson Cancer Center, fourteen out of seventeen 
standard nevi cases showed a strong expression of p27 in over 75% of the cells. Out of 22 
melanoma cases, only 3 showed expression of p27. And out of 30 cases of metastatic 
melanoma, only 4 were p27 positive. The expression of Jab1 in these same samples was 
also investigated. Jab1 was expressed in 14 out of 17 cases of standard nevi, and in 18 out 
of 19 dysplastic nevi, with 11 of those strongly Jab1-positive. While only few of the 
primary melanoma cases were p27 positive, approximately 77% of them were Jab1 
positive. Metastatic melanomas were Jab1 positive in 53% of the cases. This pattern was 
seen across different histologic types of melanoma. 233 This theme of high Jab1 and low 
p27 in cancer is seen in several studies.257, 260-262 In breast cancer, there is an increase in 
Jab1 in adjacent normal cells as compared to normal breast cancer cells.263 Interestingly, 
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there is initial evidence that cytoplasmic p27 is present in invasive tumors, yet not in non-
invasive tumors, presenting the possibility of a role for cytoplasmic p27 in metastasis.264  
 
It has been shown that Jab1 and ERα interact (either directly or indirectly) through a 
finding that Jab1 comimmunoprecipitates with ERα. Also, an increase in Jab1 levels is 
associated with hormone-induced ERα degradation. Curcumin, which inhibits CSN-
associated kinase activity and prevents the degradation of ERα, increases the amount of 
coimmunoprecipitated Jab1 and ERα, as well as blocked ERα phosphorylations and 
degradations that are ligand dependent.265  
 
It has been presented that Jab1 location is well regulated within the cell, and is present 
mostly in the nucleus, though there are small amounts in the cytoplasm. The Jab1 signal 
is also very strong in adult tissues that are terminally differentiated.266  
 
Thioredoxin and its proposed role in antiestrogen resistance: With the oxidation that 
is produced by both estrogen and tamoxifen, the redox nature of proteins cannot be 
ignored as a possible player in tamoxifen resistance. Tamoxifen-resistant breast cancer 
tumors show decreased glutathione levels, and it is suggested that the increase in 
tamoxifen-induced oxidative stress and decreased glutathione levels activate JNK and 
increase AP-1 actions, leading to growth in the presence of tamoxifen.68 As mentioned 
earlier, tamoxifen inhibits estrogen-induced thioredoxin, glutaredoxin, and thioredoxin 
reductase.43 Also, when cells proliferate in a manner that forms cellular masses, cells are 
deprived of oxygen and nutrients, which leads to cellular adaptations that allow the 
 51 
cancer cell to survive (i.e. the suppression of apoptosis).267 Trx reductase has a variant, 
labeled TrxR1b, which is thought to influence the assembly of estrogen receptor 
coactivator complex. As such, it may modulate estrogen signaling.268 When doxorubicin-
resistant small cell carcinoma lung cells are treated with selenium, the result is caspase-3-
independent apoptosis. While TrxR levels and activity increases with this treatment, the 
amount of truncated Trx does not change.269 These cancer studies on Trx do not observe 
the oxidative state of the Trx that is being measured, and results such as these could be 
due to TrxR reducing Trx and restoring its activity.  
 
As mentioned earlier, most studies on Trx and resistance focus on Trx’s anti-apoptotic 
role. Response to docetaxel, a potent anti-cancer drug used with breast cancer patients, 
has been linked to thioredoxin. In a study on Docetaxel and the gene expression that may 
predict resistance to the drug, thioredoxin was one of several proteins that, when 
overexpressed, meant there was a good chance the person would not respond to the 
anticancer drug.270 Trx expression is correlated with platinum-based drug resistance.271 
High levels of thioredoxin have been associated with resistance to cis-
diamminedichloroplatinum (II) (cisplatin), mitomycin C, doxorubicin, and etoposide. To 
test this association with docetaxel, thioredoxin expression was related to its reaction to 
estrogen receptor positivity. It was found that patients with ER negative tumors low in 
thioredoxin showed the highest response to docetaxel treatment (42.3%) and the lowest 
response (0%) was in patients who had high thioredoxin levels and were estrogen 
receptor positive. When patients were treated with thioredoxin prior to docetaxel therapy, 
thioredoxin levels rose upon treatment with the drug. While levels of thioredoxin 
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increased equally across cell samples, it was noted that it was the high level of 
thioredoxin present before docetaxel treatment that confers resistance, not the increase at 
the time of treatment.272 It is thought that thioredoxin may contribute to other anti-cancer 
drug resistances. When a thioredoxin antisense plasmid was transfected into cisplatin-
resistant T-cell leukemia cells, sensitivity to cisplatin, as well as several other anticancer 
drugs, was restored.21 When selenium treatment was added to doxorubicin-resistant cells, 
caspase-3-independent apoptosis occurred. There was also an increase in TrxR protein 
levels and activity, and truncated Trx increased.  
 
While these studies show the role of Trx as an agonist for chemotherapeutic drug 
resistance, we suggest that the role Trx plays in other protein actions (outside of reducing 
the effects of ROS) is affected by the overoxidation of Trx and can play a role in 
antiestrogen resistance (see Figure 4-LR). We suggest that the oxidative state of cells 
treated with antiestrogens will add a constant state of oxidative stress, and will create an 
adaptation in the cellular mechanism that leads to resistance to antiestrogens, namely 
through an oxidation of thioredoxin.  
 
Jab1 and a possible interaction with thioredoxin: When hepatopoietin (HPO) loses its 
sulfhydryl oxidase abilities at its cysteine residues, it is no longer able to affect AP-1 
activation due to its lack of ability to interact with Jab1. This does not affect HPOs ability 
to promote growth via the MAPK pathway.273 However, this suggests that the sulfhydryl 
ability of an interacting protein will affect its interaction with Jab1, as may be the case 
with thioredoxin. Trx has been found to compete with p27 for binding with Jab1 in 
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HEK293T (human embryonic kidney) cells, and through this, negatively regulate p27 
degradation. The possibility that Trx could affect Jab1/p27 binding in these cells was 
explored, and it was found that the addition of Trx to cells altered the direction of Jab1-
induced p27 level decrease. It was also found that the addition of Trx did not increase 
levels of p27 when Jab1 was not overexpressed. This led to a hypothesis that Trx 
competes with p27 for binding with Jab1. The researchers showed that Trx specifically 
interacts with the C-terminal of Jab1, while p27 is known to interact with the N-terminal. 
The hypothesis was that when Trx binds with Jab1, it produces a conformational change 
that inhibits the binding affinity for p27. This decrease in binding affinity could then 
allow p27 to continue to bind to the cyclin E/cdk2 complex, and inhibit cell proliferation. 
Another Jab1 effect that was inhibited by Trx binding was AP-1 activation. When Jab1 
levels were increased, Trx was found to decrease AP-1 activity. Increased Jab1 levels 
have been found in certain cancers of the pituitary, ovary and breast and in certain 
lymphomas. Because of the increased Jab1 expression in these tumors, Trx could play an 
important role in decreasing AP-1 activity, but also in keeping Jab1 from removing p27 
from the nucleus.123 Figure 5-LR shows this interaction and a possible role for Trx in 
keeping Jab1 from moving p27 out of the nucleus. The possible oxidation and 
inactivation of Trx through tamoxifen treatment can lead to an increase in p27 removal 
from the nucleus by Jab1. 
 
PTPs and thioredoxin: Particularly susceptible to oxidation are protein tyrosine 
phosphatases (PTPs), including PTEN, PTP1B, cdc25, and low molecular weight PTP.87, 
116 Several PTPs have been show to correlate with p27 levels. A downstream molecule in 
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the phosphoinositol 3’ kinase (PI3K) pathway, protein kinase B (Akt), can phosphorylate 
p27 at T157 and inhibit its import to the nucleus. This prohibits p27 from inhibiting cell 
proliferation.274 When the PI3K pathway has been activated, as it is in human cancers, it 
has been found that p27 concentrations decrease. This effect is reversed by the PI3K 
inhibitor LY294002, a “kinase-dead” PKB/Akt, or the PI3K phosphatase PTEN. When 
PI3K activation is opposed by PTEN in specific cell lines, p27 concentrations increase. It 
has been suggested that PTEN may work in this way through repressing SKP-2, a 
component of the SCFSKP2 ubiquitin ligase.237 Overexpression of the PTEN gene 
increases p27 levels, decreases cyclin D1 levels, inhibits the phosphorylation of Akt, and 
through these mechanisms inhibits cell growth in MCF-7 cells.275 In human mammary 
epithelial cells (HMEC), activation of the PI3K pathway is necessary for the cell to move 
from G1 to S because of its activation of the cyclin E/cdk2 complex.240 The CDC25A 
PTP has been linked to cdk2. CDC25 is a dual specificity PTP that dephosphorylates 
cyclin E-cdk2 inhibitory phosphorylation sites. In this way, CDC25A controls S phase 
entry and progression. PTP1B has been associated with the Src family kinases, as well as 
with other pathways.276, 277 Src has two phosphorylation sites that can be affected by 
phosphatases. While one is an inhibiting site, the other is an activation site that is 
autophosphorylated. PTP-BL dephosphorylates Src at this activation site, keeping Src 
inactivated.278 Src binding to PTP1B is proline residue dependent.279 When PTP1B is 
downregulated, a decrease in ERK1/2 phosphorylation has been shown, as well as a 
dephosphorylation of Src at the inactivation site.277 When HEK293 cells are transfected 
with both Src and TRPV6, a cation channel, the tyrosine phosphorylation that Src 
imposed on TRPV6 is dephosphorylated by PTP1B.280 
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These same PTPs are also reduced by Trx. PTEN can be oxidized by H2O2, and then 
reduced by Trx.281 CDC25 PTPs are known to react directly with ROS due to their 
catalytic cysteine residue. This reaction causes an inactivation in the CDC25 enzyme 
through creating a disulphide that can be reversed by thioredoxin.282 283 While no data is 
available for the actions Trx may have on PTP-BL, it is known that PTP-BL contains two 
cysteine residues that appear to regulate binding, and that this binding capacity is lost 
when a reducing treatment is added.284 PTP1B has been linked with thioredoxin through a 
murine study using selenium supplementation. Rats that were fed 75 or 150 μg of 
selenium/kg showed an increase in thioredoxin reductase, as well as other selenoproteins, 
and a decrease in PTP1B glutathionylation (which inhibits PTP activity).285  
 
It is possible that the oxidation of PTPs via the oxidative stress of tamoxifen treatment 
can play an important role in tamoxifen resistance through lack of interaction with 
kinases that phosphorylate p27. In the suggested case of an increase oxidized state in the 
cell by chronic tamoxifen treatment, oxidized Trx is unable to reduce p27-affecting PTPs, 
which could play a role in the continued growth of cancer cells in the presence of 
tamoxifen treatment. 
 
6. Summary 
The mechanisms of antiestrogen resistance are complex. Here we have presented the data 
involving Trx and show different ways Trx may have a role in antiestrogen resistance in 
breast cancer. As cells are chronically exposed to ROS from long-term tamoxifen 
treatment, they can adapt to this increasing level of ROS and oxidative stress. This can 
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lead to oxidation of certain cellular antioxidant systems, such as thioredoxin, causing 
them to become inactive. The inactivation of the thioredoxin antioxidant family can then 
affect other proteins such as PTPs or Jab1, or lead to the continued activation of cell 
signaling pathways such as MAPKs, leading to the activation of transcription factors such 
as AP-1 or NF-κB and subsequent cell proliferation. It is in this way that we propose that 
ROS and the thioredoxin family may play a role in tamoxifen resistance. 
 
Acknowledgments 
The Department of the Defense BCRP-funded project W81XWH-07-1-0417, BC060125, 
provided funding for this research. 
 
Reference List 
 (1)  Gadducci A, Biglia N, Sismondi P, Genazzani AR. Breast cancer and sex steroids: 
critical review of epidemiological, experimental and clinical investigations on 
etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. 
Gynecol Endocrinol 2005;20(6):343-360. 
 (2)  Clarke R, Liu MC, Bouker KB et al. Antiestrogen resistance in breast cancer and 
the role of estrogen receptor signaling. Oncogene 2003;22(47):7316-7339. 
 (3)  Kallio A, Zheng A, Dahllund J, Heiskanen KM, Harkonen P. Role of 
mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. 
Apoptosis 2005;10(6):1395-1410. 
 (4)  IARC. Monographs on the evaluation of the carcinogenic risk of chemicals to 
human.  1979. Report No.: 21. 
 (5)  IARC. Monographs on the evaluation of hormonal contraception and 
postmenopausal hormonal therapy.  1999. Report No.: 48. 
 57 
 (6)  Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer: the 
Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 
1988;48(2):246-253. 
 (7)  Roy D, Palangat M, Chen CW et al. Biochemical and molecular changes at the 
cellular level in response to exposure to environmental estrogen-like chemicals. J 
Toxicol Environ Health 1997;50(1):1-29. 
 (8)  Roy D, Colerangle JB, Singh KP. Is exposure to environmental or industrial 
endocrine disrupting estrogen-like chemicals able to cause genomic instability? 
Front Biosci 1998;3:d913-d921. 
 (9)  Roy D, Cai Q, Felty Q, Narayan S. Estrogen-induced generation of reactive 
oxygen and nitrogen species, gene damage, and estrogen-dependent cancers. J 
Toxicol Environ Health B Crit Rev 2007;10(4):235-257. 
 (10)  National Toxicology Program. Federal report on carcinogens.  2002. Report No.: 
67 (242). 
 (11)  Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 
2001;344(4):276-285. 
 (12)  Roy D, Singh KP. Estrogen-induced genetic alterations and breast, endometrial, 
testicular and prostate cancers. Current Genomics 2004;5:245-257. 
 (13)  IARC. Monographs on the evaluation of combined estrogen-progestogen 
contraceptives and menopausal therapy.  2005. Report No.: 91. 
 (14)  Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 
2006;354(3):270-282. 
 (15)  Anderson H, Bulun S, Smith I, Dowsett M. Predictors of response to aromatase 
inhibitors. J Steroid Biochem Mol Biol 2007;106(1-5):49-54. 
 (16)  Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting 
highlights: international expert consensus on the primary therapy of early breast 
cancer 2005. Ann Oncol 2005;16(10):1569-1583. 
 (17)  Ma CX, Sanchez CG, Ellis MJ. Predicting endocrine therapy responsiveness in 
breast cancer. Oncology (Williston Park) 2009;23(2):133-142. 
 (18)  Arteaga E, Villaseca P, Bianchi M, Rojas A, Marshall G. Raloxifene is a better 
antioxidant of low-density lipoprotein than estradiol or tamoxifen in 
postmenopausal women in vitro. Menopause 2003;10(2):142-146. 
 58 
 (19)  Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor 
and growth factor receptor pathways as a cause for endocrine therapy resistance in 
breast cancer. Clin Cancer Res 2005;11(2 Pt 2):865s-870s. 
 (20)  Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast 
Cancer Res Treat 2007;105 Suppl 1:33-43. 
 (21)  Marks PA. Thioredoxin in cancer--role of histone deacetylase inhibitors. Semin 
Cancer Biol 2006;16(6):436-443. 
 (22)  Yokomizo A, Ono M, Nanri H et al. Cellular levels of thioredoxin associated with 
drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer 
Res 1995;55(19):4293-4296. 
 (23)  Coleman KM, Smith CL. Intracellular signaling pathways: nongenomic actions of 
estrogens and ligand-independent activation of estrogen receptors. Front Biosci 
2001;6:D1379-D1391. 
 (24)  Jakacka M, Ito M, Weiss J, Chien PY, Gehm BD, Jameson JL. Estrogen receptor 
binding to DNA is not required for its activity through the nonclassical AP1 
pathway. J Biol Chem 2001;276(17):13615-13621. 
 (25)  Felty Q, Roy D. Estrogen, mitochondria, and growth of cancer and non-cancer 
cells. J Carcinog 2005;4(1):1. 
 (26)  Normanno N, Di MM, De ME et al. Mechanisms of endocrine resistance and 
novel therapeutic strategies in breast cancer. Endocr Relat Cancer 
2005;12(4):721-747. 
 (27)  Roy D, Felty Q, Narayan S, Jayakar P. Signature of mitochondria of steroidal 
hormones-dependent normal and cancer cells: potential molecular targets for 
cancer therapy. Front Biosci 2007;12:154-173. 
 (28)  Roy D, Felty Q, Narayan S, Jayakar P. Signature of mitochondria of steroidal 
hormones-dependent normal and cancer cells: potential molecular targets for 
cancer therapy. Front Biosci 2007;12:154-173. 
 (29)  Felty Q, Roy D. Estrogen, mitochondria, and growth of cancer and non-cancer 
cells. J Carcinog 2005;4(1):1. 
 (30)  Obrero M, Yu DV, Shapiro DJ. Estrogen receptor-dependent and estrogen 
receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced 
programmed cell death. J Biol Chem 2002;277(47):45695-45703. 
 59 
 (31)  Roy D, Liehr JG. Estrogen, DNA damage and mutations. Mutat Res 1999;424(1-
2):107-115. 
 (32)  Felty Q, Xiong WC, Sun D et al. Estrogen-induced mitochondrial reactive oxygen 
species as signal-transducing messengers. Biochemistry 2005;44(18):6900-6909. 
 (33)  Parkash J, Felty Q, Roy D. Estrogen exerts a spatial and temporal influence on 
reactive oxygen species generation that precedes calcium uptake in high-capacity 
mitochondria: implications for rapid nongenomic signaling of cell growth. 
Biochemistry 2006;45(9):2872-2881. 
 (34)  Rajapakse N, Butterworth M, Kortenkamp A. Detection of DNA strand breaks 
and oxidized DNA bases at the single-cell level resulting from exposure to 
estradiol and hydroxylated metabolites. Environ Mol Mutagen 2005;45(4):397-
404. 
 (35)  Felty Q, Singh KP, Roy D. Estrogen-induced G1/S transition of G0-arrested 
estrogen-dependent breast cancer cells is regulated by mitochondrial oxidant 
signaling. Oncogene 2005;24(31):4883-4893. 
 (36)  Abplanalp W, Scheiber MD, Moon K, Kessel B, Liu JH, Subbiah MT. Evidence 
for the role of high density lipoproteins in mediating the antioxidant effect of 
estrogens. Eur J Endocrinol 2000;142(1):79-83. 
 (37)  Cheng X, Shimizu I, Yuan Y et al. Effects of estradiol and progesterone on tumor 
necrosis factor alpha-induced apoptosis in human hepatoma HuH-7 cells. Life Sci 
2006;79(21):1988-1994. 
 (38)  Roy D, Weisz J, Liehr JG. The O-methylation of 4-hydroxyestradiol is inhibited 
by 2-hydroxyestradiol: implications for estrogen-induced carcinogenesis. 
Carcinogenesis 1990;11(3):459-462. 
 (39)  Szent-Gyorgyi A. Charge transfer and electronic mobility. Proc Natl Acad Sci U S 
A 1967;58(5):2012-2014. 
 (40)  Sunyer T, Lewis J, Collin-Osdoby P, Osdoby P. Estrogen's bone-protective 
effects may involve differential IL-1 receptor regulation in human osteoclast-like 
cells. J Clin Invest 1999;103(10):1409-1418. 
 (41)  Lean JM, Davies JT, Fuller K et al. A crucial role for thiol antioxidants in 
estrogen-deficiency bone loss. J Clin Invest 2003;112(6):915-923. 
 (42)  Lee SY, Andoh T, Murphy DL, Chiueh CC. 17beta-estradiol activates ICI 
182,780-sensitive estrogen receptors and cyclic GMP-dependent thioredoxin 
expression for neuroprotection. FASEB J 2003;17(8):947-948. 
 60 
 (43)  Ejima K, Nanri H, Araki M, Uchida K, Kashimura M, Ikeda M. 17beta-estradiol 
induces protein thiol/disulfide oxidoreductases and protects cultured bovine aortic 
endothelial cells from oxidative stress. Eur J Endocrinol 1999;140(6):608-613. 
 (44)  Kato S. Function of estrogen receptor (ER) in gene expression. Jpn J Clin Oncol 
1999;29(7):321-322. 
 (45)  Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB. Thoughts on 
tamoxifen resistant breast cancer. Are coregulators the answer or just a red 
herring? J Steroid Biochem Mol Biol 2000;74(5):255-259. 
 (46)  Custodio JB, Moreno AJ, Wallace KB. Tamoxifen inhibits induction of the 
mitochondrial permeability transition by Ca2+ and inorganic phosphate. Toxicol 
Appl Pharmacol 1998;152(1):10-17. 
 (47)  Kuohung W, Shwaery GT, Keaney JF, Jr. Tamoxifen, esterified estradiol, and 
physiologic concentrations of estradiol inhibit oxidation of low-density 
lipoprotein by endothelial cells. Am J Obstet Gynecol 2001;184(6):1060-1063. 
 (48)  Ek RO, Yildiz Y, Cecen S, Yenisey C, Kavak T. Effects of tamoxifen on 
myocardial ischemia-reperfusion injury model in ovariectomized rats. Mol Cell 
Biochem 2008;308(1-2):227-235. 
 (49)  Wakade C, Khan MM, De Sevilla LM, Zhang QG, Mahesh VB, Brann DW. 
Tamoxifen neuroprotection in cerebral ischemia involves attenuation of kinase 
activation and superoxide production and potentiation of mitochondrial 
superoxide dismutase. Endocrinology 2008;149(1):367-379. 
 (50)  Jain S, Saxena D, Kumar PG, Koide SS, Laloraya M. Effect of estradiol and 
selected antiestrogens on pro- and antioxidant pathways in mammalian uterus. 
Contraception 1999;60(2):111-118. 
 (51)  Leguene C, Clavere P, Jore D, Gardes-Albert M. [Radiolytic oxidation of 
tamoxifen with the free radicals OH- and/or HO2-]. Can J Physiol Pharmacol 
2001;79(2):184-188. 
 (52)  Kallio A, Zheng A, Dahllund J, Heiskanen KM, Harkonen P. Role of 
mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. 
Apoptosis 2005;10(6):1395-1410. 
 (53)  Tabassum H, Parvez S, Rehman H, Banerjee BD, Raisuddin S. Catechin as an 
antioxidant in liver mitochondrial toxicity: Inhibition of tamoxifen-induced 
protein oxidation and lipid peroxidation. J Biochem Mol Toxicol 2007;21(3):110-
117. 
 61 
 (54)  Dietze EC, Caldwell LE, Grupin SL, Mancini M, Seewaldt VL. Tamoxifen but 
not 4-hydroxytamoxifen initiates apoptosis in p53(-) normal human mammary 
epithelial cells by inducing mitochondrial depolarization. J Biol Chem 
2001;276(7):5384-5394. 
 (55)  Nazarewicz RR, Zenebe WJ, Parihar A et al. Tamoxifen induces oxidative stress 
and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase. 
Cancer Res 2007;67(3):1282-1290. 
 (56)  Kushnareva Y, Murphy AN, Andreyev A. Complex I-mediated reactive oxygen 
species generation: modulation by cytochrome c and NAD(P)+ oxidation-
reduction state. Biochem J 2002;368(Pt 2):545-553. 
 (57)  Lee YS, Kang YS, Lee SH, Kim JA. Role of NAD(P)H oxidase in the tamoxifen-
induced generation of reactive oxygen species and apoptosis in HepG2 human 
hepatoblastoma cells. Cell Death Differ 2000;7(10):925-932. 
 (58)  Wlassoff WA, Albright CD, Sivashinski MS, Ivanova A, Appelbaum JG, 
Salganik RI. Hydrogen peroxide overproduced in breast cancer cells can serve as 
an anticancer prodrug generating apoptosis-stimulating hydroxyl radicals under 
the effect of tamoxifen-ferrocene conjugate. J Pharm Pharmacol 
2007;59(11):1549-1553. 
 (59)  Rey JR, Cervino EV, Rentero ML, Crespo EC, Alvaro AO, Casillas M. 
Raloxifene: mechanism of action, effects on bone tissue, and applicability in 
clinical traumatology practice. Open Orthop J 2009;3:14-21. 
 (60)  Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor 
antagonist with a novel mechanism of action. Br J Cancer 2004;90 Suppl 1:S2-
S6. 
 (61)  Dowers TS, Qin ZH, Thatcher GR, Bolton JL. Bioactivation of Selective Estrogen 
Receptor Modulators (SERMs). Chem Res Toxicol 2006;19(9):1125-1137. 
 (62)  Qin Z, Kastrati I, Ashgodom RT et al. Structural modulation of oxidative 
metabolism in design of improved benzothiophene selective estrogen receptor 
modulators. Drug Metab Dispos 2009;37(1):161-169. 
 (63)  Bajetta E, Zilembo N, Bichisao E. Aromatase inhibitors in the treatment of 
postmenopausal breast cancer. Drugs Aging 1999;15(4):271-283. 
 (64)  Choueiri TK, Alemany CA, bou-Jawde RM, Budd GT. Role of aromatase 
inhibitors in the treatment of breast cancer. Clin Ther 2004;26(8):1199-1214. 
 62 
 (65)  Ye Q, Bodell WJ. Production of 8-hydroxy-2'-deoxguanosine in DNA by 
microsomal activation of tamoxifen and 4-hydroxytamoxifen. Carcinogenesis 
1996;17(8):1747-1750. 
 (66)  Okubo T, Nagai F, Ushiyama K et al. DNA cleavage and 8-
hydroxydeoxyguanosine formation caused by tamoxifen derivatives in vitro. 
Cancer Lett 1998;122(1-2):9-15. 
 (67)  Montano MM, Katzenellenbogen BS. The quinone reductase gene: a unique 
estrogen receptor-regulated gene that is activated by antiestrogens. Proc Natl 
Acad Sci U S A 1997;94(6):2581-2586. 
 (68)  Schiff R, Reddy P, Ahotupa M et al. Oxidative stress and AP-1 activity in 
tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst 2000;92(23):1926-
1934. 
 (69)  Clarke R, Liu MC, Bouker KB et al. Antiestrogen resistance in breast cancer and 
the role of estrogen receptor signaling. Oncogene 2003;22(47):7316-7339. 
 (70)  Dowsett M, Johnston S, Martin LA et al. Growth factor signalling and response to 
endocrine therapy: the Royal Marsden Experience. Endocr Relat Cancer 2005;12 
Suppl 1:S113-S117. 
 (71)  Normanno N, Di MM, De ME et al. Mechanisms of endocrine resistance and 
novel therapeutic strategies in breast cancer. Endocr Relat Cancer 
2005;12(4):721-747. 
 (72)  Miller WR. Identification and mechanisms of endocrine resistance. Breast Cancer 
Res 2008;10 Suppl 4:S19. 
 (73)  Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular 
pharmacology of antiestrogen action and resistance. Pharmacol Rev 
2001;53(1):25-71. 
 (74)  Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in 
breast cancer. Nat Rev Cancer 2009;9(9):631-643. 
 (75)  Kurebayashi J, Okubo S, Yamamoto Y, Sonoo H. Inhibition of HER1 signaling 
pathway enhances antitumor effect of endocrine therapy in breast cancer. Breast 
Cancer 2004;11(1):38-41. 
 (76)  Chu I, Blackwell K, Chen S, Slingerland J. The dual ErbB1/ErbB2 inhibitor, 
lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell 
proliferation- and estrogen-dependent gene expression in antiestrogen-resistant 
breast cancer. Cancer Res 2005;65(1):18-25. 
 63 
 (77)  Nicholson RI, Hutcheson IR, Knowlden JM et al. Nonendocrine pathways and 
endocrine resistance: observations with antiestrogens and signal transduction 
inhibitors in combination. Clin Cancer Res 2004;10(1 Pt 2):346S-354S. 
 (78)  Cui Y, Parra I, Zhang M et al. Elevated expression of mitogen-activated protein 
kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. 
Cancer Res 2006;66(11):5950-5959. 
 (79)  Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the 
redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 
2001;30(11):1191-1212. 
 (80)  Sohn KC, Jang S, Choi DK et al. Effect of thioredoxin reductase 1 on 
glucocorticoid receptor activity in human outer root sheath cells. Biochem 
Biophys Res Commun 2007;356(3):810-815. 
 (81)  Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals 
and antioxidants in normal physiological functions and human disease. Int J 
Biochem Cell Biol 2007;39(1):44-84. 
 (82)  Genestra M. Oxyl radicals, redox-sensitive signalling cascades and antioxidants. 
Cell Signal 2007;19(9):1807-1819. 
 (83)  Fruehauf JP, Meyskens FL, Jr. Reactive oxygen species: a breath of life or death? 
Clin Cancer Res 2007;13(3):789-794. 
 (84)  Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated 
mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 
2009;8(7):579-591. 
 (85)  Azad N, Rojanasakul Y, Vallyathan V. Inflammation and lung cancer: roles of 
reactive oxygen/nitrogen species. J Toxicol Environ Health B Crit Rev 
2008;11(1):1-15. 
 (86)  Zhang DX, Gutterman DD. Mitochondrial reactive oxygen species-mediated 
signaling in endothelial cells. Am J Physiol Heart Circ Physiol 
2007;292(5):H2023-H2031. 
 (87)  Salmeen A, Barford D. Functions and mechanisms of redox regulation of 
cysteine-based phosphatases. Antioxid Redox Signal 2005;7(5-6):560-577. 
 (88)  Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and 
antioxidants in oxidative stress-induced cancer. Chem Biol Interact 
2006;160(1):1-40. 
 64 
 (89)  Koehler CM, Beverly KN, Leverich EP. Redox pathways of the mitochondrion. 
Antioxid Redox Signal 2006;8(5-6):813-822. 
 (90)  Ullrich V, Kissner R. Redox signaling: bioinorganic chemistry at its best. J Inorg 
Biochem 2006;100(12):2079-2086. 
 (91)  Koehler CM, Beverly KN, Leverich EP. Redox pathways of the mitochondrion. 
Antioxid Redox Signal 2006;8(5-6):813-822. 
 (92)  Cooper CE, Patel RP, Brookes PS, rley-Usmar VM. Nanotransducers in cellular 
redox signaling: modification of thiols by reactive oxygen and nitrogen species. 
Trends Biochem Sci 2002;27(10):489-492. 
 (93)  Lv X, Wang N, Su L, Zhang S, Miao J. Inhibition of PC-PLC blocked the survival 
of mouse neural cells by up-regulating the expression of integrin beta4 and Rb. 
Dev Neurosci 2006;28(6):499-504. 
 (94)  Park IJ, Hwang JT, Kim YM, Ha J, Park OJ. Differential modulation of AMPK 
signaling pathways by low or high levels of exogenous reactive oxygen species in 
colon cancer cells. Ann N Y Acad Sci 2006;1091:102-109. 
 (95)  Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J 
Physiol Lung Cell Mol Physiol 2000;279(6):L1005-L1028. 
 (96)  Fruehauf JP, Meyskens FL, Jr. Reactive oxygen species: a breath of life or death? 
Clin Cancer Res 2007;13(3):789-794. 
 (97)  Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and 
antioxidants in oxidative stress-induced cancer. Chem Biol Interact 
2006;160(1):1-40. 
 (98)  Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals 
and antioxidants in normal physiological functions and human disease. Int J 
Biochem Cell Biol 2007;39(1):44-84. 
 (99)  Hwang YS, Jeong M, Park JS et al. Interleukin-1beta stimulates IL-8 expression 
through MAP kinase and ROS signaling in human gastric carcinoma cells. 
Oncogene 2004;23(39):6603-6611. 
 (100)  Roy D, Sarkar S, Felty Q. Levels of IL-1 beta control stimulatory/inhibitory 
growth of cancer cells. Front Biosci 2006;11:889-898. 
 (101)  Lin CW, Yang LY, Shen SC, Chen YC. IGF-I plus E2 induces proliferation via 
activation of ROS-dependent ERKs and JNKs in human breast carcinoma cells. J 
Cell Physiol 2007;212(3):666-674. 
 65 
 (102)  Schauen M, Spitkovsky D, Schubert J, Fischer JH, Hayashi J, Wiesner RJ. 
Respiratory chain deficiency slows down cell-cycle progression via reduced ROS 
generation and is associated with a reduction of p21CIP1/WAF1. J Cell Physiol 
2006;209(1):103-112. 
 (103)  Somasundaram S, Edmund NA, Moore DT, Small GW, Shi YY, Orlowski RZ. 
Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human 
breast cancer. Cancer Res 2002;62(13):3868-3875. 
 (104)  Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C. Impact of 
antioxidant supplementation on chemotherapeutic toxicity: a systematic review of 
the evidence from randomized controlled trials. Int J Cancer 2008;123(6):1227-
1239. 
 (105)  Du J, Daniels DH, Asbury C et al. Mitochondrial production of reactive oxygen 
species mediate dicumarol-induced cytotoxicity in cancer cells. J Biol Chem 
2006;281(49):37416-37426. 
 (106)  Hayashi S, Hajiro-Nakanishi K, Makino Y, Eguchi H, Yodoi J, Tanaka H. 
Functional modulation of estrogen receptor by redox state with reference to 
thioredoxin as a mediator. Nucleic Acids Res 1997;25(20):4035-4040. 
 (107)  Kitagawa H, Yamaoka I, Akimoto C et al. A reduction state potentiates the 
glucocorticoid response through receptor protein stabilization. Genes Cells 
2007;12(11):1281-1287. 
 (108)  Atsriku C, Benz CC, Scott GK, Gibson BW, Baldwin MA. Quantification of 
cysteine oxidation in human estrogen receptor by mass spectrometry. Anal Chem 
2007;79(8):3083-3090. 
 (109)  Carriere A, Galinier A, Fernandez Y, Carmona MC, Penicaud L, Casteilla L. 
[Physiological and physiopathological consequences of mitochondrial reactive 
oxygen species]. Med Sci (Paris) 2006;22(1):47-53. 
 (110)  Greene EL, Farell G, Yu S, Matthews T, Kumar V, Lieske JC. Renal cell 
adaptation to oxalate. Urol Res 2005;33(5):340-348. 
 (111)  Scheele C, Nielsen S, Pedersen BK. ROS and myokines promote muscle 
adaptation to exercise. Trends Endocrinol Metab 2009;20(3):95-99. 
 (112)  Chen WQ, Shen W, Shen DM. [The changes of ROS and mitochondria membrane 
potential in HepG2 cells on the pressure of cisplatin]. Zhonghua Gan Zang Bing 
Za Zhi 2005;13(7):531-533. 
 66 
 (113)  Mates JM, Segura JA, Alonso FJ, Marquez J. Intracellular redox status and 
oxidative stress: implications for cell proliferation, apoptosis, and carcinogenesis. 
Arch Toxicol 2008;82(5):273-299. 
 (114)  Chiarugi P. PTPs versus PTKs: the redox side of the coin. Free Radic Res 
2005;39(4):353-364. 
 (115)  Salmeen A, Barford D. Functions and mechanisms of redox regulation of 
cysteine-based phosphatases. Antioxid Redox Signal 2005;7(5-6):560-577. 
 (116)  Chiarugi P, Buricchi F. Protein tyrosine phosphorylation and reversible oxidation: 
two cross-talking posttranslation modifications. Antioxid Redox Signal 
2007;9(1):1-24. 
 (117)  Kang SW. Two axes in platelet-derived growth factor signaling: tyrosine 
phosphorylation and reactive oxygen species. Cell Mol Life Sci 2007;64(5):533-
541. 
 (118)  Chiarugi P, Cirri P. Redox regulation of protein tyrosine phosphatases during 
receptor tyrosine kinase signal transduction. Trends Biochem Sci 2003;28(9):509-
514. 
 (119)  Chiarugi P, Fiaschi T, Taddei ML et al. Two vicinal cysteines confer a peculiar 
redox regulation to low molecular weight protein tyrosine phosphatase in 
response to platelet-derived growth factor receptor stimulation. J Biol Chem 
2001;276(36):33478-33487. 
 (120)  Savitsky PA, Finkel T. Redox regulation of Cdc25C. J Biol Chem 
2002;277(23):20535-20540. 
 (121)  Barrett WC, DeGnore JP, Konig S et al. Regulation of PTP1B via 
glutathionylation of the active site cysteine 215. Biochemistry 1999;38(20):6699-
6705. 
 (122)  Tonks NK. Redox redux: revisiting PTPs and the control of cell signaling. Cell 
2005;121(5):667-670. 
 (123)  Hwang CY, Ryu YS, Chung MS et al. Thioredoxin modulates activator protein 1 
(AP-1) activity and p27Kip1 degradation through direct interaction with Jab1. 
Oncogene 2004;23(55):8868-8875. 
 (124)  Dennery PA. Effects of oxidative stress on embryonic development. Birth Defects 
Res C Embryo Today 2007;81(3):155-162. 
 67 
 (125)  Storz P. Reactive oxygen species in tumor progression. Front Biosci 
2005;10:1881-1896. 
 (126)  Felty Q, Roy D. Mitochondrial signals to nucleus regulate estrogen-induced cell 
growth. Med Hypotheses 2005;64(1):133-141. 
 (127)  Gloire G, Legrand-Poels S, Piette J. NF-kappaB activation by reactive oxygen 
species: fifteen years later. Biochem Pharmacol 2006;72(11):1493-1505. 
 (128)  Peiro C, Matesanz N, Nevado J et al. Glycosylated human oxyhaemoglobin 
activates nuclear factor-kappaB and activator protein-1 in cultured human aortic 
smooth muscle. Br J Pharmacol 2003;140(4):681-690. 
 (129)  Meyskens FL, Jr., McNulty SE, Buckmeier JA et al. Aberrant redox regulation in 
human metastatic melanoma cells compared to normal melanocytes. Free Radic 
Biol Med 2001;31(6):799-808. 
 (130)  Dumont JA, Bitonti AJ, Wallace CD, Baumann RJ, Cashman EA, Cross-Doersen 
DE. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype 
is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth 
Differ 1996;7(3):351-359. 
 (131)  Johnston SR, Lu B, Scott GK et al. Increased activator protein-1 DNA binding 
and c-Jun NH2-terminal kinase activity in human breast tumors with acquired 
tamoxifen resistance. Clin Cancer Res 1999;5(2):251-256. 
 (132)  Peralta EA, Viegas ML, Louis S, Engle DL, Dunnington GL. Effect of vitamin E 
on tamoxifen-treated breast cancer cells. Surgery 2006;140(4):607-614. 
 (133)  Nguyen P, Awwad RT, Smart DD, Spitz DR, Gius D. Thioredoxin reductase as a 
novel molecular target for cancer therapy. Cancer Lett 2006;236(2):164-174. 
 (134)  Kondo N, Nakamura H, Masutani H, Yodoi J. Redox regulation of human 
thioredoxin network. Antioxid Redox Signal 2006;8(9-10):1881-1890. 
 (135)  Forman HJ, Fukuto JM, Torres M. Redox signaling: thiol chemistry defines which 
reactive oxygen and nitrogen species can act as second messengers. Am J Physiol 
Cell Physiol 2004;287(2):C246-C256. 
 (136)  Hall G, Emsley J. Structure of human thioredoxin exhibits a large conformational 
change. Protein Sci 2010. 
 (137)  Das KC, White CW. Redox systems of the cell: possible links and implications. 
Proc Natl Acad Sci U S A 2002;99(15):9617-9618. 
 68 
 (138)  Nordberg J, Arner ES. Reactive oxygen species, antioxidants, and the mammalian 
thioredoxin system. Free Radic Biol Med 2001;31(11):1287-1312. 
 (139)  Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin 
reductase. Eur J Biochem 2000;267(20):6102-6109. 
 (140)  Demizu Y, Sasaki R, Trachootham D et al. Alterations of cellular redox state 
during NNK-induced malignant transformation and resistance to radiation. 
Antioxid Redox Signal 2008;10(5):951-961. 
 (141)  Forman HJ, Fukuto JM, Torres M. Redox signaling: thiol chemistry defines which 
reactive oxygen and nitrogen species can act as second messengers. Am J Physiol 
Cell Physiol 2004;287(2):C246-C256. 
 (142)  Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annu 
Rev Biophys Biomol Struct 2001;30:421-455. 
 (143)  Turunen N, Karihtala P, Mantyniemi A et al. Thioredoxin is associated with 
proliferation, p53 expression and negative estrogen and progesterone receptor 
status in breast carcinoma. APMIS 2004;112(2):123-132. 
 (144)  Maruyama T, Sachi Y, Furuke K et al. Induction of thioredoxin, a redox-active 
protein, by ovarian steroid hormones during growth and differentiation of 
endometrial stromal cells in vitro. Endocrinology 1999;140(1):365-372. 
 (145)  Didier C, Kerblat I, Drouet C, Favier A, Beani JC, Richard MJ. Induction of 
thioredoxin by ultraviolet-A radiation prevents oxidative-mediated cell death in 
human skin fibroblasts. Free Radic Biol Med 2001;31(5):585-598. 
 (146)  Perl A, Banki K. Genetic and metabolic control of the mitochondrial 
transmembrane potential and reactive oxygen intermediate production in HIV 
disease. Antioxid Redox Signal 2000;2(3):551-573. 
 (147)  Chang EY, Son SK, Ko HS, Baek SH, Kim JH, Kim JR. Induction of apoptosis 
by the overexpression of an alternative splicing variant of mitochondrial 
thioredoxin reductase. Free Radic Biol Med 2005;39(12):1666-1675. 
 (148)  Arai RJ, Masutani H, Yodoi J et al. Nitric oxide induces thioredoxin-1 nuclear 
translocation: possible association with the p21Ras survival pathway. Biochem 
Biophys Res Commun 2006;348(4):1254-1260. 
 (149)  Rundlof AK, Arner ES. Regulation of the mammalian selenoprotein thioredoxin 
reductase 1 in relation to cellular phenotype, growth, and signaling events. 
Antioxid Redox Signal 2004;6(1):41-52. 
 69 
 (150)  McEligot AJ, Yang S, Meyskens FL, Jr. Redox regulation by intrinsic species and 
extrinsic nutrients in normal and cancer cells. Annu Rev Nutr 2005;25:261-295. 
 (151)  Dammeyer P, Damdimopoulos AE, Nordman T, Jimenez A, Miranda-Vizuete A, 
Arner ES. Induction of cell membrane protrusions by the N-terminal glutaredoxin 
domain of a rare splice variant of human thioredoxin reductase 1. J Biol Chem 
2008;283(5):2814-2821. 
 (152)  Urig S, Becker K. On the potential of thioredoxin reductase inhibitors for cancer 
therapy. Semin Cancer Biol 2006;16(6):452-465. 
 (153)  Bjornstedt M, Xue J, Huang W, Akesson B, Holmgren A. The thioredoxin and 
glutaredoxin systems are efficient electron donors to human plasma glutathione 
peroxidase. J Biol Chem 1994;269(47):29382-29384. 
 (154)  Lemarechal H, Anract P, Beaudeux JL, Bonnefont-Rousselot D, Ekindjian OG, 
Borderie D. Impairment of thioredoxin reductase activity by oxidative stress in 
human rheumatoid synoviocytes. Free Radic Res 2007;41(6):688-698. 
 (155)  Ramachandiran S, Hansen JM, Jones DP, Richardson JR, Miller GW. Divergent 
mechanisms of paraquat, MPP+, and rotenone toxicity: oxidation of thioredoxin 
and caspase-3 activation. Toxicol Sci 2007;95(1):163-171. 
 (156)  Huber K, Patel P, Zhang L et al. 2-[(1-methylpropyl)dithio]-1H-imidazole inhibits 
tubulin polymerization through cysteine oxidation. Mol Cancer Ther 
2008;7(1):143-151. 
 (157)  Liyanage NP, Fernando MR, Lou MF. Regulation of the bioavailability of 
thioredoxin in the lens by a specific thioredoxin-binding protein (TBP-2). Exp Eye 
Res 2007;85(2):270-279. 
 (158)  Makino Y, Okamoto K, Yoshikawa N et al. Thioredoxin: a redox-regulating 
cellular cofactor for glucocorticoid hormone action. Cross talk between endocrine 
control of stress response and cellular antioxidant defense system. J Clin Invest 
1996;98(11):2469-2477. 
 (159)  Haendeler J, Tischler V, Hoffmann J, Zeiher AM, Dimmeler S. Low doses of 
reactive oxygen species protect endothelial cells from apoptosis by increasing 
thioredoxin-1 expression. FEBS Lett 2004;577(3):427-433. 
 (160)  Gon Y, Sasada T, Matsui M et al. Expression of thioredoxin in bleomycin-injured 
airway epithelium: possible role of protection against bleomycin induced 
epithelial injury. Life Sci 2001;68(16):1877-1888. 
 70 
 (161)  Kaimul AM, Nakamura H, Tanito M, Yamada K, Utsumi H, Yodoi J. 
Thioredoxin-1 suppresses lung injury and apoptosis induced by diesel exhaust 
particles (DEP) by scavenging reactive oxygen species and by inhibiting DEP-
induced downregulation of Akt. Free Radic Biol Med 2005;39(12):1549-1559. 
 (162)  Dai J, Wang X, Feng J et al. Regulatory role of thioredoxin in homocysteine-
induced monocyte chemoattractant protein-1 secretion in 
monocytes/macrophages. FEBS Lett 2008;582(28):3893-3898. 
 (163)  Kuhara T, Watanabe D, Akita Y et al. Thioredoxin upregulation by 5-
aminolaevulinic acid-based photodynamic therapy in human skin squamous cell 
carcinoma cell line. Photodermatol Photoimmunol Photomed 2008;24(3):142-
146. 
 (164)  Berggren MI, Husbeck B, Samulitis B, Baker AF, Gallegos A, Powis G. 
Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 
transfected cells and results in enhanced protection against apoptosis caused by 
hydrogen peroxide but not by other agents including dexamethasone, etoposide, 
and doxorubicin. Arch Biochem Biophys 2001;392(1):103-109. 
 (165)  Soini Y, Kahlos K, Napankangas U et al. Widespread expression of thioredoxin 
and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res 
2001;7(6):1750-1757. 
 (166)  Nonn L, Berggren M, Powis G. Increased expression of mitochondrial 
peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia 
and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res 
2003;1(9):682-689. 
 (167)  Wang W, Wang S, Howie AF, Beckett GJ, Mithen R, Bao Y. Sulforaphane, 
erucin, and iberin up-regulate thioredoxin reductase 1 expression in human MCF-
7 cells. J Agric Food Chem 2005;53(5):1417-1421. 
 (168)  Bacon JR, Plumb GW, Howie AF, Beckett GJ, Wang W, Bao Y. Dual action of 
sulforaphane in the regulation of thioredoxin reductase and thioredoxin in human 
HepG2 and Caco-2 cells. J Agric Food Chem 2007;55(4):1170-1176. 
 (169)  Karunasinghe N, Ferguson LR, Tuckey J, Masters J. Hemolysate thioredoxin 
reductase and glutathione peroxidase activities correlate with serum selenium in a 
group of New Zealand men at high prostate cancer risk. J Nutr 2006;136(8):2232-
2235. 
 (170)  Carvalho CM, Chew EH, Hashemy SI, Lu J, Holmgren A. Inhibition of the 
human thioredoxin system. A molecular mechanism of mercury toxicity. J Biol 
Chem 2008;283(18):11913-11923. 
 71 
 (171)  Imaoka H, Hoshino T, Takei S et al. Effects of thioredoxin on established airway 
remodeling in a chronic antigen exposure asthma model. Biochem Biophys Res 
Commun 2007;360(3):525-530. 
 (172)  Kawasaki K, Nishio A, Nakamura H et al. Helicobacter felis-induced gastritis was 
suppressed in mice overexpressing thioredoxin-1. Lab Invest 2005;85(9):1104-
1117. 
 (173)  Kurimoto C, Kawano S, Tsuji G et al. Thioredoxin may exert a protective effect 
against tissue damage caused by oxidative stress in salivary glands of patients 
with Sjogren's syndrome. J Rheumatol 2007;34(10):2035-2043. 
 (174)  Hokamaki J, Kawano H, Soejima H et al. Plasma thioredoxin levels in patients 
with unstable angina. Int J Cardiol 2005;99(2):225-231. 
 (175)  Rancourt RC, Lee RL, O'Neill H, Accurso FJ, White CW. Reduced thioredoxin 
increases proinflammatory cytokines and neutrophil influx in rat airways: 
modulation by airway mucus. Free Radic Biol Med 2007;42(9):1441-1453. 
 (176)  Lee RL, Rancourt RC, del VG et al. Thioredoxin and dihydrolipoic acid inhibit 
elastase activity in cystic fibrosis sputum. Am J Physiol Lung Cell Mol Physiol 
2005;289(5):L875-L882. 
 (177)  Hoshino T, Okamoto M, Takei S, Sakazaki Y, Iwanaga T, Aizawa H. Redox-
regulated mechanisms in asthma. Antioxid Redox Signal 2008;10(4):769-783. 
 (178)  Wu XW, Teng ZY, Jiang LH et al. Human thioredoxin exerts cardioprotective 
effect and attenuates reperfusion injury in rats partially via inhibiting apoptosis. 
Chin Med J (Engl ) 2008;121(9):819-826. 
 (179)  Hoshino Y, Shioji K, Nakamura H, Masutani H, Yodoi J. From oxygen sensing to 
heart failure: role of thioredoxin. Antioxid Redox Signal 2007;9(6):689-699. 
 (180)  Patel JM, Hu H, Lu L et al. Thioredoxin as a biomarker for graft rejection in lung 
transplant recipients. Biomarkers 2008;13(5):486-495. 
 (181)  Noike T, Miwa S, Soeda J, Kobayashi A, Miyagawa S. Increased expression of 
thioredoxin-1, vascular endothelial growth factor, and redox factor-1 is associated 
with poor prognosis in patients with liver metastasis from colorectal cancer. Hum 
Pathol 2008;39(2):201-208. 
 (182)  Liu GH, Qu J, Shen X. Thioredoxin-mediated negative autoregulation of 
peroxisome proliferator-activated receptor alpha transcriptional activity. Mol Biol 
Cell 2006;17(4):1822-1833. 
 72 
 (183)  Chen Y, Yu M, Jones DP, Greenamyre JT, Cai J. Protection against oxidant-
induced apoptosis by mitochondrial thioredoxin in SH-SY5Y neuroblastoma 
cells. Toxicol Appl Pharmacol 2006;216(2):256-262. 
 (184)  Yamada T, Iwasaki Y, Nagata K et al. Thioredoxin-1 protects against hyperoxia-
induced apoptosis in cells of the alveolar walls. Pulm Pharmacol Ther 
2007;20(6):650-659. 
 (185)  Xu JW, Ikeda K, Yamori Y. Inhibitory effect of polyphenol cyanidin on TNF-
alpha-induced apoptosis through multiple signaling pathways in endothelial cells. 
Atherosclerosis 2007;193(2):299-308. 
 (186)  Tan A, Nakamura H, Kondo N et al. Thioredoxin-1 attenuates indomethacin-
induced gastric mucosal injury in mice. Free Radic Res 2007;41(8):861-869. 
 (187)  Chen XP, Liu S, Tang WX, Chen ZW. Nuclear thioredoxin-1 is required to 
suppress cisplatin-mediated apoptosis of MCF-7 cells. Biochem Biophys Res 
Commun 2007;361(2):362-366. 
 (188)  Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello MP. Inhibition 
of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant 
human ovarian cancer cells. Free Radic Biol Med 2007;42(6):872-881. 
 (189)  Lan L, Zhao F, Wang Y, Zeng H. The mechanism of apoptosis induced by a novel 
thioredoxin reductase inhibitor in A549 cells: possible involvement of nuclear 
factor-kappaB-dependent pathway. Eur J Pharmacol 2007;555(2-3):83-92. 
 (190)  Wang X, Zhang J, Xu T. Cyclophosphamide as a potent inhibitor of tumor 
thioredoxin reductase in vivo. Toxicol Appl Pharmacol 2007;218(1):88-95. 
 (191)  Wang Y, Zhang H, Holmgren A, Tian W, Zhong L. Inhibitory effect of green tea 
extract and (-)-epigallocatechin-3-gallate on mammalian thioredoxin reductase 
and HeLa cell viability. Oncol Rep 2008;20(6):1479-1487. 
 (192)  Lindner DJ, Hofmann ER, Karra S, Kalvakolanu DV. The interferon-beta and 
tamoxifen combination induces apoptosis using thioredoxin reductase. Biochim 
Biophys Acta 2000;1496(2-3):196-206. 
 (193)  Liu Y, Min W. Thioredoxin promotes ASK1 ubiquitination and degradation to 
inhibit ASK1-mediated apoptosis in a redox activity-independent manner. Circ 
Res 2002;90(12):1259-1266. 
 (194)  Kondo N, Ishii Y, Kwon YW et al. Lipid raft-mediated uptake of cysteine-
modified thioredoxin-1: apoptosis enhancement by inhibiting the endogenous 
thioredoxin-1. Antioxid Redox Signal 2007;9(9):1439-1448. 
 73 
 (195)  Liu H, Nishitoh H, Ichijo H, Kyriakis JM. Activation of apoptosis signal-
regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 
requires prior dissociation of the ASK1 inhibitor thioredoxin. Mol Cell Biol 
2000;20(6):2198-2208. 
 (196)  Kwon SJ, Song JJ, Lee YJ. Signal pathway of hypoxia-inducible factor-1alpha 
phosphorylation and its interaction with von Hippel-Lindau tumor suppressor 
protein during ischemia in MiaPaCa-2 pancreatic cancer cells. Clin Cancer Res 
2005;11(21):7607-7613. 
 (197)  Hattori K, Naguro I, Runchel C, Ichijo H. The roles of ASK family proteins in 
stress responses and diseases. Cell Commun Signal 2009;7:9. 
 (198)  Junn E, Han SH, Im JY et al. Vitamin D3 up-regulated protein 1 mediates 
oxidative stress via suppressing the thioredoxin function. J Immunol 
2000;164(12):6287-6295. 
 (199)  Nadeau PJ, Charette SJ, Toledano MB, Landry J. Disulfide Bond-mediated 
Multimerization of Ask1 and Its Reduction by Thioredoxin-1 Regulate H2O2-
induced JNK Activation and Apoptosis. Mol Biol Cell 2007. 
 (200)  Huang YL, Chuang CY, Sung FC, Chen CY. Thioredoxin overexpression 
modulates remodeling factors in stress responses to cigarette smoke. J Toxicol 
Environ Health A 2008;71(22):1490-1498. 
 (201)  Akterin S, Cowburn RF, Miranda-Vizuete A et al. Involvement of glutaredoxin-1 
and thioredoxin-1 in beta-amyloid toxicity and Alzheimer's disease. Cell Death 
Differ 2006;13(9):1454-1465. 
 (202)  Lim PL, Liu J, Go ML, Boelsterli UA. The mitochondrial superoxide/thioredoxin-
2/Ask1 signaling pathway is critically involved in troglitazone-induced cell injury 
to human hepatocytes. Toxicol Sci 2008;101(2):341-349. 
 (203)  Zhang Y, Shen X. Heat shock protein 27 protects L929 cells from cisplatin-
induced apoptosis by enhancing Akt activation and abating suppression of 
thioredoxin reductase activity. Clin Cancer Res 2007;13(10):2855-2864. 
 (204)  Chen CL, Lin CF, Chang WT, Huang WC, Teng CF, Lin YS. Ceramide induces 
p38 MAPK and JNK activation through a mechanism involving a thioredoxin-
interacting protein-mediated pathway. Blood 2008;111(8):4365-4374. 
 (205)  Csiki I, Yanagisawa K, Haruki N et al. Thioredoxin-1 modulates transcription of 
cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung 
cancer. Cancer Res 2006;66(1):143-150. 
 74 
 (206)  Kim WJ, Cho H, Lee SW, Kim YJ, Kim KW. Antisense-thioredoxin inhibits 
angiogenesis via pVHL-mediated hypoxia-inducible factor-1alpha degradation. 
Int J Oncol 2005;26(4):1049-1052. 
 (207)  Zhou J, Damdimopoulos AE, Spyrou G, Brune B. Thioredoxin 1 and thioredoxin 
2 have opposed regulatory functions on hypoxia-inducible factor-1alpha. J Biol 
Chem 2007;282(10):7482-7490. 
 (208)  Shih AY, Li P, Murphy TH. A small-molecule-inducible Nrf2-mediated 
antioxidant response provides effective prophylaxis against cerebral ischemia in 
vivo. J Neurosci 2005;25(44):10321-10335. 
 (209)  Jia L, Xu M, Zhen W et al. Novel anti-oxidative role of calreticulin in protecting 
A549 human type II alveolar epithelial cells against hypoxic injury. Am J Physiol 
Cell Physiol 2008;294(1):C47-C55. 
 (210)  Stacy DR, Ely K, Massion PP et al. Increased expression of nuclear factor E2 
p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head 
Neck 2006;28(9):813-818. 
 (211)  Sakurai A, Nishimoto M, Himeno S et al. Transcriptional regulation of 
thioredoxin reductase 1 expression by cadmium in vascular endothelial cells: role 
of NF-E2-related factor-2. J Cell Physiol 2005;203(3):529-537. 
 (212)  Hansen JM, Watson WH, Jones DP. Compartmentation of Nrf-2 redox control: 
regulation of cytoplasmic activation by glutathione and DNA binding by 
thioredoxin-1. Toxicol Sci 2004;82(1):308-317. 
 (213)  Kim SK, Yang JW, Kim MR et al. Increased expression of Nrf2/ARE-dependent 
anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free Radic Biol 
Med 2008;45(4):537-546. 
 (214)  Matsuura T, Harrison RA, Westwell AD, Nakamura H, Martynyuk AE, Sumners 
C. Basal and angiotensin II-inhibited neuronal delayed-rectifier K+ current are 
regulated by thioredoxin. Am J Physiol Cell Physiol 2007;293(1):C211-C217. 
 (215)  Tamaki H, Nakamura H, Nishio A et al. Human thioredoxin-1 ameliorates 
experimental murine colitis in association with suppressed macrophage inhibitory 
factor production. Gastroenterology 2006;131(4):1110-1121. 
 (216)  Fukumoto A, Tomoda K, Kubota M, Kato JY, Yoneda-Kato N. Small Jab1-
containing subcomplex is regulated in an anchorage- and cell cycle-dependent 
manner, which is abrogated by ras transformation. FEBS Lett 2005;579(5):1047-
1054. 
 75 
 (217)  Kim KY, Shin SM, Kim JK, Paik SG, Yang Y, Choi I. Heat shock factor 
regulates VDUP1 gene expression. Biochem Biophys Res Commun 
2004;315(2):369-375. 
 (218)  Kim SY, Suh HW, Chung JW, Yoon SR, Choi I. Diverse functions of VDUP1 in 
cell proliferation, differentiation, and diseases. Cell Mol Immunol 2007;4(5):345-
351. 
 (219)  Patwari P, Higgins LJ, Chutkow WA, Yoshioka J, Lee RT. The interaction of 
thioredoxin with Txnip. Evidence for formation of a mixed disulfide by disulfide 
exchange. J Biol Chem 2006;281(31):21884-21891. 
 (220)  Deroo BJ, Hewitt SC, Peddada SD, Korach KS. Estradiol regulates the 
thioredoxin antioxidant system in the mouse uterus. Endocrinology 
2004;145(12):5485-5492. 
 (221)  Takahashi Y, Masuda H, Ishii Y, Nishida Y, Kobayashi M, Asai S. Decreased 
expression of thioredoxin interacting protein mRNA in inflamed colonic mucosa 
in patients with ulcerative colitis. Oncol Rep 2007;18(3):531-535. 
 (222)  Sheth SS, Castellani LW, Chari S et al. Thioredoxin-interacting protein deficiency 
disrupts the fasting-feeding metabolic transition. J Lipid Res 2005;46(1):123-134. 
 (223)  Shalev A. Lack of TXNIP protects beta-cells against glucotoxicity. Biochem Soc 
Trans 2008;36(Pt 5):963-965. 
 (224)  Qi W, Chen X, Gilbert RE et al. High Glucose-Induced Thioredoxin-Interacting 
Protein in Renal Proximal Tubule Cells Is Independent of Transforming Growth 
Factor-{beta}1. Am J Pathol 2007. 
 (225)  Turturro F, Von BG, Friday E. Hyperglycemia-induced thioredoxin-interacting 
protein expression differs in breast cancer-derived cells and regulates paclitaxel 
IC50. Clin Cancer Res 2007;13(12):3724-3730. 
 (226)  Turturro F, Friday E, Welbourne T. Hyperglycemia regulates thioredoxin-ROS 
activity through induction of thioredoxin-interacting protein (TXNIP) in 
metastatic breast cancer-derived cells MDA-MB-231. BMC Cancer 2007;7:96. 
 (227)  van Greevenbroek MM, Vermeulen VM, Feskens EJ et al. Genetic variation in 
thioredoxin interacting protein (TXNIP) is associated with hypertriglyceridaemia 
and blood pressure in diabetes mellitus. Diabet Med 2007;24(5):498-504. 
 (228)  Minn AH, Pise-Masison CA, Radonovich M et al. Gene expression profiling in 
INS-1 cells overexpressing thioredoxin-interacting protein. Biochem Biophys Res 
Commun 2005;336(3):770-778. 
 76 
 (229)  Nadeau PJ, Charette SJ, Toledano MB, Landry J. Disulfide Bond-mediated 
multimerization of Ask1 and its reduction by thioredoxin-1 regulate H(2)O(2)-
induced c-Jun NH(2)-terminal kinase activation and apoptosis. Mol Biol Cell 
2007;18(10):3903-3913. 
 (230)  Haendeler J, Tischler V, Hoffmann J, Zeiher AM, Dimmeler S. Low doses of 
reactive oxygen species protect endothelial cells from apoptosis by increasing 
thioredoxin-1 expression. FEBS Lett 2004;577(3):427-433. 
 (231)  Satoh M, Matter CM, Ogita H et al. Inhibition of apoptosis-regulated signaling 
kinase-1 and prevention of congestive heart failure by estrogen. Circulation 
2007;115(25):3197-3204. 
 (232)  Husbeck B, Powis G. The redox protein thioredoxin-1 regulates the constitutive 
and inducible expression of the estrogen metabolizing cytochromes P450 1B1 and 
1A1 in MCF-7 human breast cancer cells. Carcinogenesis 2002;23(10):1625-
1630. 
 (233)  Ivan D, Diwan AH, Esteva FJ, Prieto VG. Expression of cell cycle inhibitor 
p27Kip1 and its inactivator Jab1 in melanocytic lesions. Mod Pathol 
2004;17(7):811-818. 
 (234)  Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-CDK2 is 
a regulator of p27Kip1. Genes Dev 1997;11(11):1464-1478. 
 (235)  Alkarain A, Jordan R, Slingerland J. p27 deregulation in breast cancer: prognostic 
significance and implications for therapy. J Mammary Gland Biol Neoplasia 
2004;9(1):67-80. 
 (236)  Ciarallo S, Subramaniam V, Hung W et al. Altered p27(Kip1) phosphorylation, 
localization, and function in human epithelial cells resistant to transforming 
growth factor beta-mediated G(1) arrest. Mol Cell Biol 2002;22(9):2993-3002. 
 (237)  Alkarain A, Slingerland J. Deregulation of p27 by oncogenic signaling and its 
prognostic significance in breast cancer. Breast Cancer Res 2004;6(1):13-21. 
 (238)  Chu I, Sun J, Arnaout A et al. p27 phosphorylation by Src regulates inhibition of 
cyclin E-Cdk2. Cell 2007;128(2):281-294. 
 (239)  Sandhu C, Slingerland J. Deregulation of the cell cycle in cancer. Cancer Detect 
Prev 2000;24(2):107-118. 
 (240)  Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell 
cycle progression. Cell Cycle 2003;2(4):339-345. 
 77 
 (241)  Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM. 
mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol 
Cell 2008;30(6):701-711. 
 (242)  Liang J, Shao SH, Xu ZX et al. The energy sensing LKB1-AMPK pathway 
regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or 
apoptosis. Nat Cell Biol 2007;9(2):218-224. 
 (243)  Planas-Silva MD, Hamilton KN. Targeting c-Src kinase enhances tamoxifen's 
inhibitory effect on cell growth by modulating expression of cell cycle and 
survival proteins. Cancer Chemother Pharmacol 2007;60(4):535-543. 
 (244)  Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation 
in cancer. J Cell Physiol 2000;183(1):10-17. 
 (245)  Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd FA, Slingerland 
JM. Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung 
carcinoma: a prognostic factor independent of Ras. Cancer Res 1999;59(3):684-
688. 
 (246)  Tan P, Cady B, Wanner M et al. The cell cycle inhibitor p27 is an independent 
prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 
1997;57(7):1259-1263. 
 (247)  Cariou S, Catzavelos C, Slingerland JM. Prognostic implications of expression of 
the cell cycle inhibitor protein p27Kip1. Breast Cancer Res Treat 1998;52(1-
3):29-41. 
 (248)  Jordan RC, Bradley G, Slingerland J. Reduced levels of the cell-cycle inhibitor 
p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity. Am J Pathol 
1998;152(2):585-590. 
 (249)  Connor MK, Kotchetkov R, Cariou S et al. CRM1/Ran-mediated nuclear export 
of p27(Kip1) involves a nuclear export signal and links p27 export and 
proteolysis. Mol Biol Cell 2003;14(1):201-213. 
 (250)  Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase 
inhibitor p27Kip1 is instigated by Jab1. Nature 1999;398(6723):160-165. 
 (251)  Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: 
prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 
2008;8(4):253-267. 
 78 
 (252)  Sui L, Dong Y, Ohno M et al. Jab1 expression is associated with inverse 
expression of p27(kip1) and poor prognosis in epithelial ovarian tumors. Clin 
Cancer Res 2001;7(12):4130-4135. 
 (253)  Nguyen MT, Beck J, Lue H et al. A 16-residue peptide fragment of macrophage 
migration inhibitory factor, MIF-(50-65), exhibits redox activity and has MIF-like 
biological functions. J Biol Chem 2003;278(36):33654-33671. 
 (254)  Chamovitz DA, Segal D. JAB1/CSN5 and the COP9 signalosome. A complex 
situation. EMBO Rep 2001;2(2):96-101. 
 (255)  Wang H, Sun X, Luo Y, Lin Z, Wu J. Adapter protein NRBP associates with Jab1 
and negatively regulates AP-1 activity. FEBS Lett 2006;580(25):6015-6021. 
 (256)  Esteva FJ, Sahin AA, Rassidakis GZ et al. Jun activation domain binding protein 
1 expression is associated with low p27(Kip1)levels in node-negative breast 
cancer. Clin Cancer Res 2003;9(15):5652-5659. 
 (257)  Esteva FJ, Sahin AA, Rassidakis GZ et al. Jun activation domain binding protein 
1 expression is associated with low p27(Kip1)levels in node-negative breast 
cancer. Clin Cancer Res 2003;9(15):5652-5659. 
 (258)  Lu C, Li Y, Zhao Y et al. Intracrine hepatopoietin potentiates AP-1 activity 
through JAB1 independent of MAPK pathway. FASEB J 2002;16(1):90-92. 
 (259)  Kouvaraki MA, Rassidakis GZ, Tian L, Kumar R, Kittas C, Claret FX. Jun 
activation domain-binding protein 1 expression in breast cancer inversely 
correlates with the cell cycle inhibitor p27(Kip1). Cancer Res 2003;63(11):2977-
2981. 
 (260)  Kouvaraki MA, Rassidakis GZ, Tian L, Kumar R, Kittas C, Claret FX. Jun 
activation domain-binding protein 1 expression in breast cancer inversely 
correlates with the cell cycle inhibitor p27(Kip1). Cancer Res 2003;63(11):2977-
2981. 
 (261)  Emberley ED, Alowami S, Snell L, Murphy LC, Watson PH. S100A7 (psoriasin) 
expression is associated with aggressive features and alteration of Jab1 in ductal 
carcinoma in situ of the breast. Breast Cancer Res 2004;6(4):R308-R315. 
 (262)  Tsuchida R, Miyauchi J, Shen L et al. Expression of cyclin-dependent kinase 
inhibitor p27/Kip1 and AP-1 coactivator p38/Jab1 correlates with differentiation 
of embryonal rhabdomyosarcoma. Jpn J Cancer Res 2002;93(9):1000-1006. 
 (263)  Bonner SE, Morris DG, Korbonits M et al. Cell cycle dysregulation in breast 
cancer - the roles of Jab1 and Archipelago. Endocrine Abstracts 9, P89. 2005.  
 79 
 (264)  Denicourt C, Saenz CC, Datnow B, Cui XS, Dowdy SF. Relocalized p27Kip1 
tumor suppressor functions as a cytoplasmic metastatic oncogene in melanoma. 
Cancer Res 2007;67(19):9238-9243. 
 (265)  Callige M, Kieffer I, Richard-Foy H. CSN5/Jab1 is involved in ligand-dependent 
degradation of estrogen receptor {alpha} by the proteasome. Mol Cell Biol 
2005;25(11):4349-4358. 
 (266)  Fukumoto A, Tomoda K, Kubota M, Kato JY, Yoneda-Kato N. Small Jab1-
containing subcomplex is regulated in an anchorage- and cell cycle-dependent 
manner, which is abrogated by ras transformation. FEBS Lett 2005;579(5):1047-
1054. 
 (267)  Fruehauf JP, Meyskens FL, Jr. Reactive oxygen species: a breath of life or death? 
Clin Cancer Res 2007;13(3):789-794. 
 (268)  Damdimopoulos AE, Miranda-Vizuete A, Treuter E, Gustafsson JA, Spyrou G. 
An alternative splicing variant of the selenoprotein thioredoxin reductase is a 
modulator of estrogen signaling. J Biol Chem 2004;279(37):38721-38729. 
 (269)  Jonsson-Videsater K, Bjorkhem-Bergman L, Hossain A et al. Selenite-induced 
apoptosis in doxorubicin-resistant cells and effects on the thioredoxin system. 
Biochem Pharmacol 2004;67(3):513-522. 
 (270)  Iwao-Koizumi K, Matoba R, Ueno N et al. Prediction of docetaxel response in 
human breast cancer by gene expression profiling. J Clin Oncol 2005;23(3):422-
431. 
 (271)  Azuma K, Komohara Y, Sasada T et al. Excision repair cross-complementation 
group 1 predicts progression-free and overall survival in non-small cell lung 
cancer patients treated with platinum-based chemotherapy. Cancer Sci 
2007;98(9):1336-1343. 
 (272)  Kim SJ, Miyoshi Y, Taguchi T et al. High thioredoxin expression is associated 
with resistance to docetaxel in primary breast cancer. Clin Cancer Res 
2005;11(23):8425-8430. 
 (273)  Chen X, Li Y, Wei K et al. The potentiation role of hepatopoietin on activator 
protein-1 is dependent on its sulfhydryl oxidase activity. J Biol Chem 
2003;278(49):49022-49030. 
 (274)  Liang J, Zubovitz J, Petrocelli T et al. PKB/Akt phosphorylates p27, impairs 
nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 
2002;8(10):1153-1160. 
 80 
 (275)  Weng LP, Brown JL, Eng C. PTEN coordinates G(1) arrest by down-regulating 
cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid 
phosphatase activity in a breast cancer model. Hum Mol Genet 2001;10(6):599-
604. 
 (276)  Lee H, Xie L, Luo Y et al. Identification of phosphocaveolin-1 as a novel protein 
tyrosine phosphatase 1B substrate. Biochemistry 2006;45(1):234-240. 
 (277)  Liang F, Lee SY, Liang J, Lawrence DS, Zhang ZY. The role of protein-tyrosine 
phosphatase 1B in integrin signaling. J Biol Chem 2005;280(26):24857-24863. 
 (278)  Roskoski R, Jr. Src kinase regulation by phosphorylation and dephosphorylation. 
Biochem Biophys Res Commun 2005;331(1):1-14. 
 (279)  Bartholomew PJ, Jones CW, Benware A, Chernoff J, LaFlamme SE. Regulation 
of the catalytic activity of PTP1B: roles for cell adhesion, tyrosine residue 66, and 
proline residues 309 and 310. Exp Cell Res 2005;311(2):294-306. 
 (280)  Sternfeld L, Krause E, Schmid A et al. Tyrosine phosphatase PTP1B interacts 
with TRPV6 in vivo and plays a role in TRPV6-mediated calcium influx in 
HEK293 cells. Cell Signal 2005;17(8):951-960. 
 (281)  Lee SR, Yang KS, Kwon J, Lee C, Jeong W, Rhee SG. Reversible inactivation of 
the tumor suppressor PTEN by H2O2. J Biol Chem 2002;277(23):20336-20342. 
 (282)  Sohn J, Rudolph J. Catalytic and chemical competence of regulation of cdc25 
phosphatase by oxidation/reduction. Biochemistry 2003;42(34):10060-10070. 
 (283)  Rudolph J. Redox regulation of the Cdc25 phosphatases. Antioxid Redox Signal 
2005;7(5-6):761-767. 
 (284)  van den Berk LC, Landi E, Harmsen E, Dente L, Hendriks WJ. Redox-regulated 
affinity of the third PDZ domain in the phosphotyrosine phosphatase PTP-BL for 
cysteine-containing target peptides. FEBS J 2005;272(13):3306-3316. 
 (285)  Mueller AS, Klomann SD, Wolf NM et al. Redox regulation of protein tyrosine 
phosphatase 1B by manipulation of dietary selenium affects the triglyceride 
concentration in rat liver. J Nutr 2008;138(12):2328-2336. 
(286)  Bjornstrom L, Sjoberg M. Mechanisms of Estrogen Receptor Signaling: 
Convergence of Genomic and Nongenomic Actions on Target Genes. Mol 
Endocrinol 2005; 19(4):833–842. 
 
(287)  Osborne CK, Schiff R. Mechanisms of Endocrine Resistance in Breast Cancer. 
Annu Rev Med 2011; 62:14.1–14.15. 
 81 
Figures 
Figure 1 –LR 
 
Estrogen actions in breast cancer. Most well characterized is the genomic action of 
estrogen binding to the ER, and this complex binding to EREs in the DNA. Non-genomic 
actions include activation of the PI3K and MAPK pathways. More recently, cell-
signaling activation through ROS formation has been explored.23, 28,29,126,286,287 
Figure 2-LR 
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Sources of oxidants and actions of antioxidants. Schematic of major sources of ROS 
and antioxidants that counteract the oxidative effects of this ROS. 
Figure 3-LR 
 
Cellular dose/response to oxidants. While high doses of ROS can lead to apoptosis, and 
low levels can lead to cell growth, chronic exposure to antiestrogens can lead to an 
adaptation of the cell and subsequent AE resistance. 
Figure 4-LR 
 
Thioredoxin oxidation and reduction. After oxidation, thioredoxin becomes more 
susceptible to overoxidation by H2O2 until it become irreversibly inactive. The increase 
in ROS from tamoxifen treatment can lead to the oxidation and overoxidation of 
thioredoxin, and perhaps plays a role in antiestrogen resistance.  
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Figure 5-LR 
 
Proposed role of thioredoxin in AE resistance. We propose a Trx/Jab1 interaction that 
mimics the Trx/Ask1 interaction. Oxidation (inactivation) of thioredoxin from AE-
generated ROS leads to a release of Jab1. Jab1 is then free to bind to p27, carrying it    
out of the nucleus. With p27 gone, the Cyclin E/cdk2 complex is free to forward cell 
cycle progression. 
III  INCREASING THIOREDOXIN REDUCTASE EXPRESSION OR 
REDUCING JAB1 EXPRESSION REDUCES CELL PROLIFERATION IN 
TAMOXIFEN-TREATED LCC2 CELLS 
Abstract 
Antiestrogen resistance is a major problem in breast cancer treatment. While the reactive 
oxygen species that are produced by selective estrogen receptor modulators such as 
tamoxifen are not thought to play a major role in treatment, it may have a role in the 
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development of resistance. For this study we looked at the role of thioredoxin and its 
ability to alter the oxidative state of tamoxifen-resistant (LCC2) cells. We also explored 
the Jab1/thioredoxin pathway as a way thioredoxin may alter the effects of resistance on 
the cell cycle inhibitor p27. We show that overexpressing thioredoxin reductase or 
underexpressing Jab1 inhibits growth of tamoxifen-resistant cells upon tamoxifen 
treatment. We also show that p27 phosphorylation is altered when thioredoxin reductase 
or Jab1 levels are altered. This data implies a role for antioxidants in reversing tamoxifen 
resistance. Through altering p27 phosphorylation, changing the redox nature of tamoxifen 
resistant cells may not only reverse but also may prevent tamoxifen resistance. 
 
Introduction 
A major problem with the use of antiestrogens (AE) is the prevalence of resistance, either 
at the outset of treatment or after continued use, and underlying mechanisms of this 
resistance remain unclear. Selective estrogen receptor modulator (SERM) antiestrogens 
are capable of producing ROS through their metabolic activation. It is possible that 
SERMs may play a role in estrogen receptor (ER) positive breast cancer growth arrest by 
a mechanism involving ROS accumulation. Breast cancer receiving long-term 
antiestrogen treatment appears to adapt to this increased, persistent level of ROS, leading 
to the disruption of reversible redox signaling that involves redox-sensitive phosphatases 
and kinases, such as ERK and Akt. This has downstream consequences for apoptosis, cell 
cycle progression, and cell metabolism.1, 2  
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The inactivation of the thioredoxin antioxidant family can disrupt reversible redox 
signaling pathways and cause the cell to become unresponsive to certain stimuli, or lead 
to the continued activation of cell signaling pathways such as MAPKs, and further the 
activation of transcription factors and subsequent cell proliferation.3 It may also play a 
role in making Jab1 protein available to move the cell-cycle inhibitor p27 from the 
nucleus and freeing the cyclin E / cdk2 complex to forward cell progression. Thioredoxin 
(Trx) has been found to compete with p27 for binding with Jab1 in HEK293T (human 
embryonic kidney) cells, and, through this, negatively regulate p27 degradation.4  
 
There is very little research in the area of reactive oxygen species as a mechanism for 
tamoxifen resistance. One study has looked at glutathione as an antioxidant that can 
affect the oxidation of the MKP3 phosphatase. There appear to be no studies exploring 
the role of thioredoxin as an inhibitor of antiestrogen resistance. There also are no studies 
regarding the role of Jab1 in AE resistance, however, it has been shown that there needs 
to be a certain level of p27 in breast cancer cells for the cells to respond to tamoxifen, and 
that increasing MAPK pathway activation increases p27 phosphorylation and reduces 
levels of p27, leading to tamoxifen resistance.5  
 
Thioredoxin and thioredoxin reductase (TrxR) are considered prime targets for resistance 
to chemotherapeutic drugs that utilize high levels of ROS to kill breast cancer cells, such 
as docetaxel, a potent anti-cancer drug.6 However, with drugs that do not utilize ROS as 
their main mechanism, such as tamoxifen, chronic exposure to the lower levels of ROS 
produced have not been explored as part of the mechanisms of action. With the exception 
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of the previously mentioned MKP3 study, the alteration of cellular ROS has not been 
explored as a pathway to reversing/preventing tamoxifen resistance.  
 
We suggest that chronic tamoxifen usage increases ROS and inactivates the antioxidant 
Trx family through oxidation. This oxidation can affect several signaling pathways and 
lead to cell cycle progression in the presence of tamoxifen treatment. In this study we 
overexpressed thioredoxin reductase and underexpressed Jab1 proteins to explore the role 
of each in tamoxifen resistance. Our data indicate there is a role for TrxR overexpression 
or Jab1underexpression in reversing or preventing tamoxifen resistance through alteration 
of p27 phosphorylation.  
 
Materials and methods 
Cell lines, cultures, and treatments: The tamoxifen-resistant/fulvestrant-sensitive human 
breast adenocarcinoma MCF-7-variant LCC2 cell line was propagated in phenol red-free 
Dulbecco's Modified Eagle Medium F12 (DMEM/F12) with L-Glutamine and 15mM 
HEPES (Invitrogen, Grand Island, NY; Mediatech, Manassas, VA) containing 5% (v/v) 
fetal bovine serum (Invitrogen), 100 u/mL penicillin G sodium, and 100 ug/mL 
streptomycin sulfate (Invitrogen) at 37 °C in 5% CO2 atmosphere. For experimental 
purposes, cells were seeded in 5% FBS DMEM/F12 medium and allowed to adhere 
overnight. Culture medium was replaced with DMEM/F12 with 5% charcoal/dextran-
treated FBS (Invitrogen), and allowed to grow for 48 h, followed by treatments (0.1% 
DMSO, 1 μM tamoxifen, 1 μM fulvestrant [Sigma, St. Louis, MO]) as described in the 
figure legends. For cells with erucin treatment, 10 μM erucin (LKT Laboratories, St. 
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Paul, MN) was added with the DMEM/F12 with charcoal/dextran-treated FBS for the 
initial 48 hours in order to overexpress thioredoxin reductase 1 (TrxR1). Media was then 
removed from erucin-treated cells, fresh media was added, and treatments administered.  
 
Transfection procedures: pRS shRNA vector without shRNA cassette insert, pRS HuSH 
29mer shRNA constructs against COPS5 (Jab1), and pCMV6-XL4 carrying the full-
length human TrxR2 cDNA (OriGene Technologies, Rockville, MD, USA) were purified 
using MAX Efficiency® DH5α™ Competent Cells (Invitrogen) and plasmid was 
extracted using phenol extraction and ethanol precipitation. For transfection, cells were 
seeded in 6-well plates at 70%. After overnight incubation, transfection was performed 
using Fugene (1:3) and left to incubate overnight in Optimem (Invitrogen) or DMEM/F12 
with no serum or antibiotics. The next day media was changed to growth media and cells 
were allowed to recuperate overnight. Cells were seeded the next day. HuSH 29-mer non-
effective (scrambled) pRS vector (Origene) was tested and showed similar actions to the 
empty plasmid vector (data not shown). 
 
Antibodies: All antibodies used were purchased from Santa Cruz (Santa Cruz, CA), 
except the following: GAPDH (Sigma), β-actin (Sigma), and p27 phosphorylated at T157 
(Abcam, Cambridge, MA). 
 
Soft agar colony formation assay: Cells were seeded at a concentration of 500 cells/well 
in 0.25% agar on a 0.5% agar base using 5% FBS in 48-well plates. Cells were fed 2 
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times per week with treatments as described in figure legends, and colonies were counted 
on days 16 and 18. Each assay was repeated three times with triplicate treatments. 
 
BrdU cell proliferation assay: Cells were grown (2500 cells/well) in 96-well plates in 
DMEM/F12 with 5% charcoal/dextran-treated FBS for 48 h (certain wells also including 
10 μM erucin), followed by treatments in DMEM/F12 with charcoal/dextran-treated FBS 
as described in the figure legends for 48 h. A colorimetric BrdU cell proliferation assay 
was performed according to the manufacturer’s instructions (Roche, Indianapolis, IN). 
After incubation with treatments, cells were labeled for 24 hours at 37° C in 5% CO2. 
After 30 minutes of fixation and denaturing (FixDenat), cells were incubated with anti-
BrdU-peroxidase antibody (1:1000) for 90 minutes. Cells were washed three times with 
PBS, and the final substrate was added. Sample measurements were taken with Synergy 
HT (BioTek, Winooski, VT) plate reader at 370 nm (reference λ at 492 nm) at time points 
from 5-30 minutes at 5-minute intervals.  
 
Redox Western: The procedure for redox western for thioredoxin has been described in 
detail.7 Briefly, LCC2 cells were seeded at either 400,000 / well (6 well plate) or 1 x 
106/plate (100 mm plates). After overnight incubation, media with charcoal/dextran 
treated FBS was added to all cells, with 10 μM erucin added to specified wells/plates. 
After 48 hours, cells were treated as noted for 30 minutes. After washing twice with cold 
PBS, cells were scraped into 1.5 mL tubes with G lysis buffer with 50 mM iodoacetic 
acid. Samples were incubated for 30 minutes at 37°. Lysate was sonicated briefly, then 
centrifuged for 3 minutes at 2000 x g at room temperature. Lysate was transferred to new 
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tubes, and a BCA assay was performed to quantitate proteins. 50 μg was loaded in a 
native gel (15%) under non-reducing conditions and run for 90 minutes at 150V in native 
running buffer. Proteins were transferred to PVDF (GE Healthcare), blocked with 5% 
BSA, and incubated in anti-Trx antibody overnight. An SDS-PAGE (12%) was also run 
with the same lysate for loading control GAPDH or B-actin. Blots were developed using 
either a film developer (Konica Minolta) or VersaDoc imaging system using 
QuantityOne software (BioRad). 
 
Redox potential (Eh) of Trx1 was calculated using the Nernst equation through the use of 
the reduced and oxidized bands of thioredoxin. The equation Eh (mV, redox potential) = 
Eo (midpoint potential) + (RT/nF) ln(Trx1Ox /Trx1Red) was used, where Eo = -240 mV 
for Trx1 at pH 7.0 and 25°C, 30=ln and RT/nF. This equation was calculated previously 
by Go and Jones by using values [R, universal gas constant; T, absolute temperature; n, 
number of electrons; F, Faraday constant]). The ratio of oxidized and reduced Trx1 (Trx1 
Ox/Trx1 Red) band intensities was taken for each sample and used to calculate 
ln(Trx1Ox /Trx1Red). Thus, the final equation (as calculated by Go and Jones, 2009) 
reduces to Eh, Trx1 = −240 mV + 30 × ln(ratio of Trx1Ox and Trx1Red). 
Immunoblot: Cells were seeded in 100mm plates at 1 x 106 cells in DMEM/F12 with 5% 
charcoal/dextran-treated FBS and allowed to grow for 48 hours. Cells were then treated 
with DMSO and tamoxifen for 48 hrs. Cells were rinsed with cold PBS, lysed (20mM 
HEPES (pH 7.2), 50 mM NaCl, 0.5% Triton X-100, 0.1mM Na3VO4, 1mM NaF, 1x 
complete protease inhibitor (Roche)), and proteins isolated. Quantification of proteins 
was performed using the Pierce BCA Protein Assay Kit (Pierce, Rockford, IL), and lysate 
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was boiled for 5 minutes at 95-100° C. Acrylamide gel (12%) was loaded with 100 μg 
protein and run for 2.5 h at 150 volts. Proteins were transferred to PVDF and blots were 
blocked with either 5% milk or blocking buffer for phosphorylated proteins (1% milk, 
1% BSA, 50 mM NaF) in TBS-T. Blots were then incubated with anti-p27, anti-p27 
(T157), and anti-p27 (T187) (Santa Cruz, US) antibodies overnight. Secondary antibodies 
were added for one hour, and blots were imaged using either a film developer (Konica 
Minolta) or VersaDoc imaging system using QuantityOne software (BioRad). 
 
Co-immunoprecipitation: Cells were seeded in 100mm plates at 1 x 106 cells in 
DMEM/F12 with 5 % charcoal/dextran-treated FBS and allowed to grow for 48 h. Cells 
were then treated with DMSO and tamoxifen for 48 h. Cells were rinsed with cold PBS, 
lysed (NP-40 buffer, 1mM NaF, 1x complete protease inhibitor (Roche)), and proteins 
isolated. Quantification of proteins was performed using the Pierce BCA kit. 1000 μg 
lysate was precleared with 30 uL Protein A Agarose (Invitrogen) for 30 minutes. Lysate 
was separated from agarose beads, and incubated overnight with appropriate antibody (2 
ug/mL). Lysates were then incubated for 90 minutes with 50 uL Agarose A slurry, 
centrifuged, then supernatant removed. Beads were washed 3 times, and then 60 uL 2.5x 
loading buffer was added. Lysate was boiled for 10 minutes at 95-100° C, 30 uL was 
loaded in each of 2 acrylamide gels (12 and 15%), and run for 2.5 h at 150 volts. Proteins 
were transferred to PVDF and blots were blocked with 5% milk in TBS-T or 5% BSA in 
TBS-T (Trx). Blots were then incubated with anti-Jab1, anti-p27, or anti-Trx) antibodies 
overnight. After washing, secondary antibodies were added (Santa Cruz) for 1 hour. 
Images were captured using either Kodak Film or Versadoc digital imaging. 
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Results 
Upregulation of TrxR through Erucin treatment decreases proliferation and 
tumorigenicity of tamoxifen treated tamoxifen-resistant breast cancer cells 
If indeed thioredoxin oxidation is playing a role in tamoxifen resistance, we would expect 
an increase in thioredoxin reductase (and the subsequent reduction of oxidized 
thioredoxin) to decrease tamoxifen-resistant cell proliferation after tamoxifen treatment. 
We first wanted to check the validity of this hypothesis on tamoxifen-resistant cells, and 
performed a soft agar anchorage-independence assay. Anchorage-independence is a 
hallmark of tumor growth, so we used this assay to see if the overexpression of 
thioredoxin reductase 1 or 2 would create an atmosphere of tamoxifen sensitivity. We 
transfected LCC2 cells to overexpress TrxR2 or co-treated LCC2 cells with erucin to 
increase TrxR1. Cells were treated for over 2 weeks, and colonies counted on days 16 
and 18. Figure 1 shows the outcome of this experiment as representative pictures (A, B, 
C) and graphic representation of colony counts (D, E, F). We found that the 
overexpression of TrxR1 and TrxR2 each significantly decreased the number of colonies 
that formed after tamoxifen treatments.  
 
Jab1 aids in removing p27 from its inhibitory position in the nucleus. We would expect 
an underexpression of Jab1 would increase available p27 and lead to the inhibition of 
tumor growth in tamoxifen treated resistance cells. We found that indeed the 
underexpression of Jab1 through plasmid transfection also leads to significantly 
decreased colony formation. 
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We also looked at the DNA synthesis (cell proliferation) of these cells through the use of 
the BrdU incorporation assay. After incubating our cells with media with 
charcoal/dextran treated FBS, we treated the cells as noted for another 48 hours. We then 
labeled the cells for 24 hours with BrdU, and performed the BrdU assay (Roche). The 
overexpression of TrxR2 (Figure 2A), treatment of cells with erucin (overexpression of 
TrxR1, Figure 2B), and the underexpression of Jab1 (Figure 2C) show significant (p < 
0.05) decreases in DNA synthesis in LCC2 cells. 
 
Upregulation of TrxR and TrxR2 through isothiocyanate treatment and plasmid 
overexpression increases Trx and Trx2 expression in LCC2 cells 
It has been seen in HepG2 and undifferentiated Caco-2 cells that an increase in TrxR 
expression leads to an increase in expression of Trx,8 and the dietary isothiocyanates 
sulforaphane, erucin, and iberin have been found to induce thioredoxin reductase in 
MCF-7 cells.9 Our hypothesis is based on an overexpression of thioredoxin and/or 
thioredoxin 2, and so to confirm this increase in protein expression in tamoxifen-resistant 
LCC2 cells and to look at the expression of Trx2 after TrxR2 overexpression we 
performed a western blot. Figure 3A shows plasmid overexpression of TrxR2 leads to an 
increase in Trx2. Figure 3B shows the overexpression of thioredoxin reductase through 
the use of the isothiocyanate sulforaphane, and the subsequent increase in Trx.  
 
It is not only necessary to have more thioredoxin, but to also have more reduced 
thioredoxin to understand the validity of our hypothesis. As such, we also explored if the 
overexpression of thioredoxin reductase 1 and 2 led to a decrease in oxidized thioredoxin.  
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Tamoxifen increases ROS in LCC2 cells, and leads to an increase in oxidized 
thioredoxin in MCF-7 cells  
Tamoxifen has been shown to increase ROS in cells as estrogen does. We have 
previously shown that estrogen increases the oxidation of thioredoxin in MCF-7 cells. 
We wanted to explore the effect of tamoxifen on thioredoxin oxidation in breast cancer 
cells. Figure 4A shows that overexpression of TrxR2 increases levels of reduced 
thioredoxin, as does erucin treatment (Figure 4B). These data show that the reduction of 
oxidized thioredoxin occurs with the overexpression of TrxR2.  
 
Isothiocyanates are able to oxidize TrxR and glutathione reductase.10 Here we see that 
while the use of the isothiocyanate erucin increases levels of oxidized Trx, it also 
significantly increases the amount in reduced (and thus active) Trx (Figure 4B). Figure 
4C shows the redox potential as computed using the Nernst equation as noted in the 
Materials and Methods section. While the use of isothiocyanates decreases the redox 
potential due to the ratio of oxidized to reduced thioredoxin, the goal of this experiment 
was to increase the amount of reduced thioredoxin available in the cell, and this was 
achieved with isothiocyanate use. 
 
We hypothesize that the oxidation and subsequent inactivation of thioredoxin may lead to 
cell cycle signaling that promotes tamoxifen resistance. If thioredoxin is not reducing 
other proteins, these proteins may be “switched on” or “switched off” and can cause cell 
proliferation even when treated with tamoxifen. When thioredoxin is oxidized, it may not 
be able to bind to the Jab1 protein, as it has been shown to do.4 This would leave Jab1 
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free to bind to bind to p27, and carry it out of the nucleus, inhibiting p27 from controlling 
cell growth. 
 
Increased TrxR 1 and 2 increases Jab1/Trx binding 
In a variety of cancer cells, Jab1 has been negatively associated with p27 expression.11 
Jab1 has been implicated as a major cause of the translocation of p27 from the nucleus to 
the cytoplasm.12 Jab1 is thought to play a role in accelerating p27 degradation through the 
ubiquitin/proteosome pathway. Alternatively, Trx has been found to compete with p27 
for binding with Jab1 in HEK293T (human embryonic kidney) cells, and, through this, 
negatively regulate p27 degradation.4 Because of this finding, we wanted to explore the 
possibility that Trx may bind with Jab1 in breast cancer cells, and to see if altering Trx 
oxidative state would also alter Jab1/p27 binding. We performed a co-
immunoprecipitation, pulling down the Jab1 protein and probing it for Trx and for p27. 
We treated LCC2 cells as before, then incubated 1mg of protein with 2 μg Jab1 antibody 
overnight and followed the protocol as noted in Materials and Methods. Figures 5A     
and 5B show binding between Jab1 and Trx1, and figures 5C and 5D show binding 
between Jab1 and p27 after overexpression of TrxR 1 and 2. When cells are pretreated 
with isothiocyanates, an increase in binding of Jab1 and Trx occurs after treatment     
with tamoxifen. 
 
We also looked at Jab1 binding with p27, as we would expect to see Jab1/p27 binding 
decrease as Jab1/Trx binding increases. While we saw a drop in Jab1/p27 binding with 
the use of isothiocyanates, we did not see a significant decrease in Jab1/p27 binding as 
 95 
we expected when tamoxifen treatment was added. Thus we do not feel the binding of 
p27 to Jab1 is competitive with binding of Trx to Jab1. This is the first time, however, 
that Trx binding to Jab1 is shown in breast cancer cells 
 
TrxR1 and 2 overexpression and Jab1 underexpression decrease p27 
phosphorylation at T187. Increased TrxR 1 but not TrxR2 or decreased Jab1 
decrease p27 phosphorylation at T157 
p27 is a known cdk2 inhibitor. When p27 is phosphorylated and disconnects from cdk2, 
cdk2 is free to phosphorylate retinoblastoma, which can then activate the E2F gene and 
lead to cell proliferation.13, 14 We explored the phosphorylation of p27 at the T187 and 
T157 sites. The T187 site is phosphorylated by cdk2 once other sources (Src) 
phosphorylate p27 at T74 and T88.15 T77 and T88 phosphorylation weaken the p27/cdk2 
bond, and encourage T187 phosphorylation. Once p27 is phosphorylated at these sites, it 
becomes unbound from cdk2, and can be ubiquinated and subsequently degraded by the 
26S proteosome.13, 16 We hypothesize that it is at this point Jab1 can bind to p27 and aid 
in p27 degradation. We found that p27 is phosphorylated at 187 in LCC2 cells, but when 
TrxR 1 and 2 are overexpressed or Jab1 is underexpressed, T187 phosphorylation 
decreases. (Figures 6A and 6B) 
 
The T157 phosphorylation site prohibits p27 translocation into the nucleus. As such, p27 
is not available for cdk2/cyclin E binding, and cannot perform its inhibitory role. It also is 
available for and promotes cyclin D1/cdk4 assembly, which forwards cell cycle 
progression.17 Here we show that overexpression of thioredoxin reductase through 
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treatment of cells with erucin decreases phosphorylation of p27 at T157. This decrease is 
not seen when thioredoxin reductase 2 is overexpressed or Jab1 is underexpressed. 
(Figures 6A and 6B) 
 
Discussion 
As mentioned earlier, most studies on Trx and resistance to breast cancer treatment focus 
on Trx’s anti-apoptotic role in high ROS-producing chemotherapies. For example, 
response to docetaxel, a potent anti-cancer drug used with breast cancer patients, is linked 
to thioredoxin,6 and Trx expression is correlated with platinum-based drug resistance.18  
 
While these studies show the role of Trx as an agonist for chemotherapeutic drug 
resistance, we suggest that the role Trx plays in tamoxifen-treated breast cancer is 
affected by the overoxidation of Trx by the chronic low to medium levels of tamoxifen-
induced ROS, and that this can play a role in anti-estrogen resistance. We suggest that the 
oxidative state of cells treated with anti-estrogens will add a constant state of oxidative 
stress, and will create an adaptation in the cellular mechanism that leads to resistance to 
antiestrogens, namely through an oxidation of thioredoxin.  
 
We also suggest that altering Trx oxidation may alter tamoxifen-resistant cells’ reactions 
to tamoxifen, and lead to a more sensitive cell. We found that reducing Trx through an 
increase in TrxR did lead to higher levels of growth arrest and fewer tumor formations 
(soft agar) in tamoxifen-treated cells. 
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Tamoxifen is known to lead to an increase in ROS.19 Here we show that     
overexpression of TrxR in tamoxifen treated resistant cells can reduce the amount of 
oxidized thioredoxin. 
 
The role of Jab1 in tamoxifen resistance has not been explored. While Jab1 has been 
shown to bind to both p27 and Trx in HEK cells,4 this association has not been shown 
elsewhere. Here we show that altering the redox state of Trx leads to Jab1/Trx binding 
during tamoxifen treatment. We were unable to show a decrease in Jab1/p27 binding in 
these experiments.  
 
The function of p27 is also important when looking at tamoxifen resistance. While we 
show that p27 levels rise when TrxR is overexpressed, more importantly we also show 
decreased levels of phosphorylated p27 at T157 and T187. This implies that the increased 
p27 may be able to function properly in its cell cycle inhibitory role. In total, our results 
show a possible role for thioredoxin and for Jab1 in the reversal of tamoxifen resistance. 
When Trx is reduced through overexpression of TrxR, or when Jab1 levels are decreased, 
we show changes in tamoxifen-resistant LCC2 breast cancer cells that imply a shift of the 
cell towards tamoxifen sensitivity.  
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Figures 
Figure 1-LCC2 
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Upregulation of cellular and mitochondrial thioredoxin reductase reduced the 
formation of anchorage–independent colonies in tamoxifen–resistant cells. Wild type 
and cells overexpressing TrxR 1 and 2 were treated with either 0.1% DMSO or 1 μM 
tamoxifen and 1 μM fulvestrant (positive control) in soft agar for over 14 days. (A) 
Tamoxifen-resistant LCC2 cells were transfected with pCMV6-XL4 plasmid to 
overexpress mitochondrial thioredoxin reductase 2. Representative pictures of colonies 
with transfections and treatments as noted. (B) LCC2 cells were treated with 10 μM 
Erucin as well as other treatments as noted. (D & E) Graphic representation of colony 
counts with treatments as noted. Data shown are representative of minimum three 
independent experiments and are presented as number of colonies +/- SD. Values that are 
significantly different from empty vector control (TrxR2 overexpression) or DMSO 
(erucin treatment) are marked with an asterisk (*), and those significantly different from 
tamoxifen treatment are marked with two asterisks (**). 
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Downregulation of Jab1 reduced the formation of anchorage–independent colonies 
in tamoxifen-treated tamoxifen-resistant LCC2 cells. Wild type LCC2 cells and LCC2 
cells underexpressing Jab1 were treated with either 0.1% DMSO or 1 μM tamoxifen in 
soft agar for over 14 days. (C) LCC2 cells were transfected with HuSH purified pRS 
plasmid to underexpress Jab1. Representative pictures of colonies with transfections and 
treatments as noted. (F) Graphic representation of colony counts with treatments as noted. 
Data shown are representative of three independent experiments. Values that are 
significantly different from empty vector control (TrxR2 overexpression) or DMSO 
(Erucin treatment) are marked with an asterisk (*), and those significantly different from 
tamoxifen treatment are marked with two asterisks (**). Data are presented as number of 
colonies +/- SD. Values that are significantly different (p<0.05) from empty vector 
control are marked with an asterisk (*).  
 
Figure 2-LCC2 
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Upregulation of cellular and mitochondrial thioredoxin reductase decreased DNA 
synthesis in tamoxifen-treated tamoxifen-resistant LCC2 cells. Cells were treated to 
overexpress thioredoxin reductase, then treated with either 0.1% DMSO or 1 μM 
tamoxifen and 1 μM fulvestrant (positive control) for 48 hours. (A) Tamoxifen-resistant 
LCC2 cells were transfected with pCMV6-XL4 plasmid to overexpress mitochondrial 
thioredoxin reductase 2, then treated as noted in Materials and Methods section. (B) 
LCC2 cells were treated with 10 μM Erucin for 48 hours in serum-free media. 
Afterwards, starvation media was removed, fresh serum-free media added, and cells were 
treated as noted. Data shown are representative of minimum three independent 
experiments and are presented as absorbance reading +/- SD. Values that are significantly 
different from empty vector control (TrxR2 overexpression) or DMSO (erucin treatment) 
are marked with an asterisk (*), and those significantly different from tamoxifen 
treatment are marked with two asterisks (**). 
 
Downregulation of Jab1 also decreases DNA synthesis in tamoxifen-treated 
tamoxifen-resistant LCC2 cells. (C) Cells were treated to underexpress Jab1, incubated 
in serum-free media 48 hours, then treated with either 0.1% DMSO, 1 μM tamoxifen, or 
1 μM fulvestrant (positive control) for 48 hours. Data shown are representative of 
minimum three independent experiments and are presented as absorbance +/- SD. Values 
that are significantly different from empty vector control are marked with an asterisk (*). 
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Figure 3-LCC2 
 
Upregulation of TrxR2 and TrxR2 with plasmid overexpression or isothiocyanate 
treatment increases Trx2 and Trx expression in addition to TrxR2 and TrxR 
expression in LCC2 cells. (A) LCC2 cells were transfected with plasmid to overexpress 
TrxR2. Treatments were administered as noted in Materials and Methods section. (B) 
LCC2 cells were serum starved 48 hours during which specified cells were treated with 
10 μM sulforaphane. After starvation, media was replaced with fresh serum-free media, 
and cells were treated as noted. Cells were collected after 48 hours for protein analysis.  
Figure 4-LCC2 
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Thioredoxin oxidation in tamoxifen resistant cells may be reversible. (A) Tamoxifen-
resistant LCC2 cells were transfected with pCMV6-XL4 plasmid to overexpress 
mitochondrial thioredoxin reductase 2, and (B) LCC2 cells were treated with 10 μM 
erucin for 48 hours in serum-free media. Cells were then exposed to either 0.1% DMSO 
or 1 μM tamoxifen for 30 minutes. Cells were lysed and lysate run through redox western 
protocol as noted in Materials and Methods section. Data shown are representative, and 
are presented as (C) redox potential of thioredoxin. 
Figure 5-LCC2 
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Upregulation of cellular and mitochondrial thioredoxin reductase increases Jab1/ 
Trx binding and decrease Jab1 p27 binding in tamoxifen-treated tamoxifen-
resistant LCC2 cells. Cells were treated to overexpress thioredoxin reductase, then 
treated with either 0.1% DMSO or 1 μM tamoxifen for 48 hours. LCC2 cells 
overexpressing mitochondrial thioredoxin reductase by pretreatment with 10 μM 
isothiocyanate for 48 hours in serum-free media were harvested for co-
immunoprecipitation after 48 hours of treatment. (A) After immunoprecipitation of Jab1 
with anti-Jab1 antibody, precipitated proteins were probed with anti-Trx antibody. Trx 
binding was seen as greatly enhanced in sulforaphane pretreated/tamoxifen treated cells. 
(B) After immunoprecipitation of Jab1, precipitated proteins were probed with anti-p27 
antibody. Jab1/p27 binding was decreased as compared to cells without erucin pretreat.   
Figure 6-LCC2 
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Overexpression of TrxR1 through erucin treatment decreases p27 phosphorylation 
at T157 and T187. LCC2 cells were serum starved 48 hours during which specified cells 
were treated with 10 μM erucin. After starvation, media was replaced with fresh serum-
free media, and cells were treated as noted. Cells were collected after 48 hours of 
treatment for protein analysis. LCC2 cells were treated with 0.1% DMSO or 1 μM 
tamoxifen. (A) Expression of phosphorylated p27 at T157 and T187 before and after 
overexpression of TrxR2 and TrxR1 through erucin treatment. (B) Quantification of 
protein expression (T157). Phosphorylated/total p27 ratio was normalized to β-actin. (C) 
Quantification of protein expression (T187). Phosphorylated/total p27 ratio was 
normalized to β-actin. Data shown are representative of two independent experiments and 
are presented as protein expression amounts.  
 
Underexpression of Jab1 decreases p27 phosphorylation at T187. LCC2 cells were 
serum starved 48 hours, then media replaced with fresh serum-free media, and cells 
treated with 0.1% DMSO or 1 μM tamoxifen. Cells were collected after 48 hours of 
treatment for protein analysis. (A) Expression of phosphorylated p27 at T157 and T187 
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with and without underexpression of Jab1. (B) Quantification of protein expression 
(T157). Phosphorylated/total p27 ratio was normalized to β-actin. (C) Quantification of 
protein expression (T187). Data shown are representative of two independent 
experiments and are presented as protein expression amounts.  
 
IV INCREASED THIOREDOXIN REDUCTASE OR DECREASED JAB1 
LEADS TO DECREASED GROWTH IN BREAST CANCER CELLS  
UPON ESTROGEN TREATMENT THROUGH DECREASED AKT AND  
P27 PHOSPHORYLATION 
 
Abstract 
It is known that estrogen increases ROS in breast cancer cells. Thioredoxin, an enzymatic 
antioxidant, reduces proteins that have been oxidized by ROS. We wanted to show that 
mild oxidants such as estrogen could oxidize thioredoxin, causing it to be inactive and 
unable to reduce other proteins. This alteration in an antioxidant could lead to furthering 
cell proliferation by changing the redox state of the cell and leading to an increase in cell 
cycle pathways that lead to proliferation, such as the PI3K pathway. This increase in 
proliferation signaling could be a pathway for resistance to treatments such as tamoxifen, 
which has also been shown to produce ROS in low to medium doses. For this study we 
looked at how overexpressing thioredoxin reductase or underexpressing Jab1 affects 
estrogen-mediated cell proliferation in the breast cancer epithelial cell line MCF-7, as 
well as the effects of oxidized thioredoxin on Akt and p27 phosphorylation. We show 
that estrogen oxidizes thioredoxin, and that this is reversed with the overexpression of 
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thioredoxin reductase. We also show that thioredoxin reductase overexpression in MCF-7 
cells decreases Akt phosphorylation, increases p27 expression, and decreases p27 
phosphorylation. This data implies a role for antioxidants in altering estrogen-mediated 
growth of breast cancer cells. As we have already shown that it plays a role in altering 
tamoxifen resistance in breast cancer cells, this data may imply a role for thioredoxin 
reductase in preventing tamoxifen resistance. 
 
Introduction 
Estrogen actions with estrogen receptors are well known to promote pre-neoplastic and 
malignant growth. The estrogen / estrogen receptor combination can directly interact with 
the estrogen response element, or can act through a non-genomic pathway.1 Estrogen 
mechanisms in breast cancer cells have more recently included the production of 
intracellular ROS, leading to cell signaling and growth of estrogen-dependent breast 
cancer cells.2 3 At moderate levels, ROS can use reversible protein oxidation to regulate 
signaling pathways, most especially in PTPs.4 An important role of PTPs and PTKs is 
their ability to turn on and off the action of the protein on which they are exerting their 
influence.5 Structural changes to PTPs are induced by ROS, and the altered protein 
conformation leads to signaling cascade upregulation.6 Oxidation of PTPs can be 
reversed by thiol compounds7 such as thioredoxin (Trx), a 12 kDa disulphide reducing 
enzyme8, 9 that is induced by stressors such as 17β-estradiol.10  
The redox state of Trx is important to its function, and as such, the role of Trx reductase 
(TrxR) is key. In both Trx and TrxR there are cysteine molecules that are key to redox 
regulation.8, 9 Trx reductases are NADPH-dependent, and they catalyze disulfide 
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reduction at thioredoxin active sites. In turn, reduced thioredoxins catalyze the movement 
of active site dithiols to a disulfide state. This process has given the thioredoxin family a 
crucial role in cell-growth and apoptosis, as it is through this process they can regulate 
enzymes such as ribonucleotide reductase, peroxiredoxins and transcription factors.11  
 
The PTP PTEN is a phosphoinositol 3’ kinase (PI3K) inhibitor. A downstream molecule 
in the PI3K pathway, protein kinase B (Akt), can phosphorylate p27 at T157 and inhibit 
its import to the nucleus, prohibiting p27 from inhibiting cell proliferation.12 
Overexpression of the PTEN gene increases p27 levels, decreases cyclin D1 levels, 
inhibits the phosphorylation of Akt, and through these mechanisms inhibits cell growth in 
MCF-7 cells.13 The tumor suppressor PTEN can be reduced by Trx.14  
 
Several studies have explored the link between estrogen, estrogen receptor (ER) and 
thioredoxin. For example, the breast cancer cell line ZR-75-1 has been used to show that 
H2O2 treatment leads to a decrease in levels of pS2, a gene induced by estrogen. When, 
however, cells were transfected with thioredoxin, the expression of pS2 was restored in 
the H2O2-treated cells.15 Another study has shown that Trx expression may be correlated 
with better prognosis in ER+ and p53-intact patients.16 In the mouse uterus, estrogen 
treatment increases Trx, Trx2, and TrxR expression, as evidenced by mRNA levels.17 In a 
study regarding estrogen and congestive heart failure, subcutaneous, slow release pellets 
of estrogen (0.5 mg/60 day release) offered antioxidative properties. These properties 
were also associated with an increase in the expression of Trx, TrxR, and TrxR activity. 
In this form, estrogen also reduced ASK-1 activation, JNK activation, and p38 MAPK, 
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which can all be related to the increase in availability of thioredoxin. These data may 
show that thioredoxin could be conferring the antioxidative properties that are being 
linked to estrogen.18  
 
In considering breast cancer and its treatment, it is important to also explore the cell 
signaling pathways that occur due to estrogen exposure in ER+ cells, as well as those 
initiated by the treatments. While both Trx mRNA and protein are increased with 17β-
estradiol treatment, this effect is suppressed when tamoxifen treatment is given.10 Both 
estrogen and tamoxifen have been shown to increase levels of ROS in breast cancer 
cells.19 ROS can initiate signal transduction cascades that have been shown to lead to cell 
proliferation.3 In this study, we explore the role thioredoxin may have in reversing 
estrogen-mediated cell signaling. In particular, we look at the effect of oxidized Trx on 
PTEN function, as well as the downstream targets of Akt and phosphorylated p27. We 
find that altering the oxidative state of breast cancer cells with thioredoxin reductase 
leads to a decrease in cell growth through decreasing Akt phosphorylation, and 
subsequently decreasing phosphorylation of p27 at T157. 
 
Materials and methods  
Cell lines and cultures: Human breast adenocarcinoma MCF-7 cells were propagated in 
phenol red free Dulbecco's Modified Eagle Medium/F12 (DMEM/F12) with L-Glutamine 
and 15mM HEPES (Invitrogen, Grand Island, NY; Mediatech, Manassas, VA) containing 
10% (v/v) fetal bovine serum (Invitrogen; Atlanta Biologicals Lawrenceville, GA),  
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100 u/mL penicillin G sodium, and 100 ug/mL streptomycin sulfate (Invitrogen) at 37 °C 
in 5% CO2 atmosphere.  
 
Antibodies: All antibodies used were purchased from Santa Cruz (Santa Cruz, CA), 
except the following: GAPDH (Sigma), β-actin (Sigma), and p27 phosphorylated at T157 
(Abcam, Cambridge, MA). 
 
Chemicals and experimental protocol: Erucin was purchased from LKT Laboratories (St. 
Paul, MN). DMSO and 17β-estradiol were purchased from Sigma (St. Louis, MO). For 
experimental purposes, cells were seeded in 10% FBS DMEM/F12 medium and allowed 
to adhere overnight. Culture medium was replaced with serum-free DMEM/F12 and 
allowed to grow for 48 h (starvation), followed by treatments as described in figure 
legends. For cells with erucin treatment, 10 μM erucin was added with the DMEM/F12 
without FBS for the starvation period of 48 h in order to overexpress thioredoxin 
reductase 1 (TrxR1). Media with erucin was then removed, fresh serum-free media added 
without erucin, and treatments added. 
 
Transfection procedures: pRS shRNA vector without shRNA cassette insert, pRS HuSH 
29mer shRNA constructs against COPS5 (Jab1), and pCMV6-XL4 carrying the full-
length human TrxR2 cDNA (OriGene Technologies, Rockville, MD, USA) were purified 
using MAX Efficiency® DH5α™ Competent Cells (Invitrogen) and plasmid was 
extracted using phenol extraction and ethanol precipitation. For transfection, cells were 
seeded in 6-well plates at 70%. After overnight incubation, transfection was performed 
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using Fugene (1:3) (Roche, Indianapolis, IN) and left to incubate overnight in Optimem 
(Invitrogen) or DMEM/F12 without serum or antibiotics. The next day media was 
changed to growth media, and cells were seeded the following day. HuSH 29-mer non-ef-
fective (scrambled) pRS vector (Origene) was tested and showed similar actions to the 
empty plasmid vector (data not shown). 
 
Soft agar colony formation assay: Cells were seeded at a concentration of 500 cells/well 
(48-well plates) in 0.25% agarose on a 0.5% agarose base in DMEM/F12 with 10% FBS. 
Cells were fed two times per week with treatments as described in figure legends, and 
colonies were counted on day 16. Each assay was performed with triplicate treatments. 
 
BrdU cell proliferation assay: Cells were seeded at 2500 cells/well in 96-well plates in 
serum-free DMEM/F12 for 48 h (certain wells also including 10 μM erucin as described 
earlier). Treatments were added as described in figure legends for 48 h. A colorimetric 
BrdU cell proliferation assay was performed according to the manufacturer’s instructions 
(Roche). After incubation, the cells were labeled with BrdU for 24 hours at 37° C in 5% 
CO2. After 30 m of fixation/denaturing, cells were incubated with anti-BrdU-peroxidase 
antibody (1:1000) for 90 m. Cells were then washed three times with 1x PBS, and the 
final substrate added. The absorbance was measured at a wavelength of 370 nm and a 
reference wavelength of 492 nm at time points from 5-30 m at 5 m intervals.  
Immunoblot: Cells were seeded in 100mm plates at 1 x106 cells in 10% FBS DMEM/F12 
and allowed to grow overnight. Cells were then starved for 48 hours, then treated with 
DMSO and 17β-estradiol (E2) for 48 h. Cells were then rinsed with cold PBS, lysed (150 
 113 
mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS (sodium dodecyl sulphate), 
50 mM Tris, pH 8.0 0.2mM Na3VO4, 50mM NaF, 1x complete protease inhibitor 
(Roche)), and proteins isolated. Quantification of proteins was performed using the BCA 
assay (Pierce, Rockford, IL), and lysate was boiled for 5 m at 95-100° C. Acrylamide gel 
(12%) was loaded with 100 μg protein, and run for 2.5 h at 150 volts. Proteins were 
transferred to PVDF, and blots were blocked with either 5% milk or blocking buffer for 
phosphorylated proteins (1% milk, 1% BSA, 50 mM NaF) in TBS-T. Blots were then 
incubated with primary antibodies overnight. Secondary antibodies were added for one 
hour, and blots were developed using either a film developer (Konica Minolta) or 
VersaDoc imaging system using QuantityOne software (BioRad). ImageJ software (NIH) 
was used to quantify the protein expression through densitometry. This software was 
used for all assays that required densitometry. 
 
PTEN Redox Western: Cells were seeded in 6 well plates at 400,000 cells / well in 10% 
FBS DMEM/F12 and allowed to grow overnight. Cells were then grown in DMEM/F12 
without serum for 48 h, and then treated with DMSO and 17β-estradiol for 30 m in 1 mL 
of starvation media. Cells were scraped in the media and treatment, and placed in 1.5 mL 
tube containing 200 uL of ice-cold 50% trichloroacetic acid. Cells and media were 
sonicated briefly, and then centrifuged at 2000 x g for 5 m. Supernatant was removed, 
and the pellet was washed with acetone. After centrifuging again, supernatant was 
removed, and 200 uL lysis buffer was added (100 mm Tris-HCl (pH 6.8), 2% SDS, 40 
mM NEM). 30-50 uL of lysate was run under non-reducing conditions using SDS-PAGE.  
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Thioredoxin Redox Western: The procedure for redox western for thioredoxin has been 
described in detail.20 Briefly, MCF-7 cells were seeded at either 400,000 cells / well (6 
well plate) or 1 x 106  cells/plate (100 mm plates). After overnight incubation, serum-free 
media was added to all wells, with 10 μM erucin added to certain wells/plates. After 48 h, 
cells were treated as noted in figures for 30 m. After washing 2x with PBS, G lysis buffer 
with 50 mM iodoacetic acid was added and cells were scraped into 1.5 mL tubes. 
Samples were incubated for 30 m at 37°. Lysate was sonicated briefly, then centrifuged 
for 3 m at 2000 x g at room temperature. Lysate was transferred to new tubes, and BCA 
assay was performed to quantitate the proteins. 50 μg was loaded in a native separating 
gel (15%) under non-reducing conditions and run for 90 m at 150V in native running 
buffer. Proteins were transferred to PVDF, incubated in 5% BSA for 1 h, then incubated 
in anti-Trx antibody overnight. An SDS-PAGE (12%) was also run with the same lysate 
for loading control GAPDH or B-actin. Films or Versadoc images were subjected to 
densitometry using ImageJ software.  
 
Redox potential (Eh) of Trx1 was calculated using the Nernst equation through the use of 
the reduced and oxidized bands of thioredoxin. The equation  
Eh (mV, redox potential) = Eo (midpoint potential) + (RT/nF) ln(Trx1Ox /Trx1Red) was 
used, where Eo = -240 mV for Trx1 at pH 7.0 and 25°C, 30=ln and RT/nF (this was 
calculated previously by Go and Jones by using values [R, universal gas constant; T, 
absolute temperature; n, number of electrons; F, Faraday constant]). The ratio of oxidized 
and reduced Trx1 bands (Trx1 Ox/Trx1 Red) band intensities were taken for each sample  
 
 115 
and used to calculate ln(Trx1Ox /Trx1Red). Thus, the final equation (as calculated by Go 
and Jones) reduces to Eh, Trx1 = −240 mV + 30 × ln(ratio of Trx1Ox and Trx1Red).  
 
Results 
Upregulation of TrxR or downregulation of Jab1 suppresses anchorage-
independent growth and DNA synthesis in estrogen-treated MCF-7 cells 
Estrogen is known to lead to cell growth in MCF-7 cells. Our lab has shown the induction 
of mitochondrial ROS (mtROS) in estrogen-dependent breast cancer cells upon estrogen 
treatment. We have also shown the effect of antioxidants, such as ebselen and NAC, on 
reducing these mtROS, and subsequently on the reduction of estrogen-mediated growth 
in MCF-7 cells. For these experiments, we wanted to explore the role of thioredoxin 
reductase 1 and 2 on estrogen-mediated growth in MCF-7 cells. 
 
Anchorage-independent growth is a hallmark of tumor cells. As such, we performed a 
colony formation assay in soft agar with MCF-7 cells, MCF-7 cells transfected with Jab1 
shRNA to underexpress Jab1, MCF-7 cells transfected to overexpress TrxR2, and MCF-7 
cells that were co-treated with erucin to increase TrxR1. Cells were treated for over 2 
weeks, and colonies counted. Figures 1A, 1B, and 1C show representative pictures and 
graphic representations of these counts. We found that the overexpression of TrxR2 
through transfection and TrxR1 through the treatment with erucin decreased both DMSO 
and estrogen treated cells significantly. (Figure 1A and 1B) Underexpression of Jab1 also 
showed a decrease in estrogen-treated cells. (Figures 1C and 1F) These data show a role 
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for increased reduced thioredoxin or decreased Jab1 expression in reducing estrogen-
mediated growth of tumor cells. 
 
We also looked at the DNA synthesis (cell proliferation) of these cells through the use of 
the BrdU incorporation assay (Figures 2A, 2B, and 2C) and found that all three cellular 
modulations led to a decrease in DNA synthesis. These data suggest that an increase of 
thioredoxin reductase, both cellular and mitochondrial, will decrease estrogen-mediated 
growth of MCF-7 epithelial cancer cells, supposedly through the reduction of thioredoxin 
1 and thioredoxin 2 and subsequent reduction of other cell cycle proteins. It also suggests 
a role for Jab1 in estrogen–mediated growth of breast cancer. 
 
Thioredoxin is reversibly oxidized by estrogen treatment, and reduced after the 
upregulation of TrxR 
Estrogens are phenolic chemicals, (Roy and Liehr, 1990) and are known to lead to the 
production of mitochondrial ROS.19, 21 MtROS have been implicated in cell signaling in 
several pathways, including integrins, platelet-derived growth factor, epidermal growth 
factor, and nerve growth factor.22 We confirmed the increase of ROS by estrogen by 
measuring H2O2 production through the DCF assay. (Data not shown) One of the three 
major redox couples that are responsive to changes in the reducing/oxidizing (redox) 
environment in cells is Trx(SS)/Trx(SH)2.23 There are several published examples of 
Trx’s susceptibility to ROS, and there are a variety of compounds that have been found to 
oxidize Trx, such as H2O2 and superoxide.24 While it has been shown that estrogen 
treatment increases thioredoxin and thioredoxin reductase levels in bovine aortic 
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endothelial cells, we wanted to test if the mtROS produced by estrogen would have an 
oxidative effect on thioredoxin. We performed a redox western to explore the effects of 
estrogen treatment on the redox state of thioredoxin. Cells were treated for 30 m before 
lysates were prepared. 50 mM iodoacetic acid was used in 6M guanidine lysis buffer, as 
it leads to thiol alkylation. When a thiol is modified, one negative charge is added, and 
reduced thioredoxin, which will have a negative charge after IAA treatment, will run 
faster than oxidized thioredoxin in a native, non-reducing gel electrophoresis.20 
  
We found that estrogen treatment increases thioredoxin oxidation (Figure 3A) and, 
utilizing the Nernst equation as described in Materials and Methods, found that estrogen 
decreases thioredoxin redox potential (Figure 3B). The dietary isothiocyanates 
sulforaphane, erucin, and iberin have been found to induce thioredoxin reductase in 
MCF-7 cells.25 We wanted to explore if this chemical induction of TrxR would change 
the redox state of thioredoxin that was oxidized by estrogen. In HepG2 and 
undifferentiated Caco-2 cells, not only does sulforaphane induce TrxR, but also its 
substrate Trx.26 We found this to also be true of pretreating with erucin on the MCF-7 sub 
line LCC-2 cells. 
 
We found that there is an overall increase in thioredoxin due to erucin treatment, and 
there is an increase in the amount of reduced thioredoxin in erucin+estrogen-treated cells 
in relation to those treated with the vehicle (DMSO). Erucin, however, also increases the 
amount of both TrxR and Trx, and has been shown to increase oxidation of glutathione 
reductase, thioredoxin reductase and peroxiredoxin 3. We found that the redox potential 
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of thioredoxin went down with isothiocyanate treatment, but feel this avenue deserves 
further research, as the amount of reduced thioredoxin increased dramatically. As the 
goal of this experiment was to ensure an increase in reduced thioredoxin, and not 
necessarily only an increase in oxidized/reduced thioredoxin ratio, we felt the use of 
isothiocyanates achieved this goal. 
 
We explored if increasing the mitochondrial thioredoxin reductase (TrxR2) through 
transfection would have an effect on the oxidative state of cellular thioredoxin. (Figures 
3C and 3D) We found that not only is there a decrease in the oxidation level of Trx (and 
an increase in redox potential) after this overexpression, there is an unexpected increase 
in thioredoxin redox potential when Jab1 is underexpressed.  
 
These experiments show that the oxidation of thioredoxin by estrogen can be reduced 
with the use of an overexpression of thioredoxin reductase or the underexpression of 
Jab1. The oxidation of Trx can lead to its inactivity, which can affect several cell 
signaling pathways. For this study we explored PTEN oxidation and thioredoxin’s role in 
reducing PTEN and restoring its function. 
 
Upregulation of TrxR through transfection decreases the ratio of oxidized to 
reduced PTEN 
ROS plays a redox regulatory role in protein-tyrosine phosphatases (PTPs). Its signature 
motif allows for redox regulation of proteins when the cysteine residues react with ROS.4 
The PTP catalytic cysteine only requires mild oxidative conditions to be oxidized to 
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sulfenic acid (Cys-SOH). This can be averted by interactions with a protein structure such 
as a thiol.4, 5, 27, 28 We first checked for oxidation of PTEN by estrogen through non-
reducing SDS-PAGE. MCF-7 cells were transfected with TrxR2 or pretreated with 
erucin, then treated with estrogen for 30 m. We found that cells that were transfected with 
thioredoxin reductase reduced the ratio of oxidized/reduced PTEN in cells treated with 
estrogen (Figure 4A and B) We did not see similar results in cells pretreated with erucin 
to overexpress TrxR (data not shown). This may be due to the treatment time used. 
 
Downstream signaling of phosphorylated Akt is altered by modulation of 
thioredoxin reductase and Jab1 
PTEN is known to inhibit phosphoinositol 3’ kinase (PI3K). A downstream molecule in 
the PI3K pathway is protein kinase B (Akt), which can phosphorylate, and thus 
inactivate, the cell cycle inhibitor p27. We wanted to explore if the oxidation or oxidation 
and then reduction of PTEN had an effect on this pathway. We performed a western blot 
on MCF-7 cells that had been treated with estrogen, pretreated with erucin and/or 
transfected with TrxR2 cDNA or Jab1 shRNA. We found that while estrogen increases 
the expression of phosphorylated Akt at S473, increasing the expression of thioredoxin 
reductase 2 alters this estrogen-mediated phosphorylation, as seen in Figure 5A and B. 
We were not able to show that the chemical overexpression of TrxR through the use of 
erucin also decreases phosphorylation of Akt (data not shown). Again, this could be due 
to the treatment times chosen for this experiment. However, again unexpectedly, the 
downregulation of Jab1 also showed a decrease in Akt phosphorylation. 
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Overexpression of TrxR or underexpression of Jab1 alters p27 phosphorylation  
at T157 
Protein kinase B (Akt) can phosphorylate p27 at T157 and inhibit its import to the 
nucleus. This prohibits p27 from inhibiting cell proliferation.12 When p27 is in the 
cytoplasm, it aids in the assembly of cyclin D1/cdk4, which furthers cell proliferation.29 
When the PI3K pathway has been activated, as it is in human cancers, it has been found 
that p27 concentrations decrease. This effect is reversed by PTEN.30 Overexpression of 
the PTEN gene increases p27 levels, decreases cyclin D1 levels, inhibits the 
phosphorylation of Akt, and through these mechanisms inhibits cell growth in MCF-7 
cells.13 We wanted to explore the effect of an increase of thioredoxin through an 
overexpression of thioredoxin reductase on p27 phosphorylation at T157. We performed 
a western blot as outlined in the Materials and Methods section (Figure 6A and D). We 
underexpressed Jab1 and overexpressed TrxR2 and pretreated with erucin to overexpress 
both cellular and mitochondrial TrxR (TrxR1 and TrxR2 respectively) and treated as 
noted in figures. We also scanned the blots and used ImageJ to quantify the blots (Figures 
6B, 6C, 6E, 6F). We found that the overexpression of both TrxR1 and TrxR2 led to a 
decrease in the PTEN downstream target of p27 phosphorylation at T157. This data 
paired with the data on PTEN shows a possible link between the oxidation of thioredoxin, 
oxidation of PTEN, and cell cycle progression through T157 phosphorylation of p27. 
 
Discussion 
Estrogen and tamoxifen produce intracellular ROS rapidly, which can lead to cell 
signaling and the growth of estrogen-dependent breast cancer cells.2, 3, 19 Upon ROS 
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production there is a stimulus and a response to the ROS from a protein of either 
activation or inhibition, which is amplified through the activation or inhibition of effector 
molecules further downstream in the pathway. There is also reversibility so that the 
pathway can be responsive to more than just the one stimulus. Thioredoxin and 
glutathione, as well as enzymes that are associated with each, have been found to reduce 
the thiol oxidation that occurs through ROS. It has been compared to the regulatory effect 
of phosphorylation and de-phosphorylation of proteins.31  
 
Thioredoxin and glutathione are the major factors in maintaining reduced proteins,6, 32, 33 
and these reducing agents are found, in normal cells, in their reduced form. When they 
perform their reduction actions on oxidized proteins, they themselves are oxidized.    
They are then returned to their reduced forms through the use of thioredoxin reductase 
and glutathione reductase, respectively. Cysteine residues have been found to be specific 
targets for ROS when in the thiolate (-S) form, making them susceptible to modification 
by ROS. 
 
Trx has been found to compete with p27 for binding with Jab1 in HEK293T (human 
embryonic kidney) cells, and, through this, negatively regulate p27 degradation. It has 
been shown that the addition of Trx to cells altered the direction of Jab1-induced p27 
level decrease. In our study, we both overexpressed thioredoxin reductase to increase the 
amount of reduced, and thus active, thioredoxin, and underexpressed Jab1 through 
shRNA transfection to show a possible role for this pathway. We used these treatments 
on MCF-7 breast cancer cells to explore if altering the redox state of cells will alter 
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estrogen-mediated growth. We found that overexpression of both thioredoxin reductase 1 
and 2 reduces colony formation and cell proliferation effects of estrogen. We saw the 
same effects when we reduced Jab1 expression. 
 
We explored the oxidation of thioredoxin by estrogen, and found that in MCF-7 cells 
thioredoxin is oxidized by estrogen. Overexpressing thioredoxin reductase, as would be 
expected, reversed these effects of estrogen. Interestingly, the reduction of Jab1 
expression also led to a reduction in thioredoxin oxidation. We are unsure of the 
signaling pathway that may lead to this increase in redox potential by Jab1, and feel it 
deserves further study. 
 
Particularly susceptible to oxidation are protein tyrosine phosphatases (PTPs).27, 28 PTEN 
can be oxidized by H2O2, and then reduced by Trx.14 We found that estrogen-induced 
ROS oxidizes PTEN in MCF-7 cells, and that the addition of thioredoxin reductase 
reduces this oxidation. PTEN, as well as other PTPs, has been show to correlate with p27 
levels. We wanted to explore if this pathway was affected by TrxR overexpression or 
Jab1 underexpression. A downstream molecule in the phosphoinositol 3’ kinase (PI3K) 
pathway, protein kinase B (Akt) can phosphorylate p27 at T157 and inhibit its import to 
the nucleus. This prohibits p27 from inhibiting cell proliferation12 and makes it available 
for cyclin D1/cdk4 assembly which furthers cell cycle progression.29 When the PI3K 
pathway has been activated, as it is in human cancers, it has been found that p27 
concentrations decrease.30 We looked at the phosphorylation of Akt, and found it to be 
susceptible to estrogen and enzymatic antioxidants. The overexpression of thioredoxin 
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reductase, presumably through the reduction of oxidized thioredoxin and subsequent 
reduction of oxidized PTEN, led to a decrease in phosphorylated Akt at S473. This 
decrease was also seen in cells that underexpressed Jab1. Further downstream in this 
pathway, the phosphorylation of p27 at T157 was decreased by altering TrxR and Jab1 
levels in the cells. 
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Figures 
Figure 1-MCF7 
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Upregulation of cellular and mitochondrial thioredoxin reductase reduces the 
formation of anchorage–independent colonies in estrogen-treated ER+ breast 
cancer epithelial cells. MCF-7 cells were transfected to overexpress TrxR2 or were 
treated chemically with 10 μM erucin to overexpress TrxR1 and seeded in 0.25% agarose 
with DMEM and 10% FBS. Cells were treated with either 0.1% DMSO or 100 pg E2 for 
over two weeks. (A & B) Representative pictures of wells demonstrating colonies formed 
by MCF-7 cells transfected and/or treated as indicated. Also shown, graphic 
representation of colony counts. Data shown are representative of three independent 
experiments and are presented as number of colonies +/- SD. Values that are significantly 
different (p<0.05) from empty vector control (TrxR2 overexpression) or DMSO (erucin 
treatment) are marked with an asterisk (*). 
 
Downregulation of Jab1 reduced the formation of anchorage–independent colonies 
in estrogen-treated ER+ breast cancer epithelial cells. MCF-7 cells were transfected 
with the HuSH pRS plasmid to underexpress Jab1. Wild type cells and cells 
underexpressing Jab1 were treated with either 0.1% DMSO or 100 pg E2 in soft agar for 
over 14 days. (C) Representative pictures of wells demonstrating colonies formed by 
MCF-7 cells transfected and treated as indicated. Also shown, graphic representation of 
colony counts. Data shown are a representative of two independent experiments 
performed in triplicate and are presented as number of colonies +/- SD. Values that are 
significantly different (p<0.05) from empty vector control are marked with an asterisk (*) 
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Figure 2-MCF7 
 
Upregulation of cellular and mitochondrial thioredoxin reductase decreased DNA 
synthesis in estrogen-treated MCF-7 cells. Cells were treated to overexpress 
thioredoxin reductase, and then treated with either 0.1% DMSO or 100 pg E2 for 48 
hours. (A) MCF-7 cells were transfected with pCMV6-XL4 plasmid to overexpress 
mitochondrial thioredoxin reductase 2, then treated as noted in the Materials and Methods 
section. (B) MCF-7 cells were treated with 10 μM erucin for 48 hours in media without 
FBS. Afterwards, starvation media was removed, fresh media added, and treatments as 
noted were added. BrdU assay was performed as noted in Materials and Methods section. 
Data shown are representative of minimum three independent experiments and are 
presented as absorbance reading +/- SD. Values that are significantly different from 
empty vector (TrxR2 overexpression) or DMSO (erucin treatment) are marked with an 
asterisk (*). 
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Downregulation of Jab1 decreased DNA synthesis in estrogen-treated MCF-7 cells. 
Cells were treated to overexpress thioredoxin reductase, and then treated with either 0.1% 
DMSO or 100 pg E2 for 48 hours. Data shown are representative of minimum three 
independent experiments and are presented as absorbance reading +/- SD. Values that are 
significantly different from empty vector control (TrxR2 overexpression) or DMSO 
(erucin treatment) are marked with an asterisk (*). 
Figure 3-MCF7 
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Estrogen increases oxidative state of MCF-7 cells and leads to an increase in 
oxidation of Trx1. TrxR2 overexpression increases Trx redox potential. MCF-7 cells 
were seeded to 10-6 in 100 mm plates. After incubating overnight, cells were incubated 
with serum-free media for 48 hours. During this time, noted plates were treated with 10 
μM erucin. After 48 hour incubation, cells were treated for 30 minutes with 0.1% DMSO 
or 100 pg (100 ng in WT cells) 17β-estradiol. Cells were harvested in 50 mM guanidine 
lysis buffer and prepared as described in Materials and Methods. (A) MCF-7 cells were 
treated with 10 μM erucin for 48 hours in serum-free media, and (C) MCF-7 cells were 
transfected with pCMV6-XL4 plasmid to overexpress mitochondrial thioredoxin 
reductase 2. Cells were then exposed to either 0.1% DMSO or 100 pg E2 for 30 minutes. 
Cells were lysed and lysate run through redox western protocol as noted in Materials and 
Methods section. Data for DTT (reductant) and H2O2 (oxidant) are also shown. (B & D) 
Data are presented as redox potential of thioredoxin. Data shown are representative of 
three independent experiments and are presented as protein expression amounts and 
redox potential values (Nernst equation).  
 
Jab1 downregulation increases Trx redox potential. MCF-7 cells were seeded to 10-6 
in 100 mm plates. After incubating overnight, cells were incubated with serum-free 
media for 48 hours. After 48 hour incubation, cells were treated for 30 minutes with 0.1% 
DMSO or 100 pg 17β-estradiol. Cells were harvested in 50 mM guanidine lysis buffer 
and prepared as described in Materials and Methods. (C) MCF-7 cells were transfected to 
downregulate Jab1. Cells were then exposed to either 0.1% DMSO or 100 pg E2 for 30 
minutes. Cells were lysed and lysate run through redox western protocol as noted in 
 131 
Materials and Methods section. (D) Data are presented as redox potential of thioredoxin. 
Data shown are representative of three independent experiments and are presented as 
protein expression amounts and redox potential values (Nernst equation).  
Figure 4-MCF7 
 
Oxidation of PTEN by estradiol is reversed with overexpression of thioredoxin 
reductase. MCF-7 cells overexpressing TrxR1 (erucin pretreat) and TrxR2   
(transfection) were treated with 0.1% DMSO for 20 minutes or 100 pg 17β-estradiol     
for 20 or 30 minutes after 48-hour incubation in serum-free medium. Cells were 
harvested as noted   in Materials and Methods section. (A) Oxidation of PTEN is shown 
in EV (control) transfected cells, though not seen in TrxR2 transfected cells. (B) 
Quantification of oxidized PTEN/reduced PTEN ratio. Data are representative of two 
independent experiments. 
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Figure 5-MCF7 
 
Overexpression of thioredoxin reductase and underexpression of Jab1 decreases 
Akt phosphorylation at Ser473 in estrogen-treated MCF-7 cells. Transfected or 
chemically treated MCF-7 cells were treated with 0.1% DMSO or 100 pg 17β-estradiol. 
(A) Expression of phosphorylated Akt before and after overexpression of TrxR2 or 
underexpression of Jab1. (B) Quantification of protein expression. E2 time point shown is 
30-minute treatment. Akt was normalized to β-actin first. The graph shown is 
phosphorylated Akt/total normalized Akt ratio. Data shown are representative of two 
independent experiments and are presented as protein expression amounts as quantified 
by densitometry.  
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Figure 6-MCF7 
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Overexpression of TrxR1 through erucin treatment decreases p27 phosphorylation 
at T157. MCF-7 cells were treated with 0.1% DMSO or 100 pg 17β-estradiol. (A) 
Expression of p27 and phosphorylated p27 at T157 with and without overexpression of 
TrxR2. (B) Quantification of relative p27 protein expression. (C) Quantification of 
relative phosphorylated p27 expression. Phosphorylated/total p27 ratio was normalized to 
β-actin. (D) Expression of p27 and p27 phosphorylated at T157 after overexpression of 
TrxR. (E) Quantification of relative p27 protein expression. (F) Quantification of ratio of 
phosphorylated/total p27, normalized to β-actin. Data shown are representative of two 
independent experiments and are presented as protein expression amounts and redox 
potential values.  
 
Underexpression of Jab1 decreases p27 phosphorylation at T157. MCF-7 cells were 
transfected to underexpress Jab2, incubated in serum-free media 48 hours, then treated 
with 0.1% DMSO or 100 pg 17β-estradiol. (A) Expression of phosphorylated p27 at 
T157 (B) Quantification of protein expression. Phosphorylated/total p27 ratio was 
normalized to β-actin. Data shown are representative of two independent experiments and 
are presented as protein expression amounts and redox potential values.  
                 
V    CONCLUSION 
The purpose of this research was to explore the enigmatic problem of tamoxifen 
resistance in breast cancer through looking at the p27/Jab1/Trx pathway. The sub goals 
were twofold: First, to show that reducing oxidized thioredoxin through increasing 
thioredoxin reductase or that decreasing Jab1 protein can alter p27 phosphorylation; 
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second, to show these same cellular alterations can increase tamoxifen sensitivity in 
previously tamoxifen-resistance breast cancer cells.  
 
Results of this study add several significant findings to research on tamoxifen resistance 
and the p27/Jab1/Trx pathway. While there is one study that explores glutathione actions 
on MKP3 phosphatase in antiestrogen resistance, there appear to be no other studies that 
consider the role of reactive oxygen species in tamoxifen resistance. Further, the studies 
that involve thioredoxin and chemotherapeutic resistance look at the chemotherapeutics 
that use a high level of reactive oxygen species to kill breast cancer, and show that 
thioredoxin interferes with cellular death in these cases. No other study looks at the level 
of ROS produced by antiestrogens and how thioredoxin alteration by this ROS may affect 
the possibility of resistance. Findings in this study showed that thioredoxin is oxidized by 
physiologic levels of estrogen, and that reversal of this oxidation through the 
overexpression of thioredoxin reductase can lead to previously tamoxifen-resistant cells 
appearing to regain sensitivity. 
 
There is one study out that shows that p27 and thioredoxin compete for binding to Jab1, 
and when thioredoxin is not available for binding that Jab1 can bind to p27 and aid in 
removing it from the nucleus. The current study explored the relationship between these 
three proteins in tamoxifen-resistant breast cancer cells. While a thioredoxin/Jab1 
interaction was shown, p27/Jab1 binding did not appear to decrease with the reduction of 
oxidized thioredoxin. In both MCF-7 breast cancer and LCC2 tamoxifen-resistant breast 
cancer cells, reduction of Jab1 levels led to a change in response of the cells to estrogen 
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and tamoxifen, respectively. Decreasing Jab1 led to a decrease in cell growth, a    
decrease in thioredoxin oxidation, and a decrease in p27 phosphorylation. The role of 
Jab1 in tamoxifen resistance has not been explored, and as such these data add to the 
current knowledge. 
 
The current study also sought to explore if the effect thioredoxin has on the PTP PTEN 
would have downstream effects on the p27 protein. While PTEN is known to be reduced 
by thioredoxin, it has not been shown that reducing oxidized thioredoxin through 
increasing thioredoxin reductase levels affects phosphorylation of p27 at T157. This 
study shows that in both MCF-7 and LCC2 cells, altering the oxidative state of the cell 
through thioredoxin reductase can alter the effects on p27 phosphorylated stated. Two 
phosphorylation sites were shown to be dephosphorylated after an increase in levels of 
thioredoxin reductase. The PTEN/Akt pathway is implicated in this study, but further 
studies are recommended, as the time point chosen for experiments may not have been 
sufficient to show a strong link. 
 
The major goals of this study were to explore a link between oxidative stress and 
tamoxifen resistance, and specifically to look at the thioredoxin/Jab1/p27 pathway as a 
target. By identifying the specific data mentioned above, thioredoxin and Jab1 have   
been shown to be proteins that may play a role in tamoxifen resistance, and through 
further research may be proven to be potent tools for avoiding antiestrogen resistance in 
breast cancer. 
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Directions for future research 
The results of the present study are intended to start a conversation on the role of 
thioredoxin reductase, thioredoxin, and Jab1 in antiestrogen resistance. The data show 
three areas of possible research.  
 
The reduction of oxidized thioredoxin by thioredoxin reductase showed a significant 
reduction in cell growth and p27 phosphorylation in both MCF-7 cells and tamoxifen-
treated tamoxifen-resistant LCC2 cells. This effect on cancer cells, as well as the 
apparent increased sensitivity to tamoxifen, suggest that thioredoxin reductase may be a 
potent tool in delaying, reducing, or abrogating tamoxifen resistance. This is not true with 
other chemotherapeutics where thioredoxin can interfere with the onslaught of reactive 
oxygen species that the chemotherapeutic uses to kill cancer cells. In the case of 
antiestrogens that have been shown to create ROS but are not seen to use ROS as the 
main pathway of apoptosis, thioredoxin reductase may prove a useful too, and as such 
should be explored further in this role. 
 
Jab1 was explored for its role with thioredoxin in counteracting tamoxifen resistance and 
estrogen effects in MCF-7 cells. The data show that reducing Jab1 can affect tamoxifen 
sensitivity, causing a decrease in cell growth in tamoxifen-treated tamoxifen-resistant 
cells. While we were unable to show a change in p27/Jab1 binding in tamoxifen-treated 
resistant cells, there was a change in p27 phosphorylation when Jab1 levels were 
decreased. There was also an interesting finding of an increase in the reduction of 
thioredoxin when Jab1 was decreased. As such, the p27/Jab1/thioredoxin pathway 
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deserves further research to explore other possibilities of interactions between these three 
proteins, as the final result is decreased growth in both cancer and tamoxifen-resistant 
cancer cells. 
 
The data in this study show a possible role for thioredoxin in affecting the PTEN/Akt/p27 
phosphorylation pathway. As thioredoxin is known to interact with other protein   
tyrosine phosphatases, these phosphatases should be explored for an effect on 
antiestrogen resistance. The PTEN pathway deserves further exploration, as our data 
show minimal results. Other pathways may also show other targets for abrogating 
antiestrogen resistance. 
      
SUPPLEMENTAL DATA 
 
 
 
HuSH 29-mer non-effective (scrambled) pRS vector (Origene) was tested and showed 
similar actions to the empty plasmid vector. 
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